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ABSTRACT 
 
Prevalent patients were over-represented in many pulmonary hypertension 
registries and clinical trials. These patients have better survival compared with 
incident patients. As pulmonary hypertension (PH) is diagnosed and managed in 
designated pulmonary hypertension centres only in the United Kingdom (UK) and 
Ireland, this provides a unique opportunity to define the demographics, 
epidemiology and outcomes of a large cohort of purely incident, treatment-naive 
idiopathic, heritable and anorexigen-associated pulmonary arterial hypertension 
(PAH) patients.  
 
We included all newly diagnosed, treatment naive patients diagnosed in all eight 
PH centres in the UK and Ireland between January 2001 and December 2009 in 
our study. We used the same inclusion criteria used in the French and Scottish 
registries to define our idiopathic, heritable and anorexigen-associated PAH 
patients. We further refined our criteria for idiopathic, heritable and 
anorexigen-associated PAH by excluding patients with evidence of parenchymal 
lung disease on thoracic CT. These excluded patients (refer as Pre-capillary 
pulmonary hypertension co-existing lung disease in this thesis) were managed as 
idiopathic PAH by their PH physicians and otherwise satisfied the usual 
haemodynamic and pulmonary function criteria used to define idiopathic PAH in 
many PH registries and clinical trials.  
 
We divided our idiopathic, heritable and anorexigen-associated PAH patients into 
two age subgroups according to their median age to study the effect of age on 
their phenotypes and survival. We also divided our idiopathic, heritable and 
anorexigen-associated PAH patients into three subgroups according to their year 
of diagnosis to study the changing epidemiology of the disease over the past 
decade. We also compared the baseline characteristics and outcomes of our 
idiopathic, heritable and anorexigen-associated PAH patients with PAH with ‘co-
existing lung disease’ patients.  
 
Firstly, we confirmed that the demographics, epidemiology and survival of 
incident idiopathic, heritable and anorexigen-associated PAH has changed 
compared with patients from the pre-disease targeted therapy era of the 1980s, 
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and continued to evolve in the UK and Ireland over the past decade. The 
incidence of idiopathic PAH continued to increase over the past decade in the 
UK and Ireland, most likely reflecting increased referral to the pulmonary 
hypertension centres. Patients were still referred late with severe functional and 
haemodynamic impairment. Greater education is needed to raise awareness 
amongst the non-pulmonary hypertension community of the changing 
epidemiology of the disease. 
 
We have used our incident study cohort of idiopathic, heritable and anorexigen-
associated PAH to validate currently available survival prediction models in PAH. 
Our results suggested that some survival prediction models performed better 
than others.  
 
We observed different phenotypic characteristics and survival between younger 
and older idiopathic, heritable and anorexigen-associated PAH patients. Baseline 
variables with prognostic significance were also different between younger and 
older idiopathic, heritable and anorexigen-associated PAH patients. 
Interestingly, obesity was associated with better survival in older patients but 
the contrary in younger patients. 
 
We also explored the prognostic significance of short term improvement in six 
minute walk distance and functional class in response to treatment in incident 
idiopathic, heritable and anorexigen-associated PAH. Change in six minute walk 
distance after three months of pulmonary hypertension treatment was 
associated with improved survival in patients with low baseline six minute walk 
distance. Change in functional class at six months was also predictive of survival 
in our idiopathic, heritable and anorexigen-associated PAH patients.  
 
Finally, we observed that pre-capillary pulmonary hypertension with co-existing 
lung disease patients who otherwise satisfied the usual haemodynamic and 
pulmonary function criteria for idiopathic PAH had significantly different 
demographics and worse survival compared with idiopathic PAH patients. Better 
characterisation of this subgroup of PH patients will avoid bias from inclusion of 
these patients as idiopathic PAH in future clinical trials.   
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1 Chapter 1: Introduction 
 
1.1 The Normal Pulmonary Circulation 
 
The normal adult pulmonary vascular bed is a low pressure, low vascular 
resistance, highly distensible system capable of accommodating large increases 
in blood flow with minimal elevation in pulmonary artery pressure. The most 
important factors influencing pulmonary artery pressure are the hydrostatic 
pressure, intra-alveolar pressure, left atrial pressure and the alveolar gas. 
Normally, sixty percent of the resistance of the pulmonary circulation is in the 
arterial component; the capillaries and venous system account for the remaining 
forty percent (1). Systemic circulation, in contrast, is a high pressure system. As 
a result the left ventricle is larger and more muscular than the right. 
 
Kovacs et al (2) reviewed published right heart catheterisation studies data on 
1187 healthy individuals from forty seven studies in thirteen countries and 
concluded that normal mean pulmonary artery pressure (mPAP) at rest is 14 ± 3 
mmHg and is independent of sex and ethnicity. Using the customary approach to 
define the upper limit of normal as mean plus two standard deviations, the 
upper limit of normal for mPAP is around 20 mmHg. The significance of mPAP at 
rest between 21 to 24 mmHg is currently unclear. At rest, there are negligible 
differences in mPAP between the different age groups. In contrast, mPAP during 
exercise is largely age-dependent, presumably as a result of increasing stiffness 
of the left ventricle and the pulmonary vessels (3).  During mild exercise, mPAP 
is 19 ± 5 mmHg in subjects aged < 50 years compared with mPAP 29 ± 8 mmHg in 
subjects ≥ 50 years (2).  
 
1.2 Definition of Pulmonary Hypertension 
 
Pulmonary arterial hypertension is characterised by chronically elevated 
pulmonary artery pressure and pulmonary vascular resistance, leading to right 
ventricular failure and ultimately death. Pulmonary Hypertension is defined as 
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mPAP ≥ 25 mmHg at rest as assessed by right heart catheterisation (Table 1.1). 
This value was used for selecting patients in randomised controlled trials and 
registries of pulmonary arterial hypertension. Exercise and pulmonary vascular 
resistance criteria were removed from the latest definition of pulmonary 
hypertension (4).  
 
Pulmonary hypertension can be found in multiple clinical conditions. The 
subgroup of pulmonary hypertension known as pulmonary arterial hypertension 
(WHO Group 1) is a clinical condition characterised haemodynamically by the 
presence of pre-capillary pulmonary hypertension in the absence of other causes 
of pre-capillary pulmonary hypertension (5). Current guidelines recommend 
using pulmonary artery occlusion pressure (PAOP) or left ventricular end-
diastolic pressure ≤ 15 mmHg to define pre-capillary PH (4, 5) . A normal PAOP 
does not however rule out the presence of heart failure with preserved ejection 
fraction. Exercise or fluid challenge during right heart catheterisation may help 
to unmask the presence of left heart disease but lack standardisation and is not 
currently use routinely in the diagnostic work-up of patients. A comprehensive 
assessment taking into account past medical history, risk factors, 
echocardiographic and cardiac MRI parameters will provide a more reliable 
diagnosis of pulmonary arterial hypertension than a single PAOP measurement.  
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Table 1.1. Haemodynamic definitions of pulmonary hypertension (5). 
 
Definition Characteristics Clinical Group as per 
Dana Point 
Classification 
Pulmonary Hypertension mPAP ≥ 25 mmHg All 
Pre-capillary PH mPAP ≥ 25 mmHg 
PCWP ≤ 15 mmHg 
CO normal or reduced 
1. Pulmonary arterial 
hypertension 
3. PH due to lung 
diseases 
4. Chronic 
thromboembolic PH 
5. PH with unclear 
and/or multifactorial 
mechanism 
Post –capillary PH 
 
 
 
Passive 
Reactive (out of 
proportion) 
mPAP ≥ 25 mmHg 
PCWP > 15 mmHg 
CO normal or reduced 
 
TPG ≤ 12 mmHg 
TPG > 12 mmHg 
2. PH due to left heart 
disease 
Definition of abbreviations: CO = cardiac output, mPAP = mean pulmonary artery pressure, PCWP 
= pulmonary capillary wedge pressure, PH = pulmonary hypertension, TPG = transpulmonary 
gradient. 
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1.3 Classification of Pulmonary Hypertension 
 
The initial classification of pulmonary hypertension, proposed at the 1st World 
Symposium on pulmonary hypertension in Geneva (1973) designated only two 
categories: primary pulmonary hypertension when no underlying cause for 
pulmonary hypertension could be identified, and secondary pulmonary 
hypertension when an underlying cause or risk factor did exist (6). This WHO-
sponsored conference was triggered by the previous epidemic of pulmonary 
hypertension associated with aminorex. Since then, the clinical classification of 
pulmonary hypertension has gone through a series of changes. At the second 
World Symposium on pulmonary hypertension held in Evian, France (1998), 
clinical conditions with pulmonary hypertension were classified into five groups 
(‘Evian classification’) based on shared pathophysiology, clinical features and 
treatment characteristics (7). This was further refined at the third World 
Symposium held in Venice, Italy in 2003 (8). At this meeting, the term idiopathic 
PAH was substituted for primary pulmonary hypertension, new associations with 
other rare conditions were recognised and the conditions of pulmonary veno-
occlusive disease and pulmonary capillary haemangiomatosis were classified 
under PAH.  
 
The fourth World Symposium on pulmonary hypertension took place in Dana 
Point, California 2008 (4). Familial PAH was replaced with heritable PAH, which 
included idiopathic PAH with germline mutations and familial cases with or 
without identified germline mutations. This new category of heritable PAH does 
not mandate genetic testing in patients with idiopathic PAH or in familial cases 
of PAH because this would not change the clinical management. Schistosomiasis 
and chronic haemolytic anaemia associated pulmonary hypertension were 
included among the ‘associated PAH’ category. Congenital heart disease causing 
PAH was updated to include a clinical and anatomical-pathophysiological 
version. Pulmonary veno-occlusive disease and pulmonary capillary 
haemangiomatosis were felt to be distinct but not completely separable from 
the other subgroups of PAH and was therefore designated as clinical group 1’. No 
substantial changes were made to the other groups of pulmonary hypertension. 
24 
 
The Dana Point clinical classification of pulmonary hypertension is summarised in 
Table 1.2. 
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Table 1.2. Clinical classification of pulmonary hypertension (Dana Point 
classification 2008). 
 
1. Pulmonary arterial hypertension (PAH) 
1.1 Idiopathic 
1.2 Heritable 
1.2.1 BMPR2 
1.2.2 ALK1, endoglin (with or without hereditary haemorrhagic 
telangiectasia) 
1.2.3 Unknown 
1.3 Drugs and toxins induced 
1.4 Associated with PAH 
1.4.1 Connective tissue disease 
1.4.2 HIV infection 
1.4.3 Portal hypertension 
1.4.4 Congenital heart disease 
1.4.5 Schistosomiasis 
1.4.6 Chronic haemolytic anaemia 
1.5 Persistent pulmonary hypertension of the newborn 
1’. Pulmonary veno-occlusive disease and/or pulmonary capillary 
haemangiomatosis 
2. Pulmonary hypertension due to left heart disease 
2.1 Systolic dysfunction 
2.2 Diastolic dysfunction 
2.3 Valvular disease 
3. Pulmonary hypertension due to lung disease and/or hypoxaemia 
3.1 Chronic obstructive pulmonary disease 
3.2 Interstitial lung disease 
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 
3.4 Sleep-disordered breathing 
3.5 Alveolar hypoventilation 
3.6 Chronic exposure to high altitudes 
3.7 Developmental abnormalities 
4. Chronic thromboembolic  pulmonary hypertension 
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5. Pulmonary hypertension with unclear and/or multifactorial mechanisms 
5.1 Haematological disorders: myeloproliferative disorders, splenectomy 
5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis, 
lymphangioleiomyomatosis, neurofibromatosis, vasculitis 
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid 
disorders 
5.4 Others: tumour obstruction, fibrosing mediastinitis, chronic renal failure 
on dialysis 
Definition of abbreviations: ALK-1 = activin receptor-like kinase 1 gene, BMPR2 = bone 
morphogenetic protein receptor type 2, HIV = human immunodeficiency virus, PAH = pulmonary 
arterial hypertension. 
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1.4 Pathology and Pathobiology of Pulmonary Arterial 
Hypertension 
 
Pathological lesions in PAH affect the distal muscular pulmonary arteries (< 
500μm of diameter). Pulmonary veins, capillaries, bronchial circulation, airways 
and the systemic vasculature are classically unaffected. Regardless of the 
underlying aetiology, all forms of PAH share the same spectrum of 
histopathological lesions characterised by medial hypertrophy, intimal 
proliferation, fibrotic changes (concentric and/or eccentric) and adventitial 
thickening with moderate perivascular inflammatory infiltrates. In advanced 
stages of pulmonary hypertension, cells originating from within the vessel wall 
(smooth muscle cells, endothelial cells and fibroblast) assemble in a ‘plexiform’ 
(9). These ‘plexiform’ lesions are often located downstream from the occluded 
arteries and express transcription and growth factors typically seen in 
angiogenesis. These angioproliferative ‘plexiform’ lesions are not found in other 
pulmonary hypertension categories.  
 
Excessive vasoconstriction has been related to abnormal function or expression 
of potassium channels in the smooth muscle cells and to endothelial dysfunction. 
Endothelial dysfunction leads to chronically impaired production of vasodilator 
and antiproliferative substances such as thromboxane A2 and endothelin-1. 
Complex molecular and cellular abnormalities result in vascular remodelling in 
which fibroblasts, smooth muscle cells, endothelial cells, inflammatory 
infiltrates (macrophages, lymphocytes and dendritic cells) and platelets all 
appear to play a role in PAH through a combination of migration, hypertrophy 
and proliferation (5, 10, 11). In the adventitia, there is increased production of 
extracellular matrix including collagen, elastin, fibronectin and tenascin. 
Prothrombotic abnormalities have been demonstrated in PAH patients and 
thrombi are present in both the distal pulmonary arteries and the proximal 
elastic pulmonary arteries. Together with the associated vasoconstriction and 
development of in-situ thrombosis, this proliferative and obstructive remodelling 
of pulmonary blood vessels lead to reduced capacity for vasodilatation and a 
decrease in cross sectional area of the pulmonary vascular bed. The progressive 
increase in pulmonary vascular resistance leads to increase in pulmonary artery 
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pressure, reduced exercise tolerance, right heart failure and in many advanced 
cases, premature death. 
 
1.5 Pathophysiology of Pulmonary Arterial Hypertension 
 
As described in the earlier section, the normal pulmonary circulation is a low 
pressure system with little or no resting vascular tone. Any increase in mean 
pulmonary artery pressure can be passive (due to increase in downstream 
pressure), hyperkinetic (due to increase in cardiac output through the lungs) or 
due to increase in pulmonary vascular resistance. Increase in pulmonary vascular 
resistance (PVR) occurred following reduction in the cross sectional area of 
proximal (mainly capacitive) and /or distal (mainly resistive) pulmonary 
arterioles. According to the Poiseuille’s law, PVR is inversely related to the 
fourth power of the radius. PVR is therefore sensitive to small changes in the 
calibre radius. Increases in PVR may be fixed or potentially reversible. Arterial 
obstruction, obliteration and remodelling are responsible for the fixed 
component. Vasoconstriction, the reversible component is likely to be prevalent 
in a small group of patients responding to acute vasoreactivity test.  
 
Poiseuille’s law: Resistance = ∆P/Q = 8lŋ/πr4 
where  
P = pressure drop 
Q = Flow 
l = length 
ŋ = viscosity constant 
r = internal radius 
 
PVR = (mPAP – downstream pressure)/cardiac output 
where 
PVR = pulmonary vascular resistance, measured in Wood Units 
mPAP = mean pulmonary arterial pressure 
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1.6 Genetics of Pulmonary Arterial Hypertension 
 
Dresdale reported on cases of primary pulmonary hypertension from three 
members of the same family in 1954 and recognised that there may be a genetic 
component to PAH (12). Since then, significant advances have been achieved in 
understanding the genetic aspects of PAH. In 2000, the DNA sequence variations 
of the bone morphogenetic protein type II receptor (BMPR2) gene were reported 
by two separate groups of investigators (13, 14) . Heterozygous germline 
mutations in the BMPR2, a receptor from the transforming growth factor ß (TGF-
ß) superfamily were detected in 70% - 80% of familial cases of PAH, and in up to 
20% of sporadic cases (15, 16). TGF-ß superfamily comprises a large series of 
cytokine growth factors that control a host of cellular functions, amongst them, 
proliferation, migration, differentiation, apoptosis and extracellular matrix 
secretion and deposition (15).  
 
Germline BMPR2 mutation is inherited as an autosomal dominant trait with 
incomplete penetrance, with multiple unaffected generations in a family 
pedigree (17). Only ~20% of BMPR2 mutation carriers will develop PAH, 
suggesting a ‘second hit’, either genetic or environmental, may be required to 
cause disease (11).  
 
Genetic anticipation has also been reported in heritable PAH, where the disease 
occurs at earlier and earlier ages in subsequent generations (17). The usual 
mechanisms for genetic anticipation, namely trinucleotide repeat expansion and 
progressive telomere shortening have however failed to explain the apparent 
genetic anticipation in families with PAH. An alternative explanation is 
statistical artefact, where family members are diagnosed earlier and at a 
younger age through progressive improvement in clinical and genetic screening.  
 
BMPR2 mutation carriers with PAH present approximately 10 years earlier than 
non-carriers, with more severe haemodynamic compromise at diagnosis but 
similar overall survival (16). BMPR2 mutation carriers are also less likely to 
demonstrate acute vasoreactivity in response to short-acting vasodilator such as 
inhaled nitric oxide (15, 18).  
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In addition to BMPR2 mutation, several other genotypes have been associated 
with the occurrence of PAH. Mutations in the two genes that cause Hereditary 
Haemorrhagic Telangiectasia (activin A receptor type II like kinase-1 [ACVRL1, 
also known as ALK1] and the endoglin gene) have both been reported to lead to 
heritable PAH (5, 19). Compared with other patients with PAH, ACVRL1 mutation 
carriers are younger at diagnosis (even younger than BMPR2 carriers), with less 
severe haemodynamics compromise but more rapid disease progression (20). 
 
1.7 Idiopathic, Heritable and Anorexigen-associated  Pulmonary 
Arterial Hypertension 
 
Definition  
 
Idiopathic PAH corresponds to sporadic disease in which there is neither a family 
history nor an identified risk factors for PAH (8). Heritable PAH includes sporadic 
idiopathic PAH with germline mutations and clinically familial cases with or 
without identified germline mutations (8). A number of drugs and toxins have 
been identified as risk factors for PAH (Table 1.3). Amongst these drugs, 
aminorex, fenfluramine, dexfenfluramine and benfluorex are definite risk 
factors for PAH. Patients with idiopathic, heritable and anorexigens-associated 
PAH shared similar clinical, functional and haemodynamic characteristics and 
overall survival (21) and are often studied together as a group (22, 23). 
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Table 1.3. Risk level of drugs and toxins known to induce PAH (5).  
 
Definite Possible 
Aminorex Cocaine 
Fenfluramine Phenylpropanolamine 
Dexfenfluramine St John's Wort 
Benfluorex Chemotherapeutic agents 
Toxic rapeseed oil Selective serotonin reuptake inhibitors 
Pergolide 
Likely Unlikely 
Amphetamines Oral contraceptives 
L-tryptophan Oestrogens 
Methamphetamines Cigarette smoking 
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1.8 Pulmonary Hypertension Registries and Epidemiology of 
Idiopathic, Heritable and Anorexigen-associated Pulmonary 
Arterial Hypertension 
 
Disease registries describe the population characteristics (phenotypes and 
genotypes), disease frequencies (incidence and prevalence), outcomes 
(mortality and morbidity) and risk factors for that outcomes (24). In rare 
diseases like PAH, registries allow comparison of characteristics and outcomes in 
different patients population over time. Data from registries can also be used to 
predict outcomes of patients, generate hypotheses and develop prognostic 
equations. A number of pulmonary hypertension registries have existed over the 
past few decades. These registries differ in patient population and size, study 
design, period (before or after the availability of modern disease targeted 
therapies), duration of recruitment and geographical sites.  
 
The NIH registry: 
 
Information from the Division of Lung Disease of the National Heart, Lung, and 
Blood Institute (NHLBI), National Institutes of Health registry on primary 
pulmonary hypertension (the Patient Registry for the Characterisation of Primary 
Pulmonary Hypertension, commonly referred to simply as the NIH registry) 
provided comprehensive data on the natural history of primary pulmonary 
hypertension. Primary pulmonary hypertension referred to patients now 
classified as idiopathic, heritable and anorexigen-associated PAH according to 
the latest updated Dana Point classification system (Table 1.2). The NIH registry 
was a multicentre, prospective registry where 194 patients from thirty two 
medical centres in the United States with the diagnosis of primary pulmonary 
hypertension were enrolled from between 1st July 1981 and 30th Sept 1985 and 
followed through to 8th August 1988 (25, 26). Baseline demographics, clinical 
characteristics, haemodynamics parameters and survival were reported for 
primary pulmonary hypertension in an era before the availability of pulmonary 
hypertension disease targeted therapies.  
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In the NIH registry, pulmonary hypertension was defined as mPAP > 25 mmHg at 
rest or >30mmHg with exercise at right heart catheterisation. Pulmonary 
capillary wedge pressure in excess of 12mmHg was considered as pulmonary 
venous hypertension and was excluded from the NIH registry.  
 
The mean age of the NIH cohort was 36.4 years, with female to male ratio of 
1.7:1. Female to male preponderance was much higher in the black population 
(4.3:1). Nine percent of the patients were diagnosed at the age of 60 or later. 
The incidence of familial cases in the NIH registry was 6.4%, with no distinctive 
features except shorter intervals from the onset of symptoms to diagnosis. 5% of 
patients in the NIH registry had histories of appetite suppressant drug use. The 
mean interval from onset of symptoms to diagnosis was 2.0 years (median 1.3 
years) with a median survival of 2.8 years after diagnosis. Patients in the NIH 
registry had severe pulmonary hypertension with mPAP of 60mmHg, cardiac 
index of 2.3 L.min-1.m-2 and pulmonary vascular resistance index of 26 WU.m-2.  
Estimated 1, 3 and 5 year survival rates were 68%, 48% and 34% respectively. 36% 
of patients in the NIH registry were ‘prevalent’ cases who had their diagnosis of 
primary pulmonary hypertension made prior to the establishment of the registry. 
Newly diagnosed (‘incident’) patients in the NIH registry also had a shorter 
survival compared with ‘prevalent’ patients (median survival of 2.6 years vs. 3.2 
years) although the result was not statistically significant.  
 
Variables associated with poor survival in the NIH registry included New York 
Heart Association functional class of III or IV, presence of Raynaud’s 
phenomenon, elevated mean right atrial pressure, elevated mean pulmonary 
artery pressure, decreased cardiac index and decreased diffusion capacity for 
carbon monoxide (DLCO). Gender was not associated with survival in the NIH 
registry. Data from the NIH registry was used to develop a prognostic equation 
(commonly referred as the NIH equation) that estimates the probability of 
survival of primary pulmonary hypertension over a three year period (26).  
 
International Primary Pulmonary Hypertension Study: 
 
The NIH registry was followed by the International Primary Pulmonary 
Hypertension Study which recruited 95 newly diagnosed primary pulmonary 
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hypertension patients aged between 18 to 70 years from two hundred and 
twenty centres in the United Kingdom, France, Belgium and Netherlands 
between 1st September 1992 and 30th September 1994 (27). This was a 
prospective case-control study designed to explore the relationship between 
various risk factors, especially anorexigens and primary pulmonary hypertension. 
The mean age of primary pulmonary hypertension patients were 44.7 years with 
female: male ratio of 2.3:1. This study confirmed the strong association between 
primary pulmonary hypertension and the use of appetite suppressants, primarily 
the fenfluramine derivatives. In nearly two third of patients, the diagnosis was 
not established until more than a year after the onset of symptoms. This registry 
also provided the first estimates of incidence of idiopathic PAH (1.7 cases per 
million population per year in Belgium). 
 
The Swiss Registries: 
 
The first Swiss registry was a retrospective analysis of 106 pulmonary 
hypertension patients diagnosed in Switzerland from 1991 to 1999 (28). Disease 
subtypes other than idiopathic PAH were included (primary pulmonary 
hypertension 37%, venous thromboembolism 15%, collagen vascular disease 22%, 
congenital heart disease 4% and HIV/anorexigens/portal hypertension 22%). In 
that study, a significant minority (16%) had no right heart catheterisation and 
prostacyclin was the only disease targeted therapy available.  
 
This was followed by a prospective Swiss registry from January 1999 to 
December 2004 where a total of 250 patients with pulmonary hypertension 
(defined as mPAP of >25mmHg at rest or >30mmHg on exercise) were followed 
up for median of 18.8 months (29). Other subtypes of PAH were included, with 
idiopathic and familial PAH comprising 28% (n=70) of the whole cohort. 10% of all 
patients were lost to follow up and a significant number (28%) were diagnosed 
without right heart catheterisation in the later Swiss Registry. In the later Swiss 
registry, patients were also older compared with the earlier Swiss registry. 
Further subgroup analysis of idiopathic PAH in the later Swiss registry found 64% 
of idiopathic PAH being female, 66% were over age 50 years old and 90% 
presented late in functional class III and IV. Estimated incidence of idiopathic 
PAH in Switzerland was 0.8 patients per million adult in 1999 and 1.2 per million 
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in 2004. The estimated prevalence of idiopathic PAH in Switzerland in 2004 was 
8.6 per million adult inhabitants. 
 
The Chinese Registries: 
 
Information on pulmonary hypertension in the developing countries is relatively 
sparse. The first Chinese registry reported on outcomes of 72 patients with 
idiopathic or familial PAH who were followed at two institutions in China from 
January 1999 to Oct 2004 (30). PAH was defined as mPAP>25 mmHg at rest by 
right heart catheterisation or systolic pulmonary arterial pressure >40 mmHg by 
echocardiography. Only 28% (n=20) of patients had their initial diagnosis 
confirmed by right heart catheterisation and a similar number of patients were 
lost to follow up. The mean age was 35.9 years with female: male ratio of 2.4:1. 
Mean duration of symptoms to diagnosis was 2.2 years. Only conventional 
treatment such as calcium channel blockers, diuretics, digoxin and 
anticoagulation were available during the study period. Not surprisingly, the 
survival data from this study (1 year survival of 68.0% and 3 year survival of 
38.9% in idiopathic and heritable PAH) was worse compared to other more 
recent registries but comparable to the NIH data.  
 
After 2006, several types of PAH targeted therapies, including bosentan, 
sildenafil and epoprostenol became available in China. Data on demographics, 
haemodynamic characteristics and survival of idiopathic PAH in the modern 
treatment era in China was recently updated in a retrospective observational 
study (31). In this second later Chinese registry, PAH was defined as mPAP ≥ 25 
mmHg at rest or ≥ 30 mmHg on exercise, pulmonary capillary wedge pressure ≤ 
15 mmHg and PVR > 3 WU.  173 incident idiopathic PAH patients were diagnosed 
between 2007 and 2009 at five national referral pulmonary vascular centres in 
China. Patients had severe haemodynamic impairment (mPAP 63 mmHg, cardiac 
index 2.5 L.min-1, PVR 17 Wood units) and presented late after mean delay of 
3.4 years after onset of symptoms. In contrast to contemporary pulmonary 
hypertension registries from Europe and United States where the average age of 
patients was around 50 years old (32-35), Chinese idiopathic PAH patients in this 
second later Chinese registry were much younger, with mean age of 33.4 years. 
The age discrepancy for Chinese patients compared with contemporary European 
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and United States data may be partly explained by referral bias. Symptoms of 
older Chinese patients may be attributed to other co-morbid conditions and 
therefore less likely to be referred for suspicion of PAH. Healthcare coverage are 
uneven or inadequate and the tremendous cost of PAH targeted therapies posed 
a significant economic burden to many Chinese patients. Majority of patients 
were treated with a phosphodiesterase type 5 inhibitor (31.2% received 
sildenafil, 30.0% vardenafil; 17.3% bosentan and 0.2% iloprost). Despite these 
challenges, Zhang et al reported a significant improvement in survival of 
patients in the later Chinese registry compared with the earlier 2007 Chinese 
registry (31). In the modern treatment era, 1- and 3- year survival estimates of 
idiopathic PAH in China had improved to 92.1% and 75.1% respectively.  
 
Multivariate analysis of the whole cohort in the second later Chinese registry 
(173 idiopathic PAH and 103 connective tissue-associated-PAH[CTD-PAH] found 
the diagnosis of CTD-PAH, WHO functional class III and IV, DLCO < 80% predicted 
and the presence of pericardial effusion to be independent predictor of survival. 
Age, gender, six minute walk distance and mPAP were not predictive of survival 
in multivariate analysis.  
 
The Israeli Registry: 
 
A small registry was reported from Israel on primary pulmonary hypertension 
diagnosed between the years 1988-1997 (36). The study was retrospective and 
numbers were small (44 patients in total), reflecting the rarity of the condition. 
The mean age was 42.8 years with female: male ratio of 3.4:1. The treatment 
received was mostly vasodilator (mostly nifedipine) and only 6 patients (13%) 
received prostacyclins and 3 received transplantation. Median survival time was 
4 years with 1, 3 and 5 year survival rates of 82%, 57% and 43% respectively. 
Duration of symptoms and haemodynamic variables (mean pulmonary artery 
pressure, right atrial pressure and cardiac index) were associated with survival 
whereas gender and age at diagnosis were not. The estimated incidence and 
prevalence of idiopathic PAH in Israel were 1.4 and 8 patients per million 
population respectively. 
 
The Scottish Registry: 
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The Scottish registry reported on the epidemiological features of PAH in 
Scotland, using hospitalisation data from the Scottish Morbidity Record (SMR) 
scheme (1986 to 2001) and separate data from the Scottish Pulmonary Vascular 
Unit (SPVU) to provide estimations of incidence and prevalence (32). The study 
was retrospective in design. Prevalence estimates of PAH was higher from the 
SMR data. The hospitalisation data from the SMR may over-estimate the disease 
prevalence as data from the SMR scheme relied on accurate coding of hospital 
admissions and the assumption of recorded diagnoses being accurate. Based on 
the SPVU data, estimated incidence and prevalence of idiopathic PAH in the 
Scottish population were 2.6 and 9 cases per million in 2005. Despite similar 
inclusion and exclusion criteria, estimates of incidence and prevalence of PAH 
and idiopathic PAH from the Scottish registry were higher compared with 
estimates from all other registries.  
 
The French Registry: 
 
In the early 2000s, the French Network on Pulmonary Hypertension registry 
(commonly referred as the French registry) was established (33). This was the 
first major multicentre registry of pulmonary hypertension since the availability 
of pulmonary hypertension disease targeted therapies. PAH was defined as mPAP 
> 25 mmHg at rest and pulmonary capillary wedge pressure < 15 mmHg at right 
heart catheterisation. Patients with severe pulmonary function abnormalities 
(defined as % predicted FEV1, % predicted FVC or % predicted total lung capacity 
<60%) were excluded from the French registry.  
 
A total of 674 cases of PAH presented at seventeen University pulmonary 
vascular centres in France between October 2002 and October 2003 were 
prospectively enrolled and followed up for three years. Delay between onset of 
symptoms and diagnosis for the whole PAH cohort was 2.3 years. 39% of the 
French registry were idiopathic, heritable and anorexigen-associated PAH 
(n=354) with the rest comprising of connective tissue disease associated PAH 
(15.3%), congenital heart disease PAH (11.3%), portopulmonary hypertension 
(10.4%), HIV associated PAH (6.2%) and two co-existing risk factors (4.3%). The 
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mean age of idiopathic PAH was 52 years, with 62% female and 81% presenting 
late in NYHA class III and IV.  
 
The French registry included patients who were newly diagnosed during the 
recruitment phase of the registry (incident cases, 18%) as well as patients with 
established diagnosis of PAH before enrolment in the registry (prevalent cases, 
82%). Not all patients with pulmonary hypertension in France may be included as 
some patients may have good response to oral treatment outside the study 
centres and were never referred. There was a wide variation of prevalence, with 
the highest prevalence seen in Paris (the region with the best known and largest 
pulmonary hypertension centre). In fact, 64% of all cases in the French registry 
come from one Paris Centre alone, suggesting an element of selection bias.  The 
prevalence of idiopathic PAH was estimated at 5.9 cases per million population.  
 
Recently, combined 3 year follow-up data on idiopathic, heritable and 
anorexigen-associated PAH from the same cohort was reported. There was clear 
distinction between incident and prevalent idiopathic, heritable and anorexigen-
associated PAH patient, with incident patients displaying worse overall survival 
(37). In prevalent idiopathic, familial and anorexigen-associated PAH, 1-, 2- and 
3-year survival rates were 89%, 77% and 69%. In incident patients, 1-, 2- and 3-
year survival rates were 89%, 68% and 55% respectively. Moreover, within the 
prevalent population, patients in whom the diagnosis of PAH were most recently 
made had worse survival when compared with those with longer duration of 
disease prior to inclusion in the study (37).  
 
The survival of idiopathic, heritable and anorexigen-associated PAH in the 
French registry was lower compared with the survival from other pulmonary 
hypertension registries in the disease targeted therapy era.  This may be partly 
explained by the availability of treatment in France during the duration of the 
French registry. Bosentan became available only around late 2002, inhaled 
iloprost around late 2003/early 2004 and sildenafil around late 2005/early 2006 
in France.  
 
Multivariate analysis showed female gender, greater 6MWD and higher cardiac 
output were associated with better survival in idiopathic, heritable and 
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anorexigen-associated PAH (22). Outcome data from 56 incident patients and 
134 prevalent patients with idiopathic, heritable and anorexigen-associated PAH 
who were diagnosed < 3 years prior to enrolment to the French registry were 
combined to develop a survival prediction equation (commonly referred as the 
French equation) (37).  
 
The Pulmonary Hypertension Connection Registry: 
 
The Pulmonary Hypertension Connection (PHC) registry was initiated in 2004 in 
Chicago, United States and comprised of 578 patients with group I PAH from 
1982 to 2006 (23, 34). Patients were entered retrospectively from 1982 to 2004 
and prospectively thereafter. There are a few limitations to that registry. It was 
based on patients referred to the authors’ practice at a single tertiary centre. It 
was largely an observational, retrospective study and standardised diagnostic 
procedures were not followed (eg use of exercise threadmill testing instead of 
six minute walk test), making comparisons with other registries difficult and may 
not reflect routine clinical practice.  
 
Baseline right heart catheterisation data was available in 90% of patients. Only 
14% of the whole study cohort was incident cases (defined in that study as 
patients diagnosed between 2004 and 2006). Idiopathic and heritable PAH made 
up 49.0% (n=282) of all cases (23). Patients were older compared with the NIH 
registry (mean age of idiopathic, heritable and anorexigen-associated PAH in the 
PHC registry was 46 years vs 36 years in the NIH registry). Data from the PHC 
registry also suggested PAH can occur at a relatively later age, with 8.5% of all 
PAH patients diagnosed after 70 years of age (individual results for idiopathic, 
heritable and anorexigen-associated PAH were not reported). Female: male ratio 
of idiopathic, heritable and anorexigen-associated PAH was 3:1 in the PHC 
registry. The female preponderance of idiopathic, heritable and anorexigen-
associated PAH was much higher in the PHC registry compared with the NIH (25) 
(female: male ratio 1.7:1), the Scottish (32) (female: male ratio 1.7:1) and the 
French (22) (female: male ratio 1.5:1) registries. 1-, 3- and 5- year survival of 
idiopathic, heritable and anorexigen-associated PAH from the PHC registry were 
91%, 75% and 65% respectively (23). Patients diagnosed after 2002 exhibited 
better survival than those diagnosed before 2002. Age, functional class, mean 
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right atrial pressure and cardiac index were independent predictors of survival in 
idiopathic, heritable and anorexigen-associated PAH. Survival data from the 
idiopathic, heritable and anorexigen-associated PAH subgroup was used to 
develop a new survival prediction equation (commonly referred as the 
Pulmonary Hypertension Connection equation) (23). 
 
The REVEAL registry: 
 
The Registry to Evaluate Early and Long-term PAH Disease Management 
(commonly referred as the REVEAL registry) is the largest to date on-going 
registry in the United States on PAH (35, 38). Group 1 PAH patients were 
enrolled from fifty four centres in the United States between March 2006 and 
December 2009, with follow-up planned until 2014.  Diagnosis was assigned by 
the investigators enrolling subjects into the registry, based upon their 
impression of the most likely cause of a patient’s PAH. Patients were classified 
as newly diagnosed (incident cases) PAH in the REVEAL registry if the diagnostic 
right heart catheterisation occurred within the previous 90 days.  
 
PAH was defined as mPAP > 25 mmHg at rest or > 30 mmHg with exercise, 
pulmonary capillary wedge pressure < 15 mmHg and pulmonary vascular 
resistance > 3 Wood Units. The REVEAL registry also included an expanded 
criteria for patients with pulmonary capillary wedge pressure of 16-18 mmHg.  
 
The mean time from onset of symptoms to diagnostic right heart catheterisation 
amongst patients who met traditional haemodynamic criteria for PAH (n=2525) 
were 34.1 months (median 13.6 months). Amongst the 1166 patients with 
idiopathic PAH, only 15% were incident patients. Mean age of idiopathic PAH at 
diagnosis in the REVEAL registry was 50 years. This was older compared with the 
NIH registry but comparable to the more recent cohorts of idiopathic PAH from 
the French, Scottish and PHC registries.  Female: male ratio of idiopathic PAH 
was 4.1:1 in the REVEAL registry. This female preponderance was even more 
marked amongst the blacks (female: male ratio of 5.2:1) and Hispanic (female: 
male ratio of 5.6:1) idiopathic PAH populations in the REVEAL registry (38). The 
greater female preponderance in the REVEAL registry is not fully understood. It 
may be partly due to its large prevalent population. Female: male ratio in the 
41 
 
REVEAL registry increases with survival post diagnosis, with 3.3:1 within a year 
of diagnosis to 4.3: 1 at > 5 years after diagnosis.  
 
Idiopathic PAH in the REVEAL registry also have multiple co-morbidities including 
hypertension (42%), obesity (38%), sleep apnoea (27%), obstructive airway 
disease (23%), thyroid disease (20%), diabetes (14%) and ischaemic 
cardiovascular event (10%) (35). Interestingly, nearly 10% of idiopathic PAH in 
the REVEAL registry also had an associated connective tissue or collagen vascular 
disease. Despite older age at diagnosis and higher female preponderance, 
haemodynamic parameters at the time of diagnostic right heart catheterisation 
in the REVEAL registry have not changed substantially compared with patients 
from the NIH era (38). 1-, 3- and 5-year survival rates of idiopathic and heritable 
PAH patients in the REVEAL registry were 91%, 74% and 65% respectively (39).  
 
Based on data from the REVEAL registry, the low estimate for incidence of 
idiopathic and familial PAH in the United States was 1.1 cases per million. The 
true incidence of PAH is likely to be higher as patients seen outside pulmonary 
hypertension centres or seen in centres not participating in the REVEAL registry 
were not included.  
 
Data from group 1 PAH in the REVEAL registry was also used to derive a new 
survival equation (commonly referred as the REVEAL equation) and a simplified 
survival score (commonly referred as the REVEAL risk score).  
 
The Spanish Registry: 
 
The recently published Spanish REHAP (Spanish Registry of Pulmonary Arterial 
Hypertension) registry provided further insights into the epidemiology of PAH 
(40). A total of 866 PAH and 162 chronic thromboembolic pulmonary 
hypertension patients evaluated in thirty one Spanish hospitals between 1998 
and 2008 were included. 30% of patients in the REHAP registry (n=314) were 
idiopathic PAH. Three centres contributed 61% of patients in this registry. 
Patients diagnosed in the period 1998 – 2006 were entered retrospectively and 
prospectively thereafter. Patients were classified as newly diagnosed (incident) 
if the diagnostic right heart catheterisation took place between July 2007 and 
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June 2008. 16.2% of all cases were incident patients. Patients were also 
diagnosed late in the course of their disease, with delay of 2.2 years after onset 
of symptoms in incident PAH patients. In the idiopathic PAH population, 
observed survival was 89% at 1 year and 77% at 3 year. Male gender, functional 
class, mean right atrial pressure and cardiac index were independent predictors 
of survival in PAH. Estimated incidence and prevalence of idiopathic PAH in 
Spain were 1.2 and 5.6 per million population. The applicability of the NIH 
equation, French equation, PHC equation and REVEAL equation were also tested 
in this study. Observed survival of this Spanish cohort was similar to survival 
predicted from the PHC equation. The French equation slightly underestimated 
survival whereas the REVEAL equation over-estimated survival of the Spanish 
cohort.  
 
 
Each pulmonary hypertension registry was defined by its unique strengths and 
weaknesses. The NIH registry was a landmark accomplishment, but the data may 
no longer be applicable to real life patients seen in current day to day practice. 
A few of the smaller registries were set up from the late 1980s to the early 20th 
century had small patient numbers and were done in an era where current 
disease targeted therapy were not readily available or affordable to the 
patients. Direct comparison of baseline demographics and characteristics of 
patients from different registries was also complicated by the changing 
definition of PAH. Inclusion of prevalent subjects in many registries may lead to 
underestimation of mortality. Very few pulmonary hypertension registries were 
truly national studies, inclusive of all pulmonary hypertension patients within a 
single country or region. This may potentially introduce further selection bias 
and underestimate incidence and prevalence of the disease.  
 
To summarize, results from pulmonary hypertension registries to date suggest 
idiopathic PAH is increasingly been recognised and diagnosed in older 
population. This may be the result of more elderly patients been referred as 
better modern treatments are now available and increased awareness of PAH as 
a potential contributing cause of elderly patients’ symptoms. However, striking 
differences in certain baseline demographic characteristics were observed 
between the NIH, REVEAL, French and other US and European registries. The 
43 
 
underlying cause for such differences is not clear. Despite recent advances in 
diagnosis and treatment over the past 30 years, there remained significant delay 
between the onset of symptoms and diagnosis, with majority of patients 
presenting in advance state with severe haemodynamic and functional 
compromise. On a positive note, overall survival of idiopathic PAH has 
significantly improved in the era of modern therapy. 
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Table 1.4. Epidemiology of PAH and idiopathic PAH. 
 
Registry Country Year Incidence per 
million per year 
Prevalence per 
million population 
Idiopathic 
PAH 
PAH Idiopathic 
PAH 
PAH 
IPPHS Belgium 1992-
1994 
1.7 - - - 
Israeli Israel 1988-
1997 
1.4 - 8 - 
Swiss Switzerland 1999 
2004 
0.8 
1.2 
1.2 
3.5* 
- 
8.6 
- 
15.5* 
French France 2002-
2003 
- 2.4 5.9 15 
Scottish 
 
Scotland 2005 2.6 - 9 - 
REVEAL United 
States 
2006-
2007 
1.1 2.3 - 12.4 
Spanish Spain 2007-
2008 
1.2 3.7 5.6 16 
Definition of abbreviations: IPPHS = International Primary Pulmonary Hypertension Study Group, 
PAH = pulmonary arterial hypertension, REVEAL = The Registry to Evaluate Early And Long-term 
PAH disease management.  
 
* includes group 1 PAH, pulmonary hypertension with chronic lung disease, chronic 
thromboembolic pulmonary hypertension and pulmonary hypertension due to miscellaneous 
disorders.  
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Table 1.5. Baseline characteristics and survival of idiopathic pulmonary 
arterial hypertension in major pulmonary hypertension registries. 
 
Registry NIH French PHC REVEAL Spanish 
Year of 
recruitment 
1981-
1985 
2002-
2003 
1982- 
2006 
2006-
2007 
2007- 
2008 
% incidence 64% 16% 14% 15% 16% 
No of idiopathic 
PAH patients 
187 354 282 1166 314 
Age, years 36 52 46 50 46 
% female 63% 62% 76% 80% 73% 
% in FC III and IV 
at diagnosis 
71% 81% 82% 55%* 70% 
6MWD at 
diagnosis 
- 328 - 374* 382 
Haemodynamics 
RAP 
mPAP 
CI 
PVR 
PVRI 
 
9 
60 
2.3 
- 
- 
 
8§ 
52§ 
2.2§ 
- 
21.9§ 
 
11 
55 
2.0 
14 
- 
 
10 
52 
2.2 
- 
23 
 
8 
55 
2.4 
12 
- 
Survival of IPAH 
1 year 
3 year 
5 year 
 
68% 
48% 
34% 
 
89%§ 
55%§ 
- 
 
91% 
75% 
65% 
 
91% 
74% 
65% 
 
89% 
77% 
68% 
Definition of abbreviations: 6MWD = 6-minute walk distance, CI = cardiac index, FC = WHO 
functional class, mPAP = mean pulmonary artery pressure, PAH = pulmonary arterial 
hypertension, PVR = pulmonary vascular resistance, PVRI = pulmonary vascular resistance index, 
RAP = right atrial pressure 
  
*at enrolment, §incident idiopathic, heritable and anorexigen-associated PAH cohort of the 
French registry. 
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1.9 Clinical Presentation of Pulmonary Arterial Hypertension 
 
The most common initial symptom of PAH is breathlessness on exertion (25, 27). 
Other common initial symptoms include fatigue, chest pain, near syncope, 
syncope, leg oedema and palpitation (25). Clinical signs consistent with 
pulmonary hypertension such as loud second pulmonary heart sound, right-sided 
third heart sound, left parasternal lift, pansystolic murmur of tricuspid 
regurgitation and diastolic murmur of pulmonary regurgitation may be present. 
Evidence of right heart failure such as elevated jugular venous pressure, 
peripheral oedema, ascites, hepatomegaly, systemic hypotension and cool 
extremities may be seen in more advanced state. Clinical signs may be subtle 
despite the presence of significantly elevated pulmonary hypertension.  
 
1.10 Investigations of Pulmonary Arterial Hypertension  
 
The evaluation process of a patient with suspected pulmonary arterial 
hypertension requires a series of investigations to confirm the diagnosis, to 
clarify the clinical diagnosis group and the specific aetiology within the PAH 
group, and to evaluate the severity of functional and haemodynamic 
impairment.  
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Pulmonary function tests 
 
Pulmonary function tests are useful to exclude chronic lung diseases such as 
chronic obstructive pulmonary disease (COPD) and interstitial lung disease. 
Screening overnight oximetry or polysomnography is useful in patients where 
significant obstructive sleep apnoea/hypopnoea is suspected. In the NIH registry, 
idiopathic PAH patients had mild restrictive pattern (forced vital capacity was 
82% of predicted) with reduced diffusion capacity for carbon monoxide (mean 
69% of predicted) and hypoxaemia with hypocapnia (25). 
 
Electrocardiography 
 
The electrocardiogram (ECG) in idiopathic PAH may show evidence suggestive of 
pulmonary hypertension: right atrial dilatation, right axis deviation, right 
ventricular hypertrophy and strain. A normal ECG does not exclude the presence 
of pulmonary hypertension or presence of significant haemodynamic 
abnormalities (5). Most patients are in sinus rhythm (25). Supraventricular 
arrhythmias such as atrial flutter or atrial fibrillation may be present in 
advanced stages and usually leads to further clinical deterioration (5).  
 
Chest X ray 
 
Typical chest X ray findings in PAH include central pulmonary arterial dilatation, 
prominent hila from enlarged pulmonary arteries, enlarged right heart and 
pruning of the peripheral vessels due to reduced blood flow in the lung periphery 
secondary to high peripheral resistance. Chest X ray may also show evidence 
suggestive of chronic lung diseases and pulmonary venous hypertension.  
 
Echocardiography 
 
Echocardiogram is the definitive screening test for the presence of pulmonary 
hypertension (Table 1.6). It allows non-invasive assessment of the cardiac size 
and function. The peak pressure gradient of tricuspid regurgitation can be 
estimated based on the simplified Bernouli equation, where pressure gradient of 
the tricuspid regurgitation = 4 x (tricuspid regurgitation velocity)2. Pulmonary 
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artery systolic pressure can then be estimated after taking into account the right 
atrial pressure: Pulmonary artery systolic pressure = tricuspid regurgitation 
pressure gradient + estimated right atrial pressure. A fixed value of 5 or 10 
mmHg is often assumed for the right atrial pressure.  Although a useful screening 
test, echocardiogram may be inaccurate in estimating the pulmonary artery 
pressure in nearly 50% of cases (41). Other echocardiographic variables 
suggestive of pulmonary hypertension include increased velocity of pulmonary 
valve regurgitation, short acceleration time of RV ejection into the pulmonary 
artery, increased dimensions of right heart chambers, increased RV wall 
thickness and dilated main pulmonary artery. Additionally, a poor outcome can 
also be predicted by the presence of pericardial effusion, increased right atrial 
size and reduced tricuspid annular planar systolic excursion (TAPSE) (5). 
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Table 1.6. Arbitrary criteria for estimating the presence of pulmonary 
hypertension based on tricuspid regurgitation peak velocity and Doppler-
calculated pulmonary arterial systolic pressure at rest (assuming a normal 
right atrial pressure of 5mmHg) (5). 
 
Echocardiographic findings:  
Tricuspid regurgitation velocity ≤ 2.8 m/s,  
PA systolic pressure ≤ 36 mmHg, and  
no additional echocardiographic variables suggestive of PH 
PH unlikely 
Tricuspid regurgitation velocity ≤ 2.8 m/s,  
PA systolic pressure ≤ 36 mmHg, but  
presence of additional echocardiographic variables 
suggestive of PH 
 
Tricuspid regurgitation velocity 2.9 – 3.4 m/s,  
PA systolic pressure 37 - 50 mmHg, 
With or without additional echocardiographic variables 
suggestive of PH 
PH possible 
Tricuspid regurgitation velocity >3.4 m/s,  
PA systolic pressure > 50 mmHg, 
With or without additional echocardiographic variables 
suggestive of PH 
PH likely 
Definition of abbreviations: PA = pulmonary arterial, PH = pulmonary hypertension 
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Isotope ventilation perfusion scan 
 
The ventilation/perfusion (V/Q) scan is used to distinguish chronic 
thromboembolic pulmonary hypertension (CTEPH) from other causes of 
pulmonary hypertension. In CTEPH, the V/Q scan shows multiple mismatched 
segmental or larger perfusion defects. A normal V/Q scan effectively excludes 
CTEPH. In idiopathic PAH, the V/Q scan is usually normal or shows 
heterogeneous perfusion (42). 
 
Computed Tomography (CT) 
 
An absolute pulmonary artery (PA) diameter of > 29 mm or ratio between PA and 
ascending aorta >1 is supportive of pulmonary hypertension (42). Cardiac 
abnormalities may also be demonstrated on CT. In pulmonary hypertension of 
any cause, dilatation of the right heart chambers, right ventricular hypertrophy, 
flattening or reversal of the interventricular septum, presence of pericardial 
effusion and reflux of contrast into the inferior vena cava may be seen. Left 
atrial and ventricular dilatation may be seen in pulmonary hypertension 
secondary to left heart disease. High resolution CT is useful in assessing the lung 
parenchyma and contrast CT pulmonary angiography is helpful to exclude 
thromboembolic disease. 
  
Cardiac Magnetic Resonance Imaging (MRI) 
 
Cardiac MRI allows accurate quantification of the right ventricle (RV) geometry, 
RV mass, RV function and assessment of pulmonary artery flow and distensibility. 
RV end-diastolic volume, stroke volume and left ventricular end-diastolic volume 
at baseline are predictive of mortality in idiopathic PAH (43). There are also 
increasing evidence to support the role of MRI in monitoring the effects of PAH 
treatment on the RV over time (43). 
 
Exercise testing 
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The six minute walk test and cardiopulmonary exercise testing are the two most 
common tests used in clinical practice and research trials to assess exercise 
capacity in patients with pulmonary hypertension. 
 
i. Six minute walk test 
 
The six minute walk test is an unencouraged, self-paced test that determines 
submaximal exercise capacity. Patients are asked to walk on a flat surface for 6 
minutes, covering as much distance as possible at their own pace. It is non-
invasive, easy to perform and reproducible. Improvement in 6MWD over a 
treatment period of three to four months has been used as the primary endpoint 
in majority of randomised controlled trials studying novel PAH treatments.  
 
The 6 minute walk distance (6MWD) can be affected by many factors, including 
age, gender, height, weight, learning effect, patient motivation, general fitness, 
and musculoskeletal conditions. Its use may be limited in young paediatric 
patients and in patients with milder or early disease who may have a relatively 
high baseline 6MWD (the ‘ceiling’ effect) (44). Degano et al studied 49 patients 
with idiopathic, heritable and anorexigen-associated PAH who walked > 450m at 
the time of diagnosis and found treatment improved haemodynamics and 
functional class but had no significant effect on 6MWD in these group of patients 
with ‘high’ baseline walk (45).  
 
Baseline 6MWD is predictive of survival in idiopathic PAH, and also correlates 
with WHO functional class and haemodynamic parameters (33, 46). Higher 6MWD 
on treatment has also been associated with better survival (46-48). In a study of 
178 primary pulmonary hypertension patients treated with long term 
epoprostenol therapy, absolute values of 6MWD > 380 m correlated with better 
survival whereas change in 6MWD from baseline did not (48).  
 
Although widely used to assess response to treatment, no randomised clinical 
trial for PAH has ever shown that the change in 6MWD had any relationship with 
survival.  A recent meta-analysis of 16 randomised controlled trials in PAH has 
also not found any correlation between change in 6MWD and survival (49).  
Another meta-analysis of 22 randomised controlled trials in PAH studied the 
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relationship between change in 6MWD and outcomes and found improvement in 
6MWD did not reflect benefits in clinical outcomes (50).  
 
There is also currently no consensus view on what constitutes a clinically 
important or relevant change in 6MWD. Mathai et al analysed data from the 
Pulmonary Hypertension Response to Tadalafil trial and found an improvement in 
6MWD of 33 metres was associated with improvement in quality of life measures 
(51). Another study that pooled results from ten randomised clinical trials of 
PAH-targeted therapy found clinically meaningful change of 6MWD to be 42 
metres (52). The magnitude of improvement in 6MWD is also greater in 
treatment naive patients compared with patients already receiving background 
therapy.  
 
Despite its shortcomings, it is currently the only Food and Drug 
Administration(FDA) and European Agency for the Evaluation of Medicinal 
Products accepted exercise end-point for studies evaluating treatment effects in 
PAH.   
 
ii. Cardiopulmonary exercise testing 
 
Cardiopulmonary exercise testing (CPET) is another non-invasive assessment of 
cardiopulmonary and metabolic adaptation to exercise. Gas exchange and 
ventilation are continuously recorded throughout incremental exercise. CPET 
can be performed on a cycle ergometer or a treadmill. Impaired O2 transport 
and ventilation/perfusion mismatching contribute to impaired exercise tolerance 
in PAH. Typical CPET findings in PAH patients include reduced O2 uptake at 
anaerobic threshold and peak exercise, reduced peak O2 pulse (VO2/HR), peak 
work rate, peak heart rate and ventilatory efficiency. Wensel et al showed peak 
VO2 < 10.4mL/min/kg and peak systolic blood pressure below 120 mmHg to be 
independent predictors of poor outcome in idiopathic PAH (53). One major 
limitation of CPET is the lack of standardisation in the determination of key 
CPET parameters. 
 
Right heart catheterisation 
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Right heart catheterisation is required to confirm the diagnosis of pulmonary 
arterial hypertension. It allows appropriate classification of the disease, provides 
accurate assessment of the severity of the disease and allows selection of 
appropriate therapy. This is performed using a Swan-Ganz thermodilution 
catheter. The catheter is inserted into a central vein and floated through the 
right heart chambers into the pulmonary artery. The following variables are 
measured during right heart catheterisation: right atrial pressure, right 
ventricular pressure, pulmonary artery pressure and pulmonary capillary wedge 
pressure. Pulmonary vascular pressures are measured at end-expiration when 
the lungs are at functional residual capacity. Cardiac output is measured by 
thermodilution or by the Fick method. Sampling of oxygen saturations from 
different sites will help to identify any ‘step-up’ or ‘step-down’ in oxygen 
saturation to detect and quantify shunting. Transpulmonary gradient (TPG) and 
pulmonary vascular resistance are derived from the following equations:  
 
TPG  = mPAP – pulmonary capillary wedge pressure 
PVR = TPG/CO 
where  
TPG  = transpulmonary gradient 
mPAP = mean pulmonary artery pressure 
PVR  = pulmonary vascular resistance 
CO  = cardiac output 
 
Acute vasoreactivity testing should be performed at the time of right heart 
catheterisation in PAH to identify patients who may benefit from long term 
calcium channel blockers. Acute vasoreactivity is most commonly performed 
using inhaled nitric oxide. A positive acute response is defined as a reduction of 
mPAP ≥ 10 mmHg to reach an absolute value of mPAP ≤ 40 mmHg with increased 
or unchanged cardiac output. Only ~10% of idiopathic PAH are acute responders 
and about half of these acute responders are also positive long term responders 
to calcium channel blockers.  
 
1.11 Treatment of Pulmonary Arterial Hypertension  
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Conventional (supportive) therapies 
 
These include oral anticoagulants, diuretics, digoxin and oxygen, in addition to 
general measures to help alleviate symptoms (5). Patients with idiopathic PAH 
should avoid pregnancy. In-flight oxygen is recommended for pulmonary 
hypertension patients in functional class III and IV (54).  
 
Calcium channel blockers 
 
Acute vasoreactivity testing performed during right heart catheterisation 
identified patients who may benefit from long term therapy with calcium 
channel blockers (CCB). Long term therapy with CCB should only be started in 
positive acute responders (~10% of patients with idiopathic PAH). The choice of 
CCBs is based on patient’s heart rate at baseline, with a relative bradycardia 
favouring nifedipine and a relative tachycardia favouring diltiazem. About half of 
the positive acute responders are also positive long term responders to calcium 
channel blockers (55) and only in these patients is the continuation of long term 
CCBs as a single agent warranted.  
 
Disease targeted therapies 
 
In the United Kingdom and Ireland, there are currently seven approved PAH 
targeted drugs with different routes of administration (Table 1.7). The approval 
of additional drugs is expected in the near future. The currently approved 
disease targeted treatments fall into 3 classes: prostacyclin and its analogues 
that target the prostacyclin pathway, phosphodiesterase 5 inhibitors that target 
the nitric oxide pathway and endothelin receptor antagonists that target the 
endothelin-1 pathway. Each of these classes of drugs has demonstrated benefits 
in randomised controlled trials to show benefit in haemodynamics, 6MWD and 
functional class.  
 
No randomised controlled trials in PAH have been designed with mortality as a 
primary endpoint because of the limited number patients that can be recruited 
into clinical trials worldwide. Most randomised clinical trials of PAH targeted 
therapies were of three to four months duration only. Survival benefit was 
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observed in only one randomised controlled trial of intravenous (IV) epoprostenol 
in severe idiopathic PAH. Based on this result, IV epoprostenol is used as a 
rescue therapy (47) and subsequent randomised controlled trials assessing 
mortality as endpoint could not ethically be performed. Clinical trials also 
included mainly prevalent patients with stable disease resulting in low mortality 
in the study population.  Nevertheless, meta-analysis of 23 randomised 
controlled trials suggest that treatment with disease targeted therapies (after an 
average treatment period of 14.3 weeks) improved survival in PAH, with 43% 
reduction in mortality and 61% reduction in hospital stays (56). Data from 
pulmonary hypertension registries also suggested improved survival of PAH in the 
modern era of treatment compared with historical cohorts (22, 33, 57). 
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Table 1.7. Currently available PAH disease targeted therapies in the UK and 
Ireland. 
 
Treatment Route of administration 
Epoprostenol IV 
Treprostinil Inhaled, IV, SC 
Iloprost Inhaled, IV 
Bosentan oral 
Ambrisentan oral 
Sildenafil oral 
Tadalafil oral 
Definition of abbreviations: IV = intravenous, SC = subcutaneous. 
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Prostacyclins and analogues: 
 
Prostacyclin (epoprostenol, PGI2) is an arachidonic acid derivative that is 
abundantly expressed in the pulmonary vascular endothelium and exerts potent 
vasodilator, antithrombotic and antiproliferative activity by acting on the cyclic 
adenosine monophosphate pathway. In the pivotal randomised controlled trial of 
epoprostenol, 81 idiopathic PAH (known as primary pulmonary hypertension at 
the time of the study) patients in functional class III and IV were randomised to 
epoprostenol plus conventional therapy vs. conventional therapy alone (47). At 
12 weeks, the epoprostenol treated group had improved quality of life scores, 
improved functional class, increased 6MWD and improved haemodynamic 
parameters compared with the conventional group. Eight patients died during 
the 12 weeks study period, all of whom had been in the conventional therapy 
group. The result of this study led to FDA approval of epoprostenol for idiopathic 
PAH in 1995. Data from longer term observational studies also suggested 
improved long term outcomes in idiopathic PAH treated with epoprostenol (48, 
58, 59).  
 
Epoprostenol has a short half life (approximately 5 minutes) and is given as a 
continuous long term infusion via a tunnelled, cuffed central venous catheter. 
Patients usually begun on a low dose (1 to 2 ng/kg/min) and gradually titrated 
upward in increments of 1 to 2 ng/kg/min, limited by the side effects and 
tolerance. Typical side effects associated with prostanoids treatment include 
hypotension, flushing, jaw aches, headaches, nausea and diarrhoea.  
 
More stable prostacylin analogues such as treprostinil and iloprost with similar 
pharmacodynamic effects are now available for the treatment of idiopathic PAH.  
 
Treprostinil is a chemically stable, tricyclic benzidene analog of prostacyclin. It 
has a longer half-life than epoprostenol and can be administered via a 
continuous subcutaneous infusion. In a pivotal, twelve week double-blind 
placebo-controlled study of treprostinil, a total of 470 patients with PAH (of 
which n=270 were idiopathic PAH) were randomised to receive subcutaneous 
(SC) treprostinil or placebo (60). Patients randomised to SC treprostinil showed 
greater improvement in 6MWD (between-group difference in median 6MWD = 16 
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metres, p-value = 0.006), Borg dyspnoea index score, signs and symptoms of 
pulmonary hypertension and haemodynamics compared with patients 
randomised to placebo. Long term persistence of efficacy of SC treprostinil has 
also been confirmed in idiopathic PAH. In a large, open-label, observational 
study of SC treprostinil, total of 860 patients with PAH (of which n = 412 were 
idiopathic PAH) were followed up to 4 years. For the idiopathic PAH subset, 1-, 
2-, 3- and 4-year survival rates were 91%, 82%, 76% and 72% respectively (61). 
Treatment with inhaled treprostinil also resulted in improvement in 6MWD in 
patients already on oral monotherapy with either bosentan or sildenafil in the 
TRIUMPH study (62). The long term effects of inhaled treprostinil were 
confirmed in the TRIUMPH study open-label extension (63).  
 
Iloprost is a stable, synthetic analog of prostacyclin and can be administered by 
the intravenous and aerosolised route. The AIR study (The Aerosolized Iloprost 
Randomised Study) was a twelve week placebo-controlled study that evaluated 
the efficacy of daily repetitive iloprost inhalations (64). A total of 203 patients 
with PAH or chronic thromboembolic pulmonary hypertension (of which n = 102 
were idiopathic PAH) were included. This study showed inhaled iloprost 
improved exercise capacity, functional class, level of dyspnoea, quality of life 
and haemodynamics. 
 
Phosphodiesterase type-5 inhibitors:  
 
Endothelial nitric oxide synthase is the principal mediator of endothelium 
dependent vasodilation in the pulmonary circulation. Endothelium derived nitric 
oxide (NO) diffuses into pulmonary smooth muscle cells, where it stimulates 
soluble guanylate cyclase to produce cyclic guanosine monophosphate (cGMP). 
cGMP activates cGMP-dependent protein kinase G, which in turn, promotes 
vascular smooth muscle relaxation.  Degradation of the cGMP is regulated via the 
production of several distinct phosphodiesterase inhibitors. Within the 
pulmonary circulation, phosphodiesterase type 5 (PD5) is the most abundantly 
expressed isoform. Inhibiting the activity of PD5 has been shown to augment 
nitric oxide vasodilatation. Currently available PD5 inhibitors used to treat PAH 
include sildenafil and tadalafil, with sildenafil being the most commonly 
prescribed. In the pivotal twelve week double blind, placebo-controlled SUPER 
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trial which included 278 patients with PAH (of which n = 175 were idiopathic 
PAH), sildenafil improved 6MWD, symptoms and haemodynamics over placebo 
(65). Patients in the original SUPER trial were entered into an open labelled 
extension study (SUPER-2). Results of the SUPER-2 study confirmed safety, 
tolerability and efficacy of long term sildenafil with 60% of all patients improved 
or maintained their functional status and 46% improved or maintained their 
6MWD after 3 years (66).  
 
Endothelin receptor antagonists: 
  
Endothelin 1 is a vasoconstrictor that acts via two receptors, endothelin 
receptor A (ET-A) and endothelin receptor B (ET-B), to regulate vascular tone 
and cell proliferation. Lung and circulating endothelin 1 levels are increased in 
idiopathic PAH. Endothelin receptor antagonists (ERA) cause significant but 
modest improvement in pulmonary haemodynamics, exercise capacity and 
symptoms. Patients treated with ERA require monthly liver function tests.  
 
The non selective ET-A/ET-B receptor antagonist bosentan is the first orally 
active agent to be granted regulatory approval in the treatment of PAH. In the 
BREATHE-1 trial, 213 patients (of which n = 150 were idiopathic PAH) in 
functional class III and IV were randomised to bosentan (at dose of 125mg or 
250mg twice daily) or placebo. At 16 weeks, a placebo corrected 6MWD 
improvement of 44 metres was noted (67). Bosentan was also assessed in less 
functionally impaired patients (WHO functional class II) in the EARLY trial and 
demonstrated benefit in reducing pulmonary vascular resistance and preventing 
clinical worsening at 6 months (68). The long term efficacy of bosentan in 
idiopathic PAH was confirmed in a long term observational study of 169 
idiopathic PAH patients with estimated one and two year survival of 96% and 89% 
respectively in patients on first line bosentan therapy (69).  
 
Ambrisentan is a selective ET-A receptor antagonist. There is no data to suggest 
selective ET-A antagonism is superior to combined ET-A and ET-B antagonism. In 
the ARIES 1 and 2 trials, ambrisentan improved exercise capacity, 
haemodynamics and time to clinical worsening of idiopathic PAH patients (70). 
Sustained improvement in exercise capacity after two years of ambrisentan was 
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confirmed in patients who were followed in the long term extension study 
(ARIES-E study) (71). 
 
Other novel treatments: 
 
Platelet derived growth factors (PDGF) have the ability to induce proliferation 
and migration of smooth muscle cells and fibroblast, and the PDGF and its 
receptors are over-expressed in human and experimental models of PAH. Novel 
therapeutic agents, such as imatinib that inhibit tyrosine kinases are currently 
been evaluated in phase III clinical trials. Efficacy of soluble guanylate cyclase 
stimulator riociguat in PAH is also currently been studied in a phase III clinical 
trial (PATENT trial). 
 
1.12 Survival Prediction Equations in Idiopathic, Heritable and 
Anorexigen-associated Pulmonary Arterial Hypertension 
 
Although epidemiological studies suggested survival has improved compared with 
historical survival from the NIH era, outcomes of idiopathic, heritable and 
anorexigen-associated PAH remain unacceptably poor. None of the currently 
approved therapies represents a cure for this progressive and often fatal 
disease.  
 
Outcomes of Group 1 PAH subsets depend on the aetiology. Patients with 
congenital heart disease associated PAH have better survival whereas those with 
connective tissue associated PAH have worse survival compared with idiopathic 
PAH (5, 72). Idiopathic PAH patients who responded to acute vasoreactivity 
testing had the best survival (55, 73). Survival is also worse for incident (newly 
diagnosed) patients compared with prevalent patients (37).  
 
Currently, no single parameter has been shown to accurately predict survival of 
PAH when considered alone. The pulmonary hypertension literature is also 
dominated by many small, often retrospective single centre studies with limited 
power to properly assess the effects of treatment, compare multiple outcomes 
and draw meaningful conclusion (74). Many parameters were reported to be 
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associated with mortality in only a few studies or were not reproducible in other 
studies. However, analyses from major registries and clinical trial datasets have 
repeatedly identified a number of clinical, physical and haemodynamic 
parameters to have prognostic significance in PAH. These parameters include 
age, gender, six minute walk distance, functional class, heart rate, presence of 
pericardial effusion, and haemodynamic parameters (right atrial pressure, 
cardiac index, mean pulmonary artery pressure, stroke volume index, pulmonary 
vascular resistance and mixed venous oxygen saturation) (22, 23, 26, 46, 57, 74, 
75). 
 
Currently, five prognostic equations have been developed from existing datasets 
to predict outcomes of PAH patients.  
 
NIH registry equation (26): 
 
The NIH equation was derived using survival data of 194 primary pulmonary 
hypertension patients from the NIH Registry.  
 
P(t) = [H(t)]A(x,y,z) 
where 
P(t) indicates the patient’s chances of survival,  
t = 1, 2 or 3 years 
H(t) = [0.88-0.14t + 0.01t2] 
A(x,y.z) = e(0.007325x + 0.0526y – 0.3275z) 
where 
X = mean pulmonary artery pressure 
Y = mean right atrial pressure 
Z = cardiac index 
 
French registry equation (37): 
 
The French equation was derived using survival data from a combined cohort of 
56 incident and 134 prevalent idiopathic, heritable and anorexigen-associated 
PAH patients diagnosed 3 years prior to entry into the French Registry. In order 
to remove survivor bias that results from inclusion of prevalent patients, survival 
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estimates and a Cox proportional hazards model from time to diagnosis were 
adjusted for the left truncation arising from the delay between diagnosis and 
study entry (37). Patients were only in the risk setfrom their time of study entry 
(37).  
 
The probability of survival of a patient at t years post diagnosis is: 
 
P(t;x,y,z)= exp (-0.02 – 0.28t)exp (-(0.004x + 0.98y + 0.28z)) 
where 
t  = years post diagnosis 
x = 6 minute walk distance at diagnosis – 280 m 
y = 1 if female, y = 0 if male 
z = cardiac output at diagnosis – 4.0 L.min-1 
 
Pulmonary Hypertension Connection registry equation (PHC equation) (23): 
 
The PHC equation was derived from 247 patients with a diagnosis of idiopathic, 
familial and anorexigen-associated PAH. 
 
The probability of survival of a patient at t years post diagnosis is: 
P(t) = e-A(x,y,z)t 
A(x,y,z) = e(-1.270 – 0.0148x + 0.0402y – 0.361z) 
where  
P(t) = probability of survival 
t = time in years after diagnosis 
x= mean pulmonary artery pressure 
y = mean right atrial pressure 
z = cardiac index 
 
REVEAL equation (57) and REVEAL risk score (76): 
 
Predictors of 1-year survival were determined using data from 2716 Group 1 PAH 
patients enrolled in the REVEAL Registry. 19 independent predictors of survival 
were identified and used to generate a prognostic equation based on the Cox 
proportional hazard multivariate analysis.  
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Predicted 1 year survival = S0(1)exp(Z’ßγ) 
where 
S0(1) is the baseline survivor function 0.9698 
Z’ß is the sum of the patient’s individual characteristics multipled by the 
ß coefficients for each of the 19 parameters in the equation 
γ is the shrinkage coefficient (0.939) 
 
Starting with a base value of 0, the linear component is increased or decreased 
according to the variable coefficients summarised in Table 1.8.  
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Table 1.8. Variable Coefficients for the linear component of the REVEAL 
equation. 
 
 Additions and subtractions to linear component of 
equation 
WHO group 1 
subgroup 
Familial PAH, +0.7737 Po-PAH, +1.2801 
CTD-PAH, +0.4624 
Demographics 
and comorbidities 
Male > 60 years, 
+0.7779 
Renal insufficiency, 
+0.6422 
WHO FC FC I, -0.8749 FC III, +0.3454 
FC IV, +1.1402 
Vital signs Systolic BP <110mmHg,  
-0.5128 
Heart rate > 92  
beats.min-1, +0.3322 
6MWD 6MWD ≥ 440 metres, 
-0.5455 
6MWD < 165 metres, 
+0.5210 
BNP BNP < 50 pg/mL or 
NTproBNP < 300pg/mL, 
-0.6922 
BNP > 180 pg/mL or 
NTproBNP > 1500 pg/mL, 
+0.6791 
Echocardiogram Pericardial effusion,  
+0.3014 
PFT % predicted DLCO ≥ 80%, 
-0.5317 
% predicted DLCO ≤ 32%, 
+0.3756 
RHC mRAP > 20mmHg within 1 
year, +0.5816 
PVR > 32 Wood units, 
+1.4062 
Definition of abbreviations: 6MWD = six minute walk distance, BNP = brain natriuretic peptide, 
BP = blood pressure, CTD-PAH = connective tissue disease associated PAH, DLCO = diffusion 
capacity for carbon monoxide, FC = functional class, mRAP = mean right atrial pressure, 
NTproBNP = N-terminal-proBNP, PAH = pulmonary arterial hypertension, PFT = pulmonary 
function tests, Po-PAH = portal pulmonary hypertension, PVR = pulmonary vascular resistance, 
RHC = right heart catheterisation, WHO = World Health Organisation. 
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Based on the REVEAL equation, the simplified REVEAL risk score was developed. 
For a given test, a point value of zero was assigned if it was either unmeasured 
or if it did not fall above or below the threshold used in the calculator. 
Calculated risk scores can range from 0 (lowest risk) to 22 (highest risk).  
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The REVEAL risk score is an ordinal scale calculated as a baseline number of 6 to 
which qualifiers are added or subtracted based on available data, as follows: 
 
1. WHO group I +1 point  CTD-PAH 
 subgroup: +2 points  Po-PAH 
+2 points familial PAH 
2. Demographics: +1 point  renal insufficiency 
+2 points  male and > 60 years 
3. WHO FC : -2 points functional class I    
   +1 point functional class III 
   +2 points functional class IV 
4. Vital signs  +1 point systolic blood pressure < 110 mmHg 
   +1 point heart rate > 92 beats per minute 
5. 6MWD  -1 point ≥440 metres 
   +1 point <165 metres 
6. BNP  -2 points <50 pg/mL 
   +1 point >180 pg/mL 
7. Echocardiogram +1 point pericardial effusion 
8. PFT   -1 point %predicted DLCO ≥ 80% 
   +1 point % predicted DLCO ≤ 32% 
9. RHC   +1 point mRAP > 20mmHg within 1 year 
   +2 points PVR > 32 Wood Units 
Sum of above ________ 
   + 6 points 
   = REVEAL risk scores 
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Scottish Composite Score (77): 
 
The Scottish Composite Score was derived from 182 incident, treatment naive 
WHO Group 1 PAH who were diagnosed and treated at the Scottish Pulmonary 
Vascular Unit between November 2000 and September 2009. Multivariate Cox 
analysis showed age, sex, aetiology, right atrial pressure, cardiac output and 6-
minute walk distance to be independent predictor of mortality. These variables 
were used to derive the Scottish Composite Score. The Scottish Composite Score 
was designed as a simple point-based risk score to stratify patients into 
prognostic groups whereas all the other equations were developed to compute 
predicted survival probabilities at certain time points post-diagnosis. 
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Table 1.9. The Scottish Composite Score 
 
Variables Categories Points 
Age, years ≥ 70 
< 70 
1 
0 
Sex Male 
Female 
1 
0 
Aetiology CTD-PAH-SSc or Group 1 PAH 
others* 
 
Idiopathic, heritable, anorexigen-
associated PAH or CTD-PAH-non-
SSC 
1 
 
 
0 
 
Six minute walk distance, 
metres 
< 50 
50 – 149 
150 -299 
≥ 300 
3 
2 
1 
0 
Right atrial pressure, mmHg ≥ 10 
< 10 
1 
0 
Cardiac output, L.min-1 < 3 
≥ 3 
1 
0 
Definition of abbreviations: CTD-PAH = connective tissue disease associated pulmonary arterial 
hypertension, SSc = systemic sclerosis, others* = includes portopulmonary hypertension, HIV and 
pulmonary veno-occlusive disease. 
 
Scottish Composite Score risk groups: 
High risk   = score 4 – 8 
Intermediate risk  = score 2 – 3 
Low risk   = score 0 – 1 
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The Scottish Composite Score was validated in a separate cohort of incident and 
treatment naive idiopathic, heritable and anorexigen-associated PAH diagnosed 
and treated in the Pulmonary Vascular Disease Unit at Papworth Hospital 
(Cambridge, UK) between January 2001 and December 2009. The Scottish 
Composite Score also provides further risk stratification in WHO functional class 
III patients. When compared with the French and PHC equation, the Scottish 
Composite Score was more accurate than the French equation at predicting 1 
and 2 year survival and not inferior to the PHC equation (77). The validation 
cohort raw data came from parts of the data collected for this MD thesis.  
 
1.13 Limitations of Pulmonary Hypertension Registries and Survival 
Prediction Equations 
 
All pulmonary hypertension registries and their derived survival prediction 
equations have limitations. Each describes the survival of their specific 
population. Currently available survival equations are useful research tools and 
can provide clinical guidance but are not yet ready to replace clinical 
judgement. Further assessment is needed to determine whether any of the 
currently available equations confidently predict individual patient outcomes or 
whether their utility is restricted to cohort analysis.  
 
The NIH equation was the first survival prediction equation in primary pulmonary 
hypertension (which at that time included patients now classified as idiopathic, 
heritable and anorexigen-associated PAH in the latest Dana Point classification) 
and for many years formed the basis of comparison for studies of outcomes, 
including many long term clinical drug studies  (58, 61, 78, 79). This equation 
was derived from a predominantly incident cohort. On the other hand, patients 
in randomised controlled trials were usually stable prevalent patients who are 
known to have better outcomes than incident patients. In addition, important 
differences in the diagnosis, disease classification and treatment of PAH 
between the early 1980s and the current era meant that the NIH equation is 
likely to perform poorly when applied to contemporary idiopathic PAH 
populations from the modern treatment era. Indeed, the NIH equation 
underestimated survival by around 16-18% when applied to the more recent 
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idiopathic PAH cohorts from the French, REVEAL and Spanish Registries (33, 39, 
40). 
 
The study period of the PHC registry also spanned both pre- and post-modern 
treatment era (1991-2007) and this may potentially have an impact on the 
performance of the PHC equation.  
 
The REVEAL equation, REVEAL risk score and the Scottish Composite Score are 
applicable to all WHO Group 1 PAH. On the other hand, the NIH, French and PHC 
equations apply only to patients with idiopathic, heritable and anorexigen-
associated PAH. 
 
With the exception of the REVEAL equation and the REVEAL risk score, all the 
other survival prediction equations were derived using baseline parameters 
obtained at the time of diagnosis. The REVEAL equation and risk score were 
developed to be applicable at any time point in the course of a patient’s 
disease.  
 
The Scottish Composite Score was derived from a purely incident cohort. The 
PHC registry excluded patients who were already on approved PAH therapy at 
the time of referral (n=52), which in effect probably excluded prevalent 
patients. All other equations were derived from a mixed incident and prevalent 
cohort and are therefore limited by survival and immortal time bias. Newly 
diagnosed patients with severe rapidly progressive disease may not survive long 
enough to be enrolled into registries, potentially leading to underestimation of 
mortality in these survival prediction equations. Definition of incident patient 
was also variable amongst the registries. The French Registry defined incident 
cases as patients who were newly diagnosed within the 1- year recruitment 
phase whereas the REVEAL Registry defined incident cases as any patients who 
received a diagnosis of PAH within 90 days prior to study enrollment.  
 
The REVEAL risk score and Scottish Composite Score have the added advantage 
of simplicity to use. Both REVEAL equation and risk score also allow calculation 
of probability of survival even if certain data are unavailable for all predictive 
factors in the model.  
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Missing data is a limitation in all pulmonary hypertension registries, and many 
other known prognostic predictors of outcomes are not captured. Serial 
assessment was not performed and thus prediction of disease trajectory over 
time could not be assessed. Finally, none of the survival equations accounted for 
the influence of modern PAH therapies on future mortality risk.  
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2 Chapter 2: Methods 
 
2.1 Pulmonary Hypertension Service in the United Kingdom and 
Ireland 
 
The diagnosis, treatment and long term management of all adult pulmonary 
hypertension patients in the United Kingdom (UK) and Ireland are centralised to 
eight designated pulmonary hypertension centres (Table 2.1). Formal 
designation of centres was undertaken by the National Specialist Commissioning 
Advisory Group (replaced by National Commissioning Group in 2007) of the 
Department of Health in England in 2001, the National Service Division of the 
Scottish Parliament in Scotland in 1998, and the Health Service Executive in 
Ireland (80). Wales and Northern Ireland refer patients to the UK centres. The 
centralisation of management of patients with pulmonary arterial hypertension 
(PAH) to designated centres only provides a unique opportunity to perform this 
study that aim to investigate the epidemiology, characteristics, long term 
survival and treatment outcomes of all idiopathic PAH patients within a single 
region. All pulmonary hypertension centres in the UK and Ireland met the 
minimum standards for specialist unit. In the UK and Ireland, the prescription of  
PAH specific therapies (endothelin receptor antagonists, phosphodiesterase 5 
inhibitors and prostanoids) are limited to designated pulmonary centres only. 
There is therefore no indiscriminate use of PAH drugs as occurred in some other 
countries where PAH drugs may be used in classes of pulmonary hypertension 
with inadequate clinical evidence or even potential harm.   
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Table 2.1. Eight designated pulmonary hypertension centres in the UK and 
Ireland. 
 
Designated centre locations Details 
Glasgow,  
Scotland. 
Scottish Pulmonary Vascular Unit, 
Golden Jubilee National Hospital. 
Newcastle-Upon-Tyne, 
England. 
Northern Pulmonary Vascular Unit, 
Freeman Hospital. 
Sheffield, 
England. 
Sheffield Pulmonary Vascular Unit, 
Royal Hallamshire Hospital. 
Cambridge, 
England. 
Pulmonary Vascular Diseases Unit, 
Papworth Hospital. 
London, 
England. 
National Pulmonary Hypertension 
Service, Hammersmith Hospital. 
London,  
England. 
Royal Brompton Pulmonary 
Hypertension and Adult Congenital 
Heart Disease Centre. 
London, 
England. 
Pulmonary Hypertension Unit,  
Royal Free Hospital. 
Dublin, 
Ireland. 
National Pulmonary Hypertension 
Unit, Mater Misericordiae University 
Hospital. 
 
  
74 
 
2.2 Study Design and Methods 
 
This was a retrospective, longitudinal cohort study. Professor Andrew Peacock, 
the director of the Scottish Pulmonary Vascular Unit, had previously obtained 
permission from the other pulmonary hypertension centres in the UK and Ireland 
to share data. I wrote to the West of Scotland Research Ethics Committee 
outlining my study proposal. As this study was designed and conducted to define 
current care, formal ethics approval was deemed unnecessary by the West of 
Scotland Research Ethics Committee (Appendix 2).  
 
Only anonymised and non-identifiable data were collected. I first performed a 
pilot study on patients from our own centre (Scottish Pulmonary Vascular Unit). 
The data collection proforma was modified accordingly prior to travelling to the 
other pulmonary hypertension centres.  I visited each site to examine the local 
database and patient records. The diagnosis was confirmed in all cases. An 
encrypted laptop was used to store all data collected. Prior to my visit, I 
contacted the personnel department to obtain honorary contract with the 
individual hospital, the IT department to obtain approval and passwords to 
access hospital computerised records and liaised with staffs in each pulmonary 
hypertension centre to arrange workspace.  
 
Data were collected on all consecutive, newly diagnosed (incident), treatment-
naive cases of idiopathic, heritable and anorexigen-associated PAH diagnosed 
between 1st January 2001 and 31st December 2009 in all eight pulmonary 
hypertension centres in the UK and Ireland.  
 
Problems encountered during data collection: 
 
1.  Quality of local database: 
The information recorded in local databases was highly variable across the 
various centres. In a number of centres, data recorded may include only the 
basic demographics and diagnosis. To avoid missing cases, all patients on the 
local database were screened and where appropriate the medical case notes 
were retrieved and reviewed. 
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2. Misclassification of diagnosis: 
The diagnosis recorded in local databases may not be accurate or fully satisfied 
my study’s definition of idiopathic PAH. For example, a patient was recorded 
and managed as idiopathic PAH by the treating physician but had abnormal 
pulmonary function tests and/or evidence of co-existing parenchymal lung 
disease on chest CT.  
 
3. Data collection: 
The retrieval of the relevant data from the medical records was very time 
consuming. Clinic letters, discharge summaries and many investigation results 
were stored electronically in most centres, mostly under different IT systems or 
software packages. I examined each of these individually and extracted the data 
of interest. Some results were stored in different hospital departments and 
involved further liaisons with colleagues from other departments to access these 
data. For example, in one centre, I was only able to access the pulmonary 
function results stored in the pulmonary physiology lab when one of the staffs 
was working on a half-day. Although it was possible to extract a lot of data from 
various electronic sources, in majority of patients, the hospital paper medical 
records were needed for the remaining missing data. Request for paper medical 
records was time consuming (took approximately 2 weeks per request) and only 
limited number of records could be requested at any one time. In one hospital, 
to avoid delay, I pulled the medical records from the shelves in the records 
department myself. All centres involved at least two separate visits before data 
collection was fully completed.  
 
2.3 Inclusion and exclusion criteria 
 
Inclusion criteria: 
 
PAH was defined as mPAP ≥ 25mmHg at rest and pulmonary artery occlusion 
pressure (or pulmonary capillary wedge pressure) ≤ 15mmHg with normal or 
reduced cardiac output. Idiopathic PAH was defined as PAH with no identifiable 
secondary causes of pulmonary hypertension or associated risk factors. Patients 
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with heritable and anorexigen-associated PAH have similar baseline 
characteristics and outcomes to idiopathic PAH (21) and were therefore analysed 
together in this thesis.  
 
The definition of idiopathic PAH in this thesis was based on the same 
haemodynamic and pulmonary function criteria used to define idiopathic PAH  in 
the French (33) and the Scottish (32) registries.  We refined our criteria for the 
definition of idiopathic PAH by further excluding patients with radiological 
evidence of parenchymal lung disease from our idiopathic PAH cohort. These 
excluded patients with CT evidence of parenchymal lung disease who otherwise 
satisfied the standard haemodynamic and pulmonary function criteria for 
idiopathic PAH were classified in this thesis as PAH with ‘co-existing lung 
disease’ (Figure 2.1).  
 
The date of diagnosis was taken as the date of initial right heart catheterisation. 
If this cannot be located in the hospital records, then the date of first visit to 
the pulmonary hypertension centre was used. The diagnosis of idiopathic, 
heritable and anorexigen-associated PAH was made by experienced pulmonary 
vascular physicians in all pulmonary hypertension centres following systematic 
assessment with multiple modalities in a multidisciplinary setting. In all patients 
classified as PAH with ‘co-existing lung disease’ in this thesis, the underlying 
lung disease was considered by their treating pulmonary hypertension specialists 
to be either insignficant or unlikely to be the main contibuting cause of the 
individual’s pulmonary hypertension. 
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 Figure 2.1. Flow diagram showing inclusion of patients. 
*646 patients satisfying the traditional haemodynamic and pulmonary function criteria of 
idiopathic, heritable and anorexigen-associated PAH were diagnosed in all eight pulmonary 
hypertension centres in the UK and Ireland between January 2001 and December 2009. In all 
patients, mPAP ≥ 25mmHg, pulmonary artery occlusion pressure ≤ 15mmHg, cardiac output was 
normal or reduced and pulmonary function (FEV1, FVC and TLC) were ≥ 60% predicted. 
 
Definition of abbreviations: IPAH = idiopathic, heritable and anorexigen-associated pulmonary 
arterial hypertension, n= number, PAH = pulmonary arterial hypertension, PH = pulmonary 
hypertension, RHC = right heart catheterisation. 
 
Parenchymal disease = emphysema (n=88), pulmonary fibrosis (n=35), emphysema and pulmonary 
fibrosis (n=16) and others (n=7). Others include bronchiectasis (n=3), old TB changes (n=1), 
respiratory bronchiolotis (n=1), bilateral ground glass opacities (n=1), and cystic lung disease 
(n=1). 
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Exclusion criteria: 
 
Patients with mPAP at rest of <25 mmHg or pulmonary arterial occlusion 
pressure >15 mmHg were excluded.  Patients were also excluded if known to 
have connective tissue/collagen vascular disease, portal hypertension, 
haemolytic anaemia, HIV, sarcoidosis, congenital heart disease and pulmonary 
veno-occlusive disease. Patients who may have pulmonary hypertension 
secondary to significant hypoxic lung disease were excluded by abnormal 
pulmonary function test (defined as FEV1, FVC or TLC <60% predicted) (32, 33). 
 
All patients were started on conventional therapy (long term warfarin, oxygen 
and/or diuretics) unless otherwise contraindicated. No specific nationwide 
treatment algorithm was used. PAH specific therapies were commenced as felt 
appropriate at each centre, in accordance with contemporary pulmonary 
hypertension commissioning guidelines and national and European  pulmonary 
hypertension guidelines (5, 80, 81). Combination therapies were used when 
allowed and clinically indicated. Patients were followed-up as per clinical need. 
 
2.4 Data collection 
 
Baseline data on demographics, right heart catheterisation results, 6 minute 
walk distance, pulmonary function test and WHO functional class were 
collected. Follow up data were collected at 3 ± 1 month and 6 ± 2 months for 6 
minute walk distance and functional class. Co-morbidities, presenting symptoms 
and chest CT findings at diagnosis, treatment started at diagnosis and 
subsequent follow-up were also collected. Table 2.2 listed all the variables 
collected in this study. 
  
79 
 
Table 2.2. Study variables collected for all patients. 
 
1. Baseline variables: 
Demographics: 
Age 
Gender 
Ethnicity 
Height 
Weight 
Date of right heart catheterisation 
Pulmonary hypertension centre 
Duration of symptoms 
Presenting symptoms 
Functional class 
Co-morbidities 
Smoking history 
Chest CT findings 
Exercise capacity: 
6 minute walk distance 
Incremental shuttle walk distance 
Biomarkers: 
BNP and NT-proBNP 
Quality of life: 
CAMPHOR score 
Pulmonary function test: 
% predicted forced expiratory volume in one second 
% predicted forced vital capacity 
% predicted total lung capacity 
% predicted diffusion capacity for carbon monoxide 
Pulmonary haemodynamics: 
Right atrial pressure 
Systolic pulmonary artery pressure 
Diastolic pulmonary artery pressure 
Mean pulmonary artery pressure 
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Pulmonary artery occlusion pressure (wedge pressure) 
Cardiac output 
Cardiac index 
Mixed venous oxygen saturations 
Pulmonary vascular reisstance 
Pulmonary vascular resistance index 
2. Treatment started after diagnosis: 
First line treatment 
All subsequent treatment 
Lung transplantation 
Atrial septostomy 
3. Variables at follow-up ( 3-months and 6-months): 
6 minute walk distance 
Functional class 
Pulmonary function test 
Treatment 
4. Date of death 
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2.5 Epidemiology of Idiopathic, Heritable and Anorexigen-
associated Pulmonary Arterial Hypertension 
 
Idiopathic, heritable and anorexigen-associated PAH patients were divided into 
younger and older subgroups according to their median age at the time of 
diagnosis. Patients were also divided into three groups based on the year of 
diagnosis (2001-2003, 2004- 2006 and 2007-2009) to identify any changing trends 
in the epidemiology, baseline characteristics, treatment and outcomes over the 
course of the study period. The incidence and prevalence of idiopathic, 
heritable and anorexigen-associated PAH were calculated as the ratio of newly 
diagnosed (incidence) or all living patients (prevalence) and the total population 
of the United Kingdom and Ireland for the respective year.  
 
2.6 Survival and Prognostic Factors in Idiopathic, Heritable and 
Anorexigen-associated Pulmonary Arterial Hypertension 
 
Prognostic factors were assessed for the whole cohort of idiopathic, heritable 
and anorexigen-associated PAH and then separately for the two age subgroups 
(younger and older patients, divided according to the median age at the time of 
diagnosis). All cause mortality was used for survival analyses. Patients were 
followed-up until their date of death or the censoring date of 31st December 
2009 if still alive. Mortality was confirmed using pulmonary hypertension centres 
records, with the general practitioners’ records and NHS strategic tracing 
services. Survival from the time of diagnosis was estimated using the Kaplan 
Meier method and survival curves compared using log-rank test. Multivariate Cox 
regression was used to evaluate the prognostic significance of various baseline 
parameters.  
 
2.7 Validation of Survival Prediction Equations 
 
Patients with idiopathic, heritable and anorexigen-associated PAH in this thesis 
were used to validate five currently available survival prediction equations in 
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pulmonary arterial hypertension. The Brier score was used to assess the overall 
performance of individual survival prediction model.  
 
2.8 Prognostic Significance of Short Term Change in Six Minute 
Walk Distance and Functional Class 
 
The prognostic significance of change in six minute walk distance and functional 
class after three and six months of disease targeted therapies were studied in 
idiopathic, heritable and anorexigen-associated PAH patients. Patients were 
divided into high and low baseline walk according to the median baseline six 
minute walk distance.  
 
In order to assess the prognostic significance of change in functional class, the 
patients were also divided into 4 groups according to their baseline and follow-
up functional class:  
 
Group 1: Baseline functional class I and II; Follow-up functional class I and II 
 
Group 2: Baseline functional class III and IV; Follow-up functional class I and II 
 
Group 3: Baseline functional class I and II; Follow-up functional class III and IV  
 
Group 4: Baseline functional class III and IV; Follow-up functional class III and IV 
 
Survival was assessed using the Kaplan Meier method and survival curves 
compared using the log rank test. 
 
2.9 Characteristics and Outcomes of Pulmonary Arterial 
Hypertension with ‘Co-existing Lung Disease’ 
 
The baseline characteristics and outcomes of patients with PAH with ‘co-existing 
lung disease’ were assessed and compared with patients with idiopathic, 
heritable and anorexigen-associated PAH diagnosed concurrently  
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in all eight pulmonary hypertension centres in the UK and Ireland. Short term 
response to treatment in both groups of patients was assessed by the functional 
class and the change in six minute walk distance after three months of 
pulmonary hypertension disease targeted therapies.   
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3 Chapter 3: Changing Demographics, Epidemiology and 
Survival of Incident Idiopathic, Heritable and 
Anorexigen-associated Pulmonary Arterial 
Hypertension 
 
3.1 Summary 
 
Rationale: 
 
Incident pulmonary arterial hypertension was under-represented in most 
pulmonary hypertension registries and may have a different disease profile to 
prevalent disease.  
 
Objectives: 
 
To determine the characteristics and outcomes of a purely incident, treatment-
naive cohort of idiopathic, heritable and anorexigen-associated pulmonary 
arterial hypertension and to determine the changes in presentations and survival 
over the past decade in the UK and Ireland.  
 
Methods: 
 
All consecutive, incident idiopathic, heritable and anorexigen-associated 
pulmonary arterial hypertension diagnosed in all eight pulmonary hypertension 
centres in the UK and Ireland between 1st January 2001 and 31st December 2009 
were included. Patients with parenchymal lung disease (of any severity) on chest 
CT were excluded. 
 
Results: 
 
A total of 482 consecutive patients (93% idiopathic, 5% heritable and 2% 
anorexigen-associated pulmonary arterial hypertension) were newly diagnosed 
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over the study period, giving rise to an estimated incidence of 1.1 
cases/million/year and prevalence of 6.6 cases/million in 2009. Younger 
patients (age ≤ 50) had shorter duration of symptoms, less co-morbidities, better 
functional and exercise capacity, higher % DLCO, more severe haemodynamic 
impairment but better survival compared with older patients. In comparison 
with the earlier cohorts, patients diagnosed in 2007-2009 were older, more 
obese, had lower % DLCO, more co-morbidities but better survival.  
 
Conclusions: 
 
This study highlights the influence of age on the phenotypes of incident 
idiopathic, heritable and anorexigen-associated pulmonary arterial hypertension 
and has shown the changes in demographics and epidemiology over the past 
decade in a national setting. The results suggest that there may be two subtypes 
of patients: the younger subtype with more severe haemodynamic impairment 
but better survival compared with the older subtype who has more 
comorbidities. 
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3.2 Introduction 
 
Pulmonary arterial hypertension (PAH) is a rare, debilitating disorder of the 
pulmonary vasculature characterised by progressive increase of the pulmonary 
vascular resistance, right ventricular afterload, right-sided cardiac failure and in 
advanced cases, death. In rare diseases such as PAH, registries provide valuable 
information on the baseline characteristics and outcomes of the disease. In some 
of the earlier pulmonary hypertension registries, definition and assessment of  
PAH were not standardised, numbers were small and a significant number of 
patients did not have right heart catheterisation to confirm the diagnosis (28-30, 
36) . In addition, most pulmonary hypertension registries were composed of a 
mixture of incident and prevalent patients (25, 26, 33-35). However, prevalent 
patients have better prognosis compared with incident patients (37). We are 
concerned that current knowledge of pulmonary arterial hypertension based on 
data obtained from a mixed population may be biased. Patients with severe or 
rapidly progressive disease may die early and never live long enough to be 
enrolled in registries. Conversely, patients with stable disease for a number of 
years have better survival and may be over-represented in pulmonary 
hypertension registries. In addition, patients outside registry participating 
centres were not included, potentially introducing further selection bias. 
  
Recent reports from contemporary registries (22, 23, 34, 35) suggested that the 
typical idiopathic PAH patients are now older and have better survival when 
compared with patients from the NIH era (25, 26). However, it is unclear 
whether younger and older patients in the current treatment era differ in their 
baseline characteristics and long term outcomes. We are also interested to know 
whether the demographics, baseline characteristics and survival of incident 
idiopathic PAH have changed over the past decade since the availability of 
disease targeted therapies. Since 2001, the diagnosis, initiation of treatment 
and long term management of all adult pulmonary hypertension patients in the 
UK and Ireland has been centralised to eight designated pulmonary hypertension 
centres (80). This set up also provides an opportunity to study the demographic 
and survival trends of virtually all newly diagnosed, treatment-naïve patients 
within a single region with a similar healthcare system. 
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The objectives of this study were: 
1. To determine the epidemiology, baseline characteristics and outcomes of an 
incident cohort of idiopathic, heritable and anorexigen-associated PAH.  
2. To determine whether younger and older incident idiopathic, heritable and 
anorexigen-associated PAH patients differ in baseline characteristics and 
outcomes. 
3. To determine whether the demographics and epidemiology of incident 
idiopathic, heritable and anorexigen-associated PAH have changed over the past 
decade in the UK and Ireland. 
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3.3 Methods  
 
This was a longitudinal observational study. Data were collected on all 
consecutive treatment-naive, incident cases of idiopathic, heritable and 
anorexigen-associated PAH diagnosed between 1st January 2001 and 31st 
December 2009 in all eight pulmonary hypertension centres in the UK and 
Ireland. Only anonymised and non-identifiable data were collected. This study 
was designed and conducted to define current care and hence formal ethics 
approval was deemed unnecessary by the West of Scotland Research Ethics 
Committee.  
 
The diagnosis of idiopathic PAH was made at each pulmonary hypertension 
centre following systematic assessment with multiple modalities in a 
multidisciplinary setting. Idiopathic PAH was defined as PAH with no identifiable 
causes or risk factors of pulmonary hypertension. Patients with heritable and 
anorexigen-associated PAH have similar baseline characteristics and outcomes to 
idiopathic PAH (21) and were therefore analysed together in this study.  PAH was 
defined as mean pulmonary arterial pressure ≥ 25 mmHg at rest and pulmonary 
artery occlusion pressure (PAOP) ≤ 15 mmHg with a normal or reduced cardiac 
output. The date of diagnostic right heart catheterisation was taken as the date 
of diagnosis. If this could not be located in the hospital records, then date of 
first visit to the pulmonary hypertension centre was used.  
 
Patients with mPAP at rest of <25 mmHg or PAOP >15 mmHg were excluded.  
Patients with missing PAOP were excluded if echocardiogram and/or cardiac MRI 
suggested evidence of left heart disease. Patients were also excluded if known 
to have connective tissue/collagen vascular disease, portal hypertension, 
haemolytic anaemia, HIV or congenital heart disease. Patients with significantly 
abnormal pulmonary function test (FEV1, FVC or TLC <60% predicted) (32, 33) 
were excluded. Patients with radiological evidence of co-existing parenchymal 
lung disease (of any severity) on chest CT were also excluded from this study.   
 
Incidence and Prevalence: 
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The incidence and prevalence of idiopathic, heritable and anorexigen-associated 
pulmonary arterial hypertension were calculated as the ratio of newly diagnosed 
(incidence) or all living patients (prevalence) and the total population of the 
United Kingdom and Ireland for the respective year. Patients lost to follow up 
were assumed to be dead for the purpose of the prevalence count. Patients who 
were diagnosed prior to 1st January 2001 and were still alive on the 31st 
December 2009 were noted and used in the prevalence count only. 
 
Statistical Analysis: 
 
Statistical analyses were performed using SPSS 19 (SPSS Inc, Chicago, IL). Mean ± 
standard deviation or median (interquartile ranges) were used to describe 
quantitative variables. Comparisons between 2 independent groups were 
performed using Student’s t test or Mann-Whitney U test. For multiple 
comparisons of quantitative data, one way analysis of variance (ANOVA) or 
Kruskal-Wallis test were used. Categorical variables were described by 
frequencies and percentages and comparisons between groups performed using 
χ2 or Fisher‘s exact tests. Patients were divided into younger (age ≤ 50) and 
older (age > 50) subgroups by the median age at diagnosis. Patients were also 
divided into three cohorts based on the year of diagnosis (2001-2003, 2004-2006 
and 2007-2009) to identify any changing trends over the course of the study 
period.  
 
Survival endpoint was taken as either date of death or censoring. Patients were 
censored if they were transplanted, lost to follow up (date of last visit to PH 
centre was used as censor date) or if they were alive on the 31st December 2009. 
Mortality was confirmed using PH centre and general practitioner records and 
NHS strategic tracing services. Survival was estimated using the Kaplan Meier 
method and survival curves compared using the log-rank test.  
 
Multivariate Cox regression was used to evaluate the prognostic significance of 
year of diagnosis after adjusting for variables known to have prognostic 
significance (age, functional class, 6 minute walk distance, % predicted diffusion 
capacity for carbon monoxide, mean right atrial pressure and cardiac index) (22, 
23, 26, 33, 57).  
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Handling of missing data: 
 
For descriptive statistics, only patients with available data were analysed. For 
multivariate Cox regression analysis of prognostic significance of year of 
diagnosis, a missing data category (ie, data available, data not available) was 
created for each covariate to enable evaluation of patients with missing data.  
 
P-value<0.05 was considered significant throughout. 
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3.4 Results 
 
Incidence and prevalence 2001 - 2009: 
 
The combined population of the UK (http://www.statistics.gov.uk) and Ireland 
(http://www.cso.ie) in 2001- 2003, 2004 - 2006 and 2007 - 2009 were estimated 
to be 61, 62 and 64 million respectively. 121, 159 and 202 patients were 
diagnosed in the period 2001 - 2003, 2004 - 2006 and 2007 - 2009 respectively. 
This gave rise to estimated incidence (per million per  year) of idiopathic, 
heritable and anorexigen-associated PAH in the UK and Ireland of 0.7, 0.9 and 
1.1 in 2001 - 2003, 2004 - 2006 and 2007 - 2009 respectively. The estimated 
prevalence in 2009 was 6.6 cases/million population. 
 
Baseline characteristics at the time of diagnosis: 
 
 482 patients satisfied the inclusion and exclusion criteria of idiopathic, 
heritable and anorexigen-associated PAH of this study. Out of the 482 patients, 
92.9% (n=448) were idiopathic, 5.4%(n=26) heritable and 1.7% (n=8) anorexigen-
associated PAH. Baseline characteristics of the whole study cohort of idiopathic, 
heritable and anorexigen-associated PAH are shown in Table 3.1. Selective 
baseline variables were compared across four age-quartiles subgroups in Table 
3.2.  
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Table 3.1. Baseline characteristics of all idiopathic, heritable and 
anorexigen-associated PAH (n=482) and according to age subgroups (age ≤ 50 
and age > 50 subgroups). 
 
Baseline characteristics  All cases Age ≤ 50 Age > 50 p-
value* 
Age, years (n=482) 50.1(17.1) 36.5(9.3) 65.1(8.3) <0.001 
Gender, % female (n=482) 69.9%(337) 73.2%(180) 66.5%(157) 0.112 
Ethnicity, % non-white 
(n=424) 
12.3%(52) 15.4%(34) 8.9%(18) 0.041 
Symptoms: (n=437) 
Breathlessness 
Chest pain 
Peripheral oedema 
Syncope 
Dizziness 
Presyncope 
Fatigue 
Cough 
Palpitation 
Haemoptysis 
Weight loss 
Ascites 
 
98.9%(432) 
29.1%(127) 
30.9%(135) 
22.7%(99) 
19.7%(86) 
11.9%(52) 
13.5%(59) 
13.1%(57) 
8.9%(39) 
3.9%(17) 
4.8%(21) 
2.5%(11) 
 
98.5%(218) 
31.7%(70) 
23.5%(52) 
33.5%(74) 
20.4%(45) 
14.9%(33) 
14.5%(32) 
13.1%(29) 
8.6%(19) 
5.0%(11) 
3.6%(8) 
1.8%(4) 
 
99.1%(214) 
26.3%(57) 
38.4%(83) 
11.6%(25) 
19.1%(41) 
8.8%(19) 
12.5%(77) 
13.0%(28) 
9.3%(20) 
2.8%(6) 
6.0%(13) 
3.3%(7) 
 
1.0 
0.212 
0.001 
<0.001 
0.735 
0.048 
0.545 
0.976 
0.808 
0.238 
0.237 
0.376 
Duration of symptoms, 
months, median (IQR) 
(n=404) 
18.0 
(9.0-36.0) 
12.0 
(6.0-24.0) 
24.0 
(12.0-36.0) 
<0.001 
Functional class: (n=456) 
I/II 
III 
IV 
 
15.5%(72) 
66.7%(304) 
17.5%(80) 
 
19.7%(45) 
65.9%(151) 
14.4%(33) 
 
11.9%(27) 
67.4%(153) 
20.7%(47) 
 
 
0.031 
Smoking history: (n=361) 
Current smoker 
Ex-smoker 
Never smoker 
 
14.4%(52) 
41.3%(149) 
44.3%(160) 
 
16.0%(28) 
30.9%(54) 
53.1%(93) 
 
12.9%(24) 
51.1%(95) 
36.0%(67) 
 
 
<0.001 
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Baseline characteristics  All cases Age ≤ 50 Age > 50 p-
value* 
Co-morbidities: (n=455) 
IHD 
Hypertension 
Atrial fibrillation 
Diabetes 
Hypothyroidism 
 
12.1%(58) 
26.6%(121) 
5.3%(24) 
14.3%(65) 
11.6%(53) 
 
1.3%(3) 
11.0%(25) 
0%(0) 
5.3%(12) 
7.5%(17) 
 
24.2%(55) 
42.3%(96) 
10.6%(24) 
23.3%(53) 
15.9%(36) 
 
<0.001 
<0.001 
<0.001 
<0.001 
0.005 
6MWD, metres (n=260) 292.4(123.0) 330.0(118.7) 246.1(112.2) <0.001 
ISWD, metres (n=120), 
median 
190.0(82.3-
340.0) 
260.0(130.0-
360.0) 
140.0(70.0-
255.0) 
0.001 
Pulmonary Function: 
%FEV1 (n=350) 
%FVC (n=346) 
%TLC (n=204) 
%DLCO (n=331) 
 
85.3(14.7) 
94.0(16.4) 
95.4(13.9) 
62.0(20.9) 
 
85.5(13.6) 
91.2(14.6) 
96.3(13.4) 
67.0(17.6) 
 
85.1(15.8) 
96.7(17.6) 
94.4(14.3) 
56.7(22.8) 
 
0.785 
0.002 
0.324 
<0.001 
Haemodynamics: 
mRAP, mmHg (n=439) 
PASP, mmHg (n=427) 
PADP, mmHg (n=424) 
mPAP, mmHg (n=457) 
PAOP, mmHg (n=408) 
TPG, mmHg (n=404) 
SvO2, % (n=395) 
CO, L.min-1 (n=410) 
CI, L.min-1m-2 (n=366) 
PVR, WU (n=395) 
PVRI, WU.m2 (n=355) 
 
10.1(6.0) 
86.2(21.1) 
34.7(12.3) 
54.1(13.9) 
9.2(3.5) 
44.4(13.7) 
61.5(9.5) 
4.0(1.5) 
2.1(0.7) 
12.8(6.3) 
23.1(10.3) 
 
10.0(5.8) 
88.7(22.6) 
38.6(12.9) 
57.2(14.9) 
8.8(3.5) 
47.8(14.5) 
62.5(10.3) 
4.0(1.5) 
2.1(0.7) 
13.9(6.7) 
24.8(11.2) 
 
10.2(6.1) 
83.8(19.2) 
31.1(10.5) 
51.0(12.2) 
9.5(3.5) 
41.3(12.2) 
60.0(8.6) 
4.0(1.5) 
2.1(0.7) 
11.8(5.8) 
21.5(9.1) 
 
0.738 
0.016 
<0.001 
<0.001 
0.035 
<0.001 
0.053 
0.830 
0.683 
0.001 
0.003 
Data expressed as % (n) or mean (SD) unless otherwise stated.  
 
*Comparisons are for age ≤ 50 vs. age > 50 years.  
 
Definition of abbreviations: 6MWD = 6 minute walk distance, CI= cardiac index, CO= cardiac 
output,  % DLCO = % predicted diffusion capacity for carbon monoxide, %FEV1 = % predicted forced 
expiratory volume in 1 second, %FVC = % predicted forced vital capacity, IHD = ischaemic heart 
disease, IQR = interquartile range  ISWD = incremental shuttle walk distance, mPAP = mean 
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pulmonary artery pressure, mRAP= mean right atrial pressure, PADP = pulmonary artery diastolic 
pressure, PAOP= pulmonary artery occlusion pressure, PASP = pulmonary artery systolic pressure, 
PVR= pulmonary vascular resistance, PVRI= pulmonary vascular resistance index, SvO2= mixed 
venous oxygen saturation, %TLC= % predicted total lung capacity, TPG= transpulmonary gradient, 
WU= Wood Units.  
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Table 3.2. Selective baseline characteristics of incident idiopathic, heritable 
and anorexigen-associated pulmonary arterial hypertension according to age 
quartile subgroups. 
 
Variables Age ≤ 36 
years 
Age 37-50 
years 
Age 51–65 
years 
Age >65 
years 
p-
value* 
Gender, % 
female 
(n=482) 
71.9%(92) 74.6%(88) 68.3%(84) 64.6%(73) 0.373 
Duration, 
months, 
median(IQR) 
12.0 
(6.0-24.0) 
12.0 
(8.0-24.0) 
24.0 
(12.0-36.0) 
22.0 
(12.0-
36.0) 
<0.001 
6MWD, 
metres 
(n=260) 
362.8 
(105.2) 
299.2 
(123.2) 
286.7 
(103.1) 
208.9 
(107.9) 
<0.001 
%DLCO 
(n=331) 
66.7(15.9) 67.2(19.4) 61.4(21.1) 51.0(23.5) <0.001 
mPAP, 
mmHg 
(n=457) 
58.9(17.7) 55.5(11.2) 53.6(10.9) 48.1(13.0) <0.001 
PAOP, 
mmHg 
(n=408) 
8.8(3.5) 8.8(3.5) 9.5(3.3) 9.5(3.8) 0.218 
TPG, mmHg 
(n=404) 
49.2(17.1) 46.5(11.3) 43.9(10.7) 38.2(13.0) <0.001 
PVRI, 
WU.m2 
(n=355) 
25.0(12.6) 24.6(9.6) 22.9(8.6) 19.9(9.6) 0.005 
Data expressed as % (n) or mean (SD) unless otherwise indicated 
Definition of abbreviations: see Table 3.1. 
*Comparisons are for the 4 age-quartile groups. P-values relate to overall difference between the 
4 age-quartile subgroups. 
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Age and gender: 
 
The median age of incident idiopathic, heritable and anorexigen-associated PAH 
in this study was 50.0 years (IQR  36.0-65.0) and was similar between males and 
females. There was no statistically significant difference in gender ratio across 
the 4 age quartiles. 13.5%(n=65) of patients were over 70 years of age at the 
time of diagnosis. 
 
 
 
Figure 3.1: Distribution of age of incident idiopathic, heritable and 
anorexigen-associated pulmonary arterial hypertension by gender. 
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Ethnicity: 
 
Ethnicity data were available in 424 patients of which 12.3% were of non-white 
ethnic origin. Compared with whites, non-whites were younger (39.5 years [IQR 
32.0-59.8] vs 50.0 years [IQR 36.0-65.0], p=0.015), had greater female 
predominance (% female 84.6% vs. 68.3%, p=0.016) and lower proportion of 
current and/or ex-smoker (34.2% vs 58.6%, p=0.007). There was no statistically 
significant difference in body mass index (BMI), functional class, exercise 
capacity or haemodynamics between whites and non-whites. Patients with 
missing ethnicity data had similar baseline characteristics to the white ethnic 
group. 
 
Body mass index (BMI): 
 
Mean BMI was 28.3 ± 6.3 kg/m2 and was higher in females (females: 28.8 ± 6.6 
kg/m2 vs. males: 27.3 ± 5.5 kg/m2, p=0.02). 37.9% of females and 24.8% of males 
were obese.  
 
Symptoms: 
 
Presenting symptoms were available in 437 patients . The median duration of 
symptoms (n=404) was 18.0 months (IQR 9.0-36.0) and was similar in males and 
females. Dyspnoea was the most common symptom (98.9%, n=432) at the time of 
diagnosis. Other less common symptoms included peripheral oedema (30.9%, 
n=135), chest pain (29.1%, n=127), syncope (22.7%, n=99), light-headedness 
(19.7%, n=86), fatigue (13.5%, n=59), cough (13.1%, n=57), pre-syncope (11.9%, 
n=52), palpitation (8.9%, n=39), weight loss (4.8%, n=21) and haemoptysis (3.9%, 
n=17). 
 
Older (age > 50 years) patients were more likely to present with peripheral 
oedema whereas younger (age ≤ 50 years) patients were more likely to present 
with syncope and presyncope (Table 3.1).  
 
Baseline exercise capacity and functional class: 
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Baseline exercise capacity was evaluated with 6 minute walk test in 260 patients 
and incremental shuttle walk test in 120 patients. Mean 6MWD and median 
incremental shuttle walk distance at the time of diagnosis were 292.4 ± 123.0 
metres  and 190.0 metres (IQR 82.3-340.0) respectively.  
 
The majority of patients had severe symptoms by the time of diagnosis, with 
66.7% and 17.5% in functional class III and IV respectively. Distribution of 
functional class was similar between males and females. A greater proportion of 
younger patients were in functional class I/II compared with older patients 
(Table 3.1). 
 
Smoking History: 
 
14.4% (n=52) and 41.3% (n=149) of patients were current and ex-smokers 
respectively. History of smoking was more prevalent in older (table 3.1) and 
male patients (11.4% of male patients were current and 57.9% ex-smoker 
compared with 15.8% and 33.6% of female patients were current and ex-smoker 
respectively, p<0.001).  
 
Pulmonary function: 
 
Patients had preserved spirometry and lung volumes but disproportionately 
reduced % DLCO (Table 3.1). Older patients had lower %DLCO compared with their 
younger counterparts (Table 3.1 and Table 3.2). 
 
When compared across smoking history subgroups, ex-smoker had lower %DLCO 
(55.9% ± 20.8%) compared with never (65.9% ± 20.2%, p=0.001) and current 
smoker (64.6% ± 21.3%, one way ANOVA p=0.001).  
 
Pulmonary haemodynamics: 
 
Patients had severe haemodynamic compromise (Table 3.1) and this was similar 
for males and females. Younger patients had significantly higher mean 
pulmonary artery pressures and transpulmonary gradient, lower pulmonary 
artery occlusion pressures, similar cardiac indices, and higher pulmonary 
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vascular resistance indices compared with older patients (Table 3.1 and Table 
3.2)  
 
Treatment: 
 
First line treatment data were available in 479 patients. 44.3% (n=212) of 
patients were started on an endothelin receptor antagonist, 29.2% (n=140) 
phosphodiesterase type 5 inhibitor, 18.8% (n=90) prostaglandins, 5.0% (n=24) 
calcium channel blocker, 2.1%(n=10) combination therapy and 0.6% (n=3) 
patients received no treatment.  
 
46.3% (n=222) and 6.0% (n=29) of patients received combination and triple 
therapy respectively at some point of their disease.  A higher proportion of 
younger patients received sequential combination therapy (57.6% vs 34.5%, 
p<0.001), triple therapy (10.6% vs 1.3%, p<0.001), prostaglandins (51.8% vs 
28.1%, p<0.001), calcium channel blocker (10.2% vs 3.0%, p=0.002) and 
transplantation (5.3% vs 0.4%, p=0.002) compared with their older counterparts. 
There was no statistically significant difference in treatment between males and 
females . 
 
14 patients received heart-lung or bilateral lung transplantation and 12 patients 
had atrial septostomy over the study period.  
 
Comparison of baseline characteristics according to year of diagnosis: 2001-3 
vs 2004-6 vs 2007-9. 
 
In the later cohort (2007-2009), patients were older, more obese, had more co-
morbidities and lower %DLCO (Table 3.3). There was no statistically significant 
difference in gender, distribution of functional class, exercise capacity or 
pulmonary haemodynamics over the three time periods.  
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Table 3.3. Baseline characteristics and treatment of the study cohort 
according to the year of diagnosis. 
 
Baseline characteristics 
and treatment 
2001 - 
2003 
2004 – 
2006 
2007 – 
2009 
p-
value* 
Age, years, median (IQR) 
(n=482) 
45.0 
(34.5-59.0) 
52.0 
(36.0-65.0) 
52.0 
(37.8-68.0) 
0.003 
Duration, months, 
median (IQR) (n=404) 
18.0 
(8.0-39.0) 
18.0 
(8.5-30.0) 
18.0 
(10.0-30.0) 
0.883 
BMI, kg/m2 (n=398) 28.1(6.4) 26.9(5.8) 29.8(6.5) <0.001 
% obese (n=398) 31.2%(29) 25.5%(37) 43.1%(69) 0.004 
Co-morbidities (n=455) 
IHD 
Diabetes 
 
5.8%(7) 
5.7%(6) 
 
11.4%(18) 
15.0%(23) 
 
16.3%(33) 
18.3%(36) 
 
0.018 
0.012 
%DLCO (n=331) 68.6(21.8) 61.8(19.0) 59.2(21.3) 0.009 
First line treatment 
(n=479) 
PD5i 
ERA 
Prostaglandins 
CCB 
Combination 
None 
 
 
7.6%(9) 
51.3%(61) 
31.1%(37) 
7.6%(9) 
2.5%(3) 
0%(0) 
 
 
20.8%(33) 
57.9%(92) 
17.0%(27) 
3.1%(5) 
0.6%(1) 
0.6%(1) 
 
 
48.8%(98) 
29.4%(59) 
12.9%(26) 
5%(10) 
3.0%(6) 
1.0%(2) 
 
 
 
 
<0.001 
Definition of abbreviations: BMI = body mass index, CCB = calcium channel blockers, %DLCO = % 
predicted diffusion capacity for carbon monoxide, ERA = endothelin receptor antagonists, IHD = 
ischaemic heart disease, PD5i = phosphodiesterase 5 inhibitors.  
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Survival:  
 
129 patients died over the study period with observed 1, 2, 3 and 5 year survival 
of 92.7%, 84.0%, 73.3% and 61.1% respectively. Younger patients (aged ≤ 50 
years) had better survival with 1, 2, 3 and 5 year survival of 94.7%, 91.0%, 87.2% 
and 74.7% compared with 1, 2, 3 and 5 year survival of 90.0%, 75.5%, 57.1% and 
43.7% in patients aged >50 years (Figure 3.3, log- rank, p<0.001). Patients aged 
>50 years were more likely to die compared with patients aged ≤50 years 
(unadjusted hazard ratio 3.0, p<0.001). 
 
There was no difference in overall survival for the 3 time periods (Figure 3.2). 
However, after adjusting for age, functional class, 6 minute walk distance, % 
diffusion capacity for carbon monoxide, mean right atrial presssure and cardiac 
index, patients diagnosed in 2001 -2003 were more likely to have a shorter 
survival time compared with patients diagnosed in 2007-2009 (hazard ratio 1.96, 
p=0.019).  
 
 
 
Figure 3.2. Kaplan meier survival 
curves according to year of diagnosis 
(2001-2003, 2004-2006, 2007-2009) in 
incident idiopathic, heritable and 
anorexigen-associated pulmonary 
arterial hypertension. 
Years from 
diagnosis 
0 2 4 6 8 
No at risk 
2001-2003 
2004-2006 
2007-2009 
 
121 
159 
202 
 
93 
135 
53 
 
70 
65 
0 
 
58 
1 
0 
 
8 
0 
0 
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Figure 3.3. Kaplan Meier survival curves according to age in incident 
idiopathic, heritable and anorexigen-associated pulmonary arterial 
hypertension. Figure 3.3a. Patients ≤ 50 years old (corresponding to median 
age) had better survival compared with patients >50 years old. Figure 3.3b. 
Patients were divided into 4 groups according to age quartiles. 
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3.5 Discussion 
 
Our study described the largest series so far reported of incident, treatment-
naive, idiopathic, heritable and anorexigen-associated PAH patients. This was a 
national study encompassing all patients diagnosed with idiopathic, heritable 
and anorexigen-associated PAH in the UK and Ireland.  Firstly, we found age 
influenced the phenotypic characteristics of patients. Secondly, we found 
despite the aging demographics over the past decade, survival of idiopathic, 
heritable and anorexigen-associated PAH patients in the UK and Ireland have 
improved. On the other hand, there was no change in duration of symptoms 
before diagnosis. Patients were still diagnosed late with severe functional and 
haemodynamic impairment.  
 
Our study showed age influenced the phenotypic characteristics of incident 
idiopathic, heritable and anorexigen-associated PAH. Although we dichotomised 
our study cohort into the younger and older subgroups and showed significant 
differences between the two, in real-life these are likely to represent the two 
ends of a continuous spectrum of the same disease. When the study cohort was 
divided into 4 groups by age quartile, similar relationship was observed between 
these variables and aging.  Co-morbidities in the older patients may partly 
explain their worse functional capacity despite their less severe haemodynamic 
impairment. Although Shapiro et al also reported similar age related findings 
with lower 6-minute walk distance, transpulmonary gradient and pulmonary 
vascular resistance in elderly patients with pulmonary hypertension, 28% of all 
patients and 56% of the elderly group in that study had pulmonary artery 
occlusion pressure ≥ 15mmHg and thus did not meet the haemodynamic criteria 
for idiopathic PAH (82). Although a normal pulmonary artery occlusion pressure 
does not exclude pulmonary venous hypertension (83), especially in older 
patients with comorbidities, we believe it is unlikely many patients in this study 
were misclassified . All patients were diagnosed by multidisciplinary teams of 
pulmonary vascular experts at each centre in accordance with contemporary 
national and international pulmonary hypertension guidelines (5, 80, 81). 
Routine work-up of all new patients include ECG, echocardiogram and cardiac 
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MRI. Results of these assessment were taken into consideration in a 
multidisciplinary setting before a final diagnosis was made in any new patient.  
 
Younger patients in this study had a significantly higher frequency of syncope 
and presyncope whereas older patients were more likely to present with 
peripheral oedema. Syncope and presyncope were also common in childhood 
idiopathic PAH whereas oedema was rare (84). Younger patients with their 
better functional class and exercise capacity may exert themselves further 
leading to presyncope or syncope. The onset of peripheral oedema may reflect 
right ventricular failure. Interestingly, even in patients with similar mean right 
atrial pressure, older patients are still more likely to present with oedema 
compared with younger patients in this study (results not shown). Older 
patients, despite their less severe haemodynamic impairment appeared to have 
less physiological reserve than their younger counterparts to cope with the 
progressive pulmonary hypertension and subsequent failing right ventricle. This 
needs to be taken into account when deciding the choice of treatment for 
individual patient.  
 
Older patients in this study had lower %DLCO compared with their younger 
counterparts. Most reference equations for DLCO  use age, height and gender in a 
linear equation to predict DLCO (85).  However, the rate of decline of DLCO 
accelerates with aging (86). This may  therefore potentially result in 
overprediction of  predicted DLCO in older patients. A higher proportion of 
current/ex-smoker observed in older patients in this study may also explain their 
lower % DLCO due to the presence of co-existing smoking related lung disease. 
However, we have excluded patients with any co-existing parenchymal lung 
disease from this study. As parenchymal lung  abnormalities on chest CT are 
difficult to quantify objectively, we therefore excluded abnormalities of all 
severity from this study of idiopathic, heritable and anorexigen-associated PAH 
patients.  
 
The demographics, epidemiology and survival of idiopathic, heritable and 
anorexigen-associated PAH have changed in the UK and Ireland between 2001 
and 2009. We observed that over the nine year study period, patients were 
older, more obese, and had more co-morbidities in the later years. We speculate 
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that these changing demographics are largely due to changes in the referral 
pattern rather than an actual change in the disease. Alternatively, this may 
indicate that we are dealing with two possible subtypes of patients: younger 
patients similar to the primary pulmonary hypertension cohort of the NIH era 
(25) versus older patients characterised by the presence of co-morbidities. The 
incidence of idiopathic, heritable and anorexigen-associated PAH also appeared 
to increase year on year, largely due to rising number of referrals to PH centres. 
Although there was no difference in overall survival between the three time 
periods, when survival was adjusted for age and other known prognostic factors, 
it is encouraging to observe that the survival of incident idiopathic, heritable 
and anorexigen-associated PAH in the UK and Ireland has improved over the past 
decade. On the other hand, delays in diagnosis persist. Not only was the delay 
unchanged within the UK and Ireland over the past decade, there was no 
improvement when compared with patients in the NIH registry from the 1980s 
(25). We believe the persistent delay in diagnosis over time is largely due to the 
increasing proportion of elderly PAH patients. We found older patients have 
longer duration of symptoms before diagnosis. It is possible that the non-specific 
pulmonary hypertension symptoms were more commonly attributed to their old 
age or other more common illnesses before PAH was suspected. More education 
is therefore needed outside the pulmonary hypertension community to recognise 
that idiopathic PAH is no longer a disease affecting young patients only.  
 
The main limitation of our study is the unavoidable incompleteness in our 
dataset due to its observational nature, with a small amount of missing data and 
uneven frequency of follow-up and investigations performed at each visit. Future 
studies looking into the relationship between age and right heart function at 
baseline and on treatment may help to understand the phenotypic and survival 
differences observed between the younger and older patients.   
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3.6 Conclusion 
 
The current UK and Ireland study is the largest incident series of treatment-
naive idiopathic, heritable and anorexigen-associated PAH patients to date. We 
have shown that younger patients have different phenotype and survival 
compared with their older counterparts. The demographics and epidemiology of 
incident idiopathic, heritable and anorexigen-associated PAH have changed and 
survival has improved between 2001 and 2009. However, patients still presented 
in advanced stages. Awareness of the changing demographics and epidemiology 
of idiopathic, heritable and anorexigen-associated PAH as reported in this study 
is imperative to the early diagnosis and treatment of this otherwise rare and 
fatal disease.  
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4 Chapter 4: Validation of Pulmonary Hypertension 
Survival Prediction Equations 
 
4.1 Summary 
 
Rationale: 
 
The NIH equation, French equation, Pulmonary Hypertension Connection (PHC) 
equation, REVEAL equation and REVEAL risk score are currently available to 
predict prognosis in pulmonary arterial hypertension (PAH).  It is unclear 
whether these survival prediction models that were all derived from a mixed 
incident-prevalent cohort are applicable to a purely incident PAH population. 
 
Objectives: 
 
To test the applicability of currently available PAH survival prediction equations 
in a purely incident cohort of idiopathic, heritable and anorexigen-associated 
PAH patients.  
 
Methods: 
 
482 patients with incident idiopathic, heritable and anorexigen-associated PAH 
diagnosed in all eight centres in the UK and Ireland between 2001 and 2009 were 
included in this study to validate the survival prediction equations. Patients with 
parenchymal lung disease (of any severity) on chest CT were excluded from this 
study. Observed survival was estimated using life table analysis and compared 
with predicted survival in the same patients calculated using the NIH equation, 
French equation, PHC equation, REVEAL equation and REVEAL risk score.  
 
Results: 
 
The NIH equation underestimated survival of our study cohort. Although the 
REVEAL equation, REVEAL risk score and Pulmonary Hypertension Connection 
108 
 
equation were derived from mixed incident-prevalent cohorts, all three models 
accurately predicted survival of our incident cohort at 1 year. 
 
Conclusion: 
 
Some survival equations more accurately predicted survival of our incident study 
cohort than others.  
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4.2 Introduction 
 
Five survival prediction equations or models are currently available to predict 
prognosis in pulmonary arterial hypertension (PAH): National Institute of Health 
(NIH) equation (26), French equation (37), Pulmonary Hypertension Connection  
(PHC) equation (23), REVEAL equation (57) and REVEAL risk score (76).  These 
survival prediction equations were individually derived from pulmonary 
hypertension registries that differ in size, duration and period of recruitment, 
patient population, length of follow-up, timing of assessment of prognostic 
variables, geographical region and healthcare system. It is also recognised that 
previously diagnosed ‘prevalent’ patients have better survival compared with 
newly-diagnosed ‘incident’ patients. The NIH, French and PHC equations were 
derived from idiopathic, heritable and anorexigen-associated PAH population. On 
the other hand, both REVEAL models’ derivation population included group I PAH 
patients with diagnosis other than idiopathic, heritable and anorexigen-
associated PAH.  It is unclear whether any of these five models that were all 
derived from a mixed incident-prevalent cohort are applicable to a purely 
incident PAH population.  
 
The aim of this study was to validate the five currently available PAH survival 
prediction equations using a purely incident cohort of idiopathic, heritable and 
anorexigen-associated PAH patients diagnosed in the UK and Ireland between 
2001 and 2009.  
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4.3 Methods.  
 
The study cohort included all consecutive, newly diagnosed (incident), 
treatment–naive cases of idiopathic, heritable and anorexigen-associated PAH 
(n=482) diagnosed in all eight pulmonary hypertension centres in the UK and 
Ireland between 1st January 2001 and 31st December 2009. Patients with 
radiological evidence of co-existing parenchymal lung disease (of any severity) 
on chest CT were excluded from this study.  Inclusion and exclusion criteria of 
idiopathic, heritable and anorexigen-associated PAH used for validation of 
survival equations in this study were described in details in the methods section 
of chapter 3.    
 
Statistical Analysis: 
 
Analyses were performed using SPSS 18 (SPSS Inc, Chicago, IL) and SAS v9.2 (SAS 
Institute, Cary, NC). Survival endpoint was taken as either date of death or 
censoring. Patients were censored if they were transplanted, lost to follow up 
(date of last visit to pulmonary hypertension centre was used as censor date) or 
if they were alive on the 31st December 2009.  
 
Expected survival was calculated for each patient for each of the survival 
prediction equations and compared with observed survival of the same patient 
estimated using the Kaplan Meier method. To assess the overall performance of 
each prediction model, Brier score with a weighted function that takes censoring 
into consideration was used. At each time point, the Brier score is the average 
of squared difference between observed and predicted survival for each patient. 
The Brier score for a model (survival prediction equation or risk score) can range 
from 0 to 1, with lower score representing higher accuracy. For example, if a 
model predicts survival probability of 70% and the patient survived, then the 
Brier score is (0.7-1)2=0.09. Conversely, if a model predicts survival probability 
of 70% and the patient died, then the Brier score is (0.7-0)2= 0.49. The 
differences in Brier score between the five survival prediction models were 
compared in matched patient groups. The upper and lower 95% confidence 
intervals were obtained from 50,000 bootstrap re-samples.  
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Handling of missing data: 
 
As not all patients have a calculable probability of survival for all five survival 
prediction models, Brier scores were derived from patients where probability of 
survival from all five models were all available. The results were similar when 
analyses were repeated on all patients with available probability of survival. 
 
P-value<0.05 was considered significant throughout. 
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4.4 Results 
 
Comparisons of survival prediction equations (all patients): 
 
The baseline characteristics of the validation cohort (n=482 incident idiopathic, 
heritable and anorexigen-associated PAH) have been described in the previous 
chapter (chapter 3, Table 3.1). Some survival prediction equations performed 
better (i.e, lower brier score) than others at predicting survival of our study 
population (Table 4.1). At 1 year, there was no difference in accuracy between 
the two REVEAL models and the PHC equation (Table 4.2). Both REVEAL equation 
and REVEAL risk score performed better than the French equation at predicting 
survival of our study cohort at 1 year (Table 4.2). At 2 and 3 year, both the PHC 
and French equations performed better than the NIH equation (Tables 4.3 and 
4.4). There was no statistically significant differences in Brier scores between 
the French equation and the PHC equation at predicting survival at 2 and 3 year 
(Tables 4.3 and 4.4). The accuracy of all survival equations (NIH, French and 
PHC) decreased with time from diagnosis (Table 4.1).  
 
Figure 4.1 shows the survival curves of actual observed survival of our UK and 
Ireland validation cohort versus predicted survival of the same patients 
calculated using the NIH, French, PHC and REVEAL equations. Predicted survival 
from the REVEAL and PHC equations were comparable to the observed survival of 
our UK and Ireland incident idiopathic, heritable and anorexigen-associated PAH 
study cohort. The NIH and French equations under-estimated survival of our 
study cohort. 
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Table 4.1. Brier scores of survival prediction models (all patients). 
 
 Brier scores via bootstrap (95% Confidence interval) 
Survival 
prediction 
models 
1 year  
prediction 
2 year 
prediction 
3 year  
prediction 
NIH equation 0.1231 
(0.1034-0.1448) 
0.2103 
(0.1836-0.2384) 
0.2799 
(0.2437-0.3137) 
French equation 0.0642 
(0.0413-0.0919) 
0.1206 
(0.0918-0.1539) 
0.1831 
(0.1458-0.2251) 
PHC equation 0.0499 
(0.0214-0.0851) 
0.1015 
(0.0651-0.1439) 
0.1691 
(0.1263-0.2181) 
REVEAL 
equation 
0.0462 
(0.0177-0.0815) 
  
REVEAL risk 
score 
0.0468 
(0.0193-0.0809) 
  
 
  
114 
 
Table 4.2. Brier scores differences via bootstrapping for 1-year prediction for 
all patients. 
 
Survival prediction models Brier score 
differences 
95% Confidence 
Interval 
p-value 
French equation – REVEAL 
equation 
0.0181 0.0019 to 0.0331 0.031 
NIH equation – REVEAL equation 0.0769 0.0509 to 0.1004 <0.001 
PHC equation – REVEAL equation 0.0038 -0.0027 to 0.0119 0.296 
REVEAL risk score – REVEAL 
equation 
0.0007 -0.0050 to 0.0055 0.763 
French equation – PHC equation 0.0143 -0.0046 to 0.0314 0.124 
NIH equation – PHC equation 0.0731 0.0484 to 0.0959 <0.001 
REVEAL risk score – PHC equation -0.0031 -0.0106 to 0.0030 0.373 
French equation – NIH equation -0.0588 -0.0774 to -0.0393 <0.001 
REVEAL risk score – NIH equation -0.0762 -0.0985 to -0.0518 <0.001 
French equation – REVEAL risk 
score 
0.0174 0.0023 to 0.0315 0.026 
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Table 4.3. Brier scores differences via bootstrapping for 2-year prediction for 
all patients. 
 
Survival prediction models Brier score 
differences 
95% Confidence 
Interval 
p-value 
French equation – PHC equation 0.0191 -0.0144 to 0.0513 0.244 
NIH equation – PHC equation 0.1087 0.0681 to 0.1469 <0.001 
French equation – NIH equation -0.0896 -0.1195 to -0.0587 <0.001 
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Table 4.4. Brier scores differences via bootstrapping for 3-year prediction for 
all patients. 
 
Survival prediction models Brier score 
differences 
95% Confidence 
Interval 
p-value 
 
French equation – PHC 
equation 
 
0.0140 
 
-0.0297 to 0.0562 
 
0.521 
 
NIH equation – PHC equation 
 
0.1088 
 
0.0512 to 0.1623 
 
<0.001 
 
French equation – NIH 
equation 
 
-0.0949 
 
-0.1371 to -0.0499 
 
<0.001 
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Figure 4.1. Observed versus predicted survival using the NIH equation, 
French equation, PHC equation and REVEAL equation for all patients. Only 1-
year predicted survival was calculated for the REVEAL equation. 
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Comparisons of survival prediction equations in female patients: 
 
The above analyses were repeated within gender subgroups. In female patients, 
the NIH equation had higher Brier scores compared with all other survival 
prediction models. There were no statistically significant differences between 
the French equation, PHC equation, REVEAL equation and REVEAL risk scores at 
predicting survival of our female incident patients (Tables 4.5, 4.6, 4.7 and 4.8). 
Figure 4.2 shows the survival curves of actual observed survival of our female 
subgroup versus predicted survival of the same patients calculated using the 
NIH, French, PHC and REVEAL equations. 
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Table 4.5. Comparison of survival prediction models using the Brier scores in 
female idiopathic, heritable and anorexigen-associated PAH patients.  
 
Females patients Brier scores via bootstrap (95% Confidence interval) 
Survival prediction 
models 
1 year 
prediction 
2 year 
prediction 
3 year 
prediction 
NIH equation 0.1209 
(0.1005–0.1433) 
0.2057 
(0.1796-0.2335) 
0.2731 
(0.2391-0.3096) 
French equation 0.0547 
(0.0305-0.0847) 
0.1117 
(0.0831-0.1442) 
0.1679 
(0.1324-0.2071) 
PHC equation 0.0488 
(0.0212-0.0846) 
0.1006 
(0.0640-0.1430) 
0.1708 
(0.1268-0.2208) 
REVEAL equation 0.0477 
(0.0182-0.0848) 
  
REVEAL risk score 0.0465 
(0.0182-0.0815) 
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Table 4.6. Brier scores differences via bootstrapping for 1-year prediction in 
female idiopathic, heritable and anorexigen-associated PAH patients. 
 
Survival prediction models 
(female patients) 
Brier score 
differences 
95% Confidence 
Interval 
p-value 
French equation – REVEAL 
equation 
0.0070 -0.0037 to 0.0159 0.180 
NIH equation – REVEAL equation 0.0731 0.0485 to 0.0957 <0.001 
PHC equation – REVEAL equation 0.0011 -0.0043 to 0.0059 0.658 
REVEAL risk score – REVEAL 
equation 
-0.0012 -0.0066 to 0.0025 0.671 
French equation – PHC equation 0.0059 -0.0055 to 0.0152 0.270 
NIH equation – PHC equation 0.0721 0.0495 to 0.0935 <0.001 
REVEAL risk score – PHC equation -0.0023 -0.0079 to 0.0027 0.382 
French equation – NIH equation -0.0661 -0.0835 to -0.0484 <0.001 
REVEAL risk score – NIH equation -0.0744 -0.0956 to -0.0516 <0.001 
French equation – REVEAL risk 
score 
0.0082 -0.0016 to 0.0160 0.089 
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Table 4.7. Brier scores differences via bootstrapping for 2-year prediction in 
female idiopathic, heritable and anorexigen-associated PAH patients. 
 
Survival prediction models 
(female patients) 
Brier score 
differences 
95% Confidence 
Interval 
p-value 
French equation – PHC equation 0.0111 -0.0131 to 0.0334 0.359 
NIH equation – PHC equation 0.1051 0.0664 to 0.1413 <0.001 
French equation – NIH equation -0.0940 -0.1224 to -0.0652 <0.001 
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Table 4.8. Brier scores differences via bootstrapping for 3-year prediction in 
female idiopathic, heritable and anorexigen-associated PAH patients. 
 
Survival prediction models 
(female patients) 
Brier score 
differences 
95% Confidence 
Interval 
p-value 
French equation – PHC 
equation 
-0.0029 -0.0371 to 0.0304 0.866 
NIH equation – PHC equation 0.1024 0.0459 to 0.1552 <0.001 
French equation – NIH 
equation 
-0.1053 -0.1467 to -0.0629 <0.001 
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Figure 4.2. Observed versus predicted survival using the NIH equation, 
French equation, PHC equation and REVEAL equation for female idiopathic, 
heritable and anorexigen-associated PAH patients.  
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Comparisons of survival prediction equations in male patients: 
 
In male idiopathic, heritable and anorexigen-associated PAH patients, the Brier 
score of the NIH equation was significantly higher compared with all other 
survival prediction models (Table 4.9). There was no difference in Brier scores 
between the REVEAL equation and REVEAL risk score in predicting 1 year survival 
of our male patients (Table 4.10). However, unlike in the female patients, the 
French equation also had higher Brier score compared with the PHC equation, 
REVEAL equation and REVEAL risk score for predicting 1-year survival of our male 
patients (Table 4.10). At 2 and 3 year, Brier score of the French equation for 
predicting survival of our male patients was significantly lower than the NIH 
equation but higher compared with the PHC equation (Tables 4.11 and 4.12). 
Figure 4.3 shows the survival curves of actual observed survival of the male 
patients versus predicted survival of the same patients calculated using the NIH, 
French, PHC and REVEAL equations. 
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Table 4.9. Comparison of 5 survival prediction models using the Brier scores 
for male idiopathic, heritable and anorexigen-associated PAH patients.  
 
Males patients Brier scores via bootstrap (95% Confidence interval) 
Survival prediction 
models 
1 year  
prediction 
2 year  
prediction 
3 year  
prediction 
NIH equation 0.1288 
(0.1114 to 0.1474) 
0.2240 
(0.1956 to 0.2531) 
0.2945 
(0.2607 to 0.3295) 
French equation 0.0892 
(0.0706 to 0.1097) 
0.1502 
(0.1204 to 0.1828) 
0.2396 
(0.1982 to 0.2858) 
PHC equation 0.0531 
(0.0252 to 0.0880) 
0.1045 
(0.0683 to 0.1453) 
0.1650 
(0.1223 to 0.2147) 
REVEAL equation 0.0418 
(0.0163 to 0.0727) 
  
REVEAL risk score 0.0475 
(0.0232 to 0.0768) 
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Table 4.10. Brier scores differences via bootstrapping for 1-year prediction in 
male idiopathic, heritable and anorexigen-associated PAH patients. 
 
Survival prediction models (male 
patients) 
Brier score 
differences 
95% Confidence 
Interval 
p-value 
French equation – REVEAL 
equation 
0.0474 0.0229 to 0.0712 <0.001 
NIH equation – REVEAL equation 0.0870 0.0565 to 0.1129 <0.001 
PHC equation – REVEAL equation 0.0113 0.0016 to 0.0238 0.011 
REVEAL risk score – REVEAL 
equation 
0.0057 -0.0011 to 0.0128 0.102 
French equation – PHC equation 0.0361 0.0060 to 0.0642 0.018 
NIH equation – PHC equation 0.0757 0.0444 to 0.1029 <0.001 
REVEAL risk score – PHC equation -0.0056 -0.0162 to 0.0036 0.261 
French equation – NIH equation -0.0396 -0.0613 to -0.0161 0.002 
REVEAL risk score – NIH equation -0.0813 -0.1063 to -0.0524 <0.001 
French equation – REVEAL risk 
score 
0.0417 0.0185 to 0.0641 0.001 
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Table 4.11. Brier scores differences via bootstrapping for 2-year prediction in 
male idiopathic, heritable and anorexigen-associated PAH patients. 
 
Survival prediction models (male 
patients) 
Brier score 
differences 
95% Confidence 
Interval 
p-value 
French equation – PHC equation 0.0457 -0.0053 to 0.0955 0.081 
NIH equation – PHC equation 0.1194 0.0743 to 0.1618 <0.001 
French equation – NIH equation -0.0738 -0.1078 to -0.0360 <0.001 
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Table 4.12. Brier scores differences via bootstrapping for 3-year prediction in 
male idiopathic, heritable and anorexigen-associated PAH patients. 
 
Survival prediction models (male 
patients) 
Brier score 
differences 
95% Confidence 
Interval 
p-value 
French equation – PHC equation 0.0747 0.0085 to 0.1403 0.027 
NIH equation – PHC equation 0.1295 0.0671 to 0.1863 <0.001 
French equation – NIH equation -0.0549 -0.1051 to 0.0013 0.055 
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Figure 4.3. Observed versus predicted survival using the NIH equation, 
French equation, PHC equation and REVEAL equation for male idiopathic, 
heritable and anorexigen-associated PAH patients.  
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4.5 Discussion 
 
We validated five PAH survival prediction equations with our incident cohort of 
idiopathic, heritable and anorexigen-associated PAH and demonstrated 
superiority of some prediction equations over others.  
 
The ability to predict prognosis helps to guide treatment decisions. This includes 
selection of patients for prostacyclins and/or combination treatment and early 
consideration of lung transplantation.  The NIH equation (26) was derived from a 
cohort of 194 patients with primary pulmonary hypertension (equivalent to 
idiopathic or heritable PAH in the latest Dana Point Classification) from the 
1980s in the pre-disease targeted therapy era. This NIH equation was used in 
many clinical trials to suggest survival benefit of the study drug. The mean age 
of patients in the NIH registry was 36 years compared with 50 years in our 
patients. As discussed in Chapter 3, the epidemiology of idiopathic PAH has 
evolved and survival has improved since the NIH registry era. The NIH equation 
also underestimated survival when applied to cohorts of idiopathic PAH derived 
from participants of pulmonary hypertension clinical trials or other 
contemporary pulmonary hypertension registries (33, 40, 87). Our results 
confirmed that the NIH equation under- estimated survival of incident 
idiopathic, heritable and anorexigen-associated PAH in the UK and Ireland and 
should no longer be used in the current age of modern PAH therapies.  
 
The French equation (37) also under-estimated survival of our study cohort. We 
believe there are three possible explanations. Firstly, the French equation may 
simply reflect outcomes of patients in France in 2002-2006, at a time when 
several currently approved PAH therapies were not yet available (37). Secondly, 
patients with less severe disease and/or those who remained stable on oral 
therapies may not be referred to one of the French University Hospitals.  In 
contrast, our study is a truly national study inclusive of all idiopathic PAH 
patients of all severity in the UK and Ireland. Finally, in addition to using the 
same pulmonary function criteria as the French registry, we have also excluded 
patients with any radiological evidence of co-existing parenchymal lung disease 
from our study. These patients with co-existing lung disease (refers to as 
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precapillary PH with ‘co-existing lung disease’ in Chapter 7 of this thesis) 
otherwise fit the ‘standard’ haemodynamic criteria for idiopathic PAH and may 
be included in the French registry. However, despite similar short term 
improvement in 6 minute walk distance in response to PAH disease targeted 
therapies, these patients with ‘co-existing lung disease’ had worse survival 
compared with idiopathic PAH patients (see Chapter 7 for details). Interestingly, 
the French equation more accurately predicted survival of our female patients 
and significantly underestimated survival of our male patients. The male gender 
was also independently associated with worse survival in the French registry 
despite similar baseline characteristics and management between male and 
female patients.  
 
Although the PHC equation and both REVEAL survival prediction models were 
derived from a mixed incident and prevalent population, they accurately 
predicted survival of our purely incident study cohort. The derivation cohort of 
both REVEAL survival models also included group I PAH patients with diagnosis 
other than idiopathic PAH. That did not appear to affect the performances of 
both REVEAL models in predicting survival of our patients which comprised of 
purely idiopathic, heritable and anorexigen-associated PAH patients only. 
Although some of the parameters in the REVEAL models were missing or not 
routinely performed in our patients, the REVEAL models were designed to handle 
missing data and did not appear to affect the performance of both REVEAL 
models. Although both REVEAL equation (57) and REVEAL risk score (76) had 
lower Brier scores than the PHC (23) equation, the differences were not 
statistically significant. In addition, analyses of REVEAL equation and risk score 
were limited to 1 year prediction only. As there was no difference in accuracy 
between the REVEAL equation (57), REVEAL risk score (76) and the PHC equation 
(23), user-friendliness of an survival prediction model may also influence its 
applicability in daily clinical practice.  
 
All survival prediction models were better at predicting  survival at 1 year than 
at longer terms. This is not unexpected as the course of disease of a patient can 
be highly variable. Any deteriorations and/or changes to treatment during 
follow-up may have an impact on their subsequent outcome. 
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The Scottish Composite Score was also developed recently to predict survival of 
incident PAH patients. A significant majority of the derivation cohort of the 
Scottish Composite Score came from patients in this study. The performance of 
the Scottish Composite Score was therefore not validated in this study.   
 
The main limitation of our study is the unavoidable incompleteness in our 
dataset due to its observational nature, with a small amount of missing data and 
uneven frequency of follow-up and investigations performed at each visit.   
 
  
133 
 
4.6 Conclusion 
 
Some survival prediction equations more accurately predict survival of incident 
idiopathic, heritable and anorexigen-associated PAH patients in the UK and 
Ireland than others. Differences in baseline characteristics, treatment practice 
and time period between our patients and survival equations derivation 
populations need to be taken into account when applying these equations in 
daily clinical practice. 
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5 Chapter 5: Effect of Age on Prognostic Factors in 
Incident Idiopathic, Heritable and Anorexigen-
associated Pulmonary Arterial Hypertension  
 
5.1 Summary 
 
Rationale: 
 
Younger and older idiopathic, heritable and anorexigen-associated pulmonary 
arterial hypertension patients have different phenotypic characteristics and 
survival and may also have different prognostic predictors.  
 
Objectives: 
 
To determine the baseline prognostic factors associated with survival in 
idiopathic pulmonary arterial hypertension and to evaluate whether these 
prognostic predictors are different between younger and older patients. 
 
Methods: 
 
We studied 482 consecutive, incident, idiopathic, heritable and anorexigen-
associated pulmonary arterial hypertension diagnosed in all eight pulmonary 
hypertension centres in the UK and Ireland between 2001-2009. Patients with 
parenchymal lung disease (of any severity) on chest CT were excluded from this 
study. Patients were divided into younger (age ≤ 50 years) and older (age >50 
years) subgroups by the median age at diagnosis. 
 
Results: 
 
Univariate survival analyses were performed in the age ≤ 50 and age > 50 
subgroups. Body mass index (BMI) ≥ 30, lower 6 minute walk distance (6MWD), 
lower % predicted diffusion capacity for carbon monoxide (%DLCO), higher mean 
pulmonary artery pressure and lower mixed venous oxygen saturations (SvO2) 
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were markers of poor prognosis in the age ≤ 50 subgroup. In the age > 50 
subgroup, male gender, BMI < 30, functional class IV, low 6MWD, low %DLCO , low 
SvO2 and low cardiac index were associated with worse survival. Age, 6MWD and 
%DLCO were independent predictors of survival of the whole cohort in 
multivariate analysis. Significant interactions were observed between age and 
BMI. BMI ≥30 was associated with better survival in the age > 50 subgroup but 
worse survival in the age ≤ 50 subgroup.  
 
Conclusion: 
 
Our results suggest prognostic variables in incident idiopathic, heritable and 
anorexigen-associated pulmonary arterial hypertension may be different in 
younger and older patients. In addition, obesity may have a protective effect in 
older idiopathic, heritable and anorexigen-associated pulmonary arterial 
hypertension patients.   
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5.2 Introduction 
 
Numerous registries and clinical trials have reported on prognostic factors in 
idiopathic pulmonary arterial hypertension (22, 26, 36, 57, 74, 88). However, 
prevalent patients are over-represented in many of these studies, and prevalent 
patients have better outcomes when compared with incident patients (37). We 
have shown in the previous chapter of this thesis (Chapter 3) that younger (age ≤ 
50 years) and older (age > 50 years) incident idiopathic, heritable and 
anorexigen-associated PAH patients have different phenotypes and survival (89). 
We hypothesised that prognostic factors other than age itself may also be 
different in younger versus older incident idiopathic, heritable and anorexigen-
associated PAH patients. All patients with idiopathic, heritable and anorexigen-
associated PAH are diagnosed and treated in designated pulmonary hypertension 
centres in the UK and Ireland. This provides a unique opportunity to study the 
prognostic significance of various variables in a large national, purely incident 
cohort of patients. Potential survival bias introduced by prevalent patients is 
avoided as our study included only incident cases.  Furthermore, unlike the 
highly selected patients in clinical trials, our patients are representative of real 
life patients seen in day to day practice.  
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5.3 Methods 
 
This was a longitudinal observational study of all consecutive, newly diagnosed, 
treatment-naive idiopathic, heritable and anorexigen-associated pulmonary 
arterial hypertension (PAH) patients diagnosed in all eight pulmonary centres in 
the UK and Ireland between 1st January 2001 and 31st December 2009. Details of 
inclusion and exclusion criteria of idiopathic, heritable and anorexigen-
associated PAH have been described in the previous chapter (Chapter 3.3: 
Methods). The date of diagnostic right heart catheterisation was taken as the 
date of diagnosis. Body mass index (BMI) values were calculated using height and 
weight values at the time of diagnostic right heart catheterisation. All patients 
were treatment naive prior to their diagnosis of idiopathic, heritable and 
anorexigen-associated PAH. The choice of pulmonary hypertension treatment 
started at diagnosis was at the discretion of the treating pulmonary hypertension 
specialist and in accordance with contemporary pulmonary hypertension 
guidelines (5, 80, 90). Patients were divided into younger (age ≤ 50) and older 
(age > 50) subgroups according to the median age at the time of diagnosis. This 
study was designed and conducted to describe current care and hence formal 
ethics approval was deemed unnecessary by the West of Scotland Research 
Ethics Committee.  
 
Statistical analysis: 
 
Statistical analysis was performed using SPSS 19 (SPSS Inc, Chicago, IL). 
Continuous variables were described by mean ± standard deviation and 
categorical variables described by frequencies and percentages unless otherwise 
indicated. Continuous variables were compared using student t-test or Mann 
Whitney U test. Categorical variables were compared using χ2 or Fisher exact 
test. Paired t-test was used to compare the difference between mean values of 
6-minute walk distance (6MWD) at baseline and follow-up. Survival was 
estimated from the time of diagnosis and survival endpoint taken as either the 
date of death or date of censoring. Patients were censored if they were 
transplanted (n=14), lost to follow up (date of last visit to pulmonary 
hypertension centre was used as censor date) or if they were alive on the last 
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day of the study (31st December 2009). All cause mortality was used for survival 
analysis.  
 
Patients were divided into younger (age ≤ 50) and older (age > 50) subgroups 
according to the median age at diagnosis. Univariate Cox regression analyses 
were performed to identify baseline variables that predicted survival in the 
whole cohort, and in the younger and older subgroups. Variables considered 
were as follows: age, gender, ethnicity, BMI, duration of symptoms, functional 
class, 6MWD, diffusion capacity for carbon monoxide (DLCO) and haemodynamics 
parameters. BMI was re-coded as non-obese (BMI <30) and obese (BMI ≥ 30). 
Variables with p < 0.1 in the univariate analyses were entered into the 
multivariate Cox regression analysis. To allow inclusion of all patients in survival 
analyses, a missing data category (data available or data missing) was created 
for each covariate and included in the multivariate model when that covariate 
was analysed.  
 
The analyses of age-variable interactions were used to investigate whether the 
effect of variables on survival depended on the age of patients. The product of 
the two variables was included in the model to describe the interaction. Two 
variables were said to interact in the effect on survival if the effect of the first 
variable was significantly different at the different levels of the second variable. 
Results of all Cox regression analyses were expressed as hazard ratios with 95% 
confidence interval. The survival analyses were repeated with time from onset 
of symptoms as the start of follow-up to account for potential lead time bias 
introduced by differential delay in diagnosis between younger and older 
patients. P-value <0.05 were considered significant throughout. 
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5.4 Results  
 
Baseline characteristics, treatment and survival of study cohort: 
 
A total of 482 idiopathic, heritable and anorexigen-associated PAH patients 
fulfilled the inclusion criteria and were included in the analyses. Selective 
baseline characteristics of patients and first-line treatment started at the time 
of diagnosis are shown in table 5.1. Detailed descriptions of baseline 
characteristics of the study cohort can be found in previous chapter (Chapter 3). 
Kaplan Meier survival estimates at 1, 2, 3 and 5 years were 92.7%, 84.0%, 73.3% 
and 61.1% respectively. 
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Table 5.1. Baseline variables and first line treatment started at diagnosis for 
study cohort (n=482). 
 
 Mean (SD) or %(n) 
Age, years (n=482) 50.1(17.1) 
Gender (n=482): 
% female 
 
69.9%(337) 
WHO functional class (n=456): 
I/II 
III 
IV 
 
15.5%(72) 
66.7%(304) 
17.5%(80) 
BMI  ≥ 30 (n=398) 33.9%(135) 
6MWD, metres (n=260) 292.4(123.0) 
% DLCO (n=331) 62.0%(20.9) 
Haemodynamics: 
mPAP, mmHg (n=457) 
SvO2, % (n=395) 
Cardiac index, L.min-1.m-2 (n=366) 
PVRI, WU.m2 (n=355) 
 
54.1(13.9) 
61.5(9.5) 
2.1(0.7) 
23.1(10.3) 
Treatment started at the time of diagnosis: 
(n=479) 
Endothelin receptor antagonist 
Phosphodiesterase 5 inhibitor 
Prostaglandins 
Calcium channel blocker 
Combination therapy 
None 
 
 
44.3%(212) 
29.2%(140) 
18.8%(90) 
5.0%(24) 
2.1%(10) 
0.6%(3) 
Definition of abbreviations: 6MWD= 6 minute walk distance, BMI = body mass index, % DLCO= % 
predicted diffusion capacity for carbon monoxide, mPAP= mean pulmonary artery pressure, 
mRAP= mean right atrial pressure, PAOP= pulmonary artery occlusion pressure, PVR= pulmonary 
vascular resistance, PVRI= pulmonary vascular resistance index, SvO2= mixed venous oxygen 
saturation, WU= Wood Units. 
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Predictors of survival at baseline: 
 
Univariate Cox regression analyses (Table 5.2) showed BMI ≥ 30, lower 6MWD, 
lower %DLCO, higher mean pulmonary artery pressure (mPAP) and lower mixed 
venous oxygen saturation (SvO2) as markers of poor prognosis in the age ≤ 50 
subgroup. In the age >50 subgroup, male gender, BMI < 30, functional class IV, 
low 6MWD, low %DLCO, low SvO2 and low cardiac index were associated with 
worse survival.  
 
The results of first order interaction between age-BMI and age-mPAP in the 
whole cohort were shown in Table 5.3. Interaction terms between age and all 
other variables were not significant at p<0.05. Regardless of the BMI or mPAP, 
patients in the age > 50 subgroup had poorer survival. In the age > 50 subgroup, 
patients with BMI ≥ 30 had a lower risk of death whereas in the age ≤ 50 
subgroup, patients with BMI ≥ 30 had a higher risk of death. The test for an age-
BMI interaction on survival indicated a highly statistically significant risk 
difference. Similarly, the test for an age-mPAP interaction on survival also 
indicated a statistically significant risk difference. 
 
As significant first order interaction was found between age-BMI and age-mPAP, 
a  multivariate Cox regression model containing interaction terms between age 
and these two variables (in addition to variables that were significant in the 
univariate analyses) were considered. The interaction term between age-mPAP 
was no longer significant in the final model. The final model with both 
interactions terms is shown in Table 5.4. Age, 6MWD, %DLCO and SvO2 were 
independent predictors of survival. In patients aged > 50, BMI ≥ 30 were 
associated with better survival (hazard ratio = 0.326, p = 0.016). The interaction 
between age and BMI remained significant when survival analysis was repeated 
using time from onset of symptom as the start of follow-up (Table 5.5, Table 5.6 
and Table 5.7). 
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Table 5.2. Univariate Cox proportional hazard regression analyses of baseline 
variables predictive of survival in the whole cohort and by age subgroups (age 
≤50 years and age > 50 years). 
 
Univariate 
analyses 
All patients Age ≤ 50 years 
subgroup 
Age > 50 years 
subgroup 
p-
value 
HR (95% CI) p-
value 
HR (95% CI) p-
value 
HR (95% CI) 
Age ≤ 50 
Age >50 
 
<0.001 
1 
3.012 
(2.078–4.366) 
 N/A  N/A 
Female 
Male  
 
0.131 
1 
1.326 
(0.919-1.914) 
 
0.924 
1 
0.967 
(0.486-1.925) 
 
0.048 
1.556 
(1.003-2.412) 
White 
Non-white 
 
0.037 
1 
0.442 
(0.205-0.953) 
 
0.072 
1 
0.161 
(0.022-1.181) 
 
0.429 
1 
0.712 
(0.308-1.650) 
BMI < 30 
BMI ≥ 30 
 
0.931 
1 
0.982 
(0.649-1.486) 
 
0.030 
1 
2.170 
(1.078-4.368) 
 
0.012 
 
1 
0.512 
(0.303-0.865) 
WHO FC 
I+II 
III 
 
IV 
 
 
0.019 
0.010 
 
0.006 
 
1 
2.368 
(1.230-4.558) 
2.816 
(1.339-5.921) 
 
0.055 
0.053 
 
0.988 
 
1 
3.216 
(0.983-10.521) 
1.014 
(0.169-6.074) 
 
0.045 
0.147 
 
0.019 
 
 
1 
1.794 
(0.815-3.950) 
2.808 
(1.188-6.639) 
6MWD <0.001 0.994 
(0.992-0.996) 
0.015 0.995 
(0.991-0.999) 
0.002 0.995 
(0.993-0.998) 
%DLCO <0.001 0.974 
(0.964-0.985) 
<0.001 0.967 
(0.949-0.985) 
0.027 0.986 
(0.973-0.998) 
mRAP 0.012 1.037 
(1.008-1.067) 
0.092 1.047 
(0.993-1.103) 
0.113 1.027 
(0.994-1.062) 
mPAP 0.462 1.005 
(0.992-1.018) 
0.001 1.031 
(1.012-1.051) 
0.637 0.997 
(0.982-1.011) 
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Univariate 
analyses 
All patients Age ≤ 50 years 
subgroup 
Age > 50 years 
subgroup 
p-
value 
HR (95% CI) p-
value 
HR (95% CI) p-
value 
HR (95% CI) 
SVO2 <0.001 0.955 
(0.937-0.974) 
0.004 0.954 
(0.924-0.985) 
0.002 0.958 
(0.933-0.984) 
CI 0.013 0.669 
(0.487-0.919) 
0.442 0.812 
(0.477-1.382) 
0.007 0.562 
(0.371-0.852) 
N/A = not applicable 
 
Definition of abbreviations: 6MWD = six minute walk distance, BMI = body mass index, CI = 
cardiac index, %DLCO = % predicted diffusion capacity for carbon monoxide, HR = hazard ratio, 
mPAP = mean pulmonary artery pressure, RAP = mean right atrial pressure, SvO2 = mixed venous 
oxygen saturations, WHO FC = World Health Organisation functional class.  
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Table 5.3. First order interaction between age and baseline variables.  
 
 p-value Hazard ratio 95% confidence 
interval 
Model 1. 
Age  > 50 
BMI ≥ 30 
Age > 50 * BMI ≥ 30 
 
<0.001 
0.031 
0.001 
 
5.012 
2.154 
0.240 
 
2.992 – 8.396 
1.071 – 4.332 
0.100 – 0.574 
Model 2. 
Age > 50 
mPAP 
Age > 50 * mPAP 
 
<0.001 
0.001 
0.008 
 
20.789 
1.031 
0.996 
 
4.545 - 95.090 
1.012 – 1.050 
0.942 – 0.991 
Age ≤ 50 and BMI < 30 were the reference groups. 
 
Definition of abbreviations: See Table 5.2. 
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Table 5.4. Multivariate Cox proportional hazard regression analysis of 
baseline variables predictive of survival of the whole cohort (with interaction 
terms). 
 
Multivariate analysis All patients 
p-value HR (95% CI) 
Age > 50  <0.001 3.784 (2.152-6.653) 
Non-white 0.084 0.502 (0.230-1.096) 
Functional class III 
Functional class IV 
0.242 
0.533 
1.508 (0.758-3.001) 
1.291(0.579-2.877) 
6MWD 0.013 0.997 (0.994-0.999) 
%DLCO 0.002 0.982 (0.971-0.994) 
mRAP 0.404 1.015 (0.980-1.052) 
SVO2 0.057 0.976 (0.951-1.001) 
CI 0.292 0.810 (0.548-1.198) 
BMI ≥ 30 0.096 1.862 (0.895-3.874) 
mPAP 0.601 1.004 (0.989-1.019) 
Interactions: 
Age > 50 * BMI ≥ 30 
Age > 50 * mPAP 
 
0.016 
0.632 
 
0.327 (0.132-0.872) 
0.584 (0.065-5.275) 
Definition of abbreviations: See Table 5.2.   
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Table 5.5. Univariate Cox proportional hazard regression analyses of baseline 
variables predictive of survival in whole cohort using time from onset of 
symptoms as ‘times zero’ for survival analyses. 
 
Univariate 
analyses 
All patients Age ≤ 50 years 
subgroup 
Age > 50 years 
subgroup 
p-
value 
HR (95% CI) p-
value 
HR (95% CI) p-
value 
HR (95% CI) 
Age ≤ 50 
Age >50 
 
<0.001 
1 
2.788 
(1.842-4.222) 
    
Female 
Male  
 
0.205 
1 
1.307 
(0.864-1.977) 
 
0.852 
1 
0.874 
(0.379-2.016) 
 
0.145 
1 
1.435 
(0.883-2.330) 
White 
Non-white 
 
0.044 
1 
0.393 
(0.159-0.973) 
 
0.119 
1 
0.204 
(0.028-1.509) 
 
0.513 
1 
0.711 
(0.256-1.975) 
BMI < 30 
BMI ≥ 30 
 
0.811 
1 
0.946 
(0.600-1.491) 
 
0.080 
1 
2.003 
(0.920-4.364) 
 
0.029 
1 
0.530 
(0.299-0.938) 
WHO FC 
I+II 
III 
 
IV 
 
 
0.059 
0.019 
 
0.039 
 
1 
2.397 
(1.156-4.969) 
2.448 
(1.046-5.728) 
 
0.037 
0.045 
 
0.828 
 
1 
4.323 
(1.031-18.134) 
0.766 
(0.069-8.454) 
 
0.210 
0.371 
 
0.103 
 
1 
1.475 
(0.629-3.459) 
2.207 
(0.852-5.715) 
6MWD 0.001 0.996 
(0.994-0.998) 
0.176 0.997 
(0.993-1.001) 
0.144 0.998 
(0.994-1.001) 
%DLCO <0.001 0.978 
(0.967-0.988) 
0.002 0.971 
(0.952-0.989) 
0.080 0.988 
(0.974-1.001) 
mRAP 0.008 1.044 
(1.011-1.077) 
0.056 1.062 
(0.999-1.128) 
0.179 1.025 
(0.989-1.062) 
mPAP 0.820 1.002 
(0.988-1.016) 
0.047 1.021 
(1.000-1.043) 
0.897 1.001 
(0.981-1.022) 
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Univariate 
analyses 
All patients Age ≤ 50 years 
subgroup 
Age > 50 years 
subgroup 
p-
value 
HR (95% CI) p-
value 
HR (95% CI) p-
value 
HR (95% CI) 
SVO2 <0.001 0.952 
(0.932-0.972) 
0.003 0.946 
(0.912-0.982) 
0.006 0.962 
(0.936-0.989) 
CI 0.008 0.610 
(0.424-0.878) 
0.243 0.678 
(0.354-1.301) 
0.005 0.518 
(0.327-0.820) 
Definition of abbreviations: See Table 5.2.   
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Table 5.6. First order interaction between age and body mass index using 
time from onset of symptoms as ‘times zero’ for survival analyses. 
Interaction terms between age and all other variables were not significant.  
 
Model p-value Hazard ratio 95% confidence 
interval 
Age  > 50 
BMI ≥ 30 
Age > 50 * BMI ≥ 30 
<0.001 
0.060 
0.005 
4.641 
2.112 
0.253 
2.584-8.337 
0.969-4.603 
0.096-0.665 
Age ≤ 50 and BMI < 30 were the reference groups.  
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Table 5.7. Multivariate Cox proportional hazard regression analysis of 
baseline variables predictive of survival in the whole cohort (with interaction 
terms) using time from onset of symptoms as ‘times zero’ for survival 
analyses. 
 
Multivariate analysis All patients 
p-value Hazard ratio (95% CI) 
Age > 50  0.003 2.650 (1.404-5.000) 
Non-white 0.209 0.547 (0.214-1.401) 
Functional class III 
Functional class IV 
0.272 
0.480 
1.544 (0.711-3.351) 
1.406 (0.547-3.613) 
6MWD 0.173 0.998 (0.995-1.001) 
%DLCO 0.004 0.982 (0.969-0.994) 
mRAP 0.420 1.015 (0.979-1.053) 
SvO2 0.174 0.980 (0.953-1.009) 
CI 0.087 0.681 (0.438-1.057) 
BMI ≥ 30 0.157 1.787 (0.800-3.993) 
Interactions: 
Age > 50 * BMI ≥ 30 
 
0.028 
 
0.327 (0.121-0.885) 
Definition of abbreviations: See Table 5.2.  
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Age, body mass index and survival: 
 
BMI had a normal distribution in our patients (Figure 5.1). Compared with non-
obese patients, obese patients were older, more likely to be female, had higher 
right atrial and pulmonary artery occlusion pressure and were more likely to 
have systemic hypertension and diabetes. When analysed within age-subgroups, 
the above differences between non-obese and obese patients remained 
significant in the older (age > 50) subgroup only (Table 5.8). There were no 
significant differences in duration of symptoms, functional class, haemodynamic 
impairment (mPAP, SvO2 and pulmonary vascular resistance index), choice of 
first line treatment and proportion who received combination therapy between 
non-obese and obese patients when analysed within age-subgroups.  
 
Figure 5.2 showed the Kaplan Meier survival curves of incident idiopathic, 
heritable and anorexigen-associated PAH according to age and BMI. Unadjusted 
mean survivals of patients with different BMI are shown in Figure 5.3. In the 
younger subgroup (age ≤ 50), the best survival was observed in those with 
normal BMI. In the older subgroup (age > 50), underweight patients had the 
worst survival, followed by normal weight patients, with mildly obese patients 
having the best survival.  
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Figure 5.1. Distribution of BMI values displayed a bell-shaped, normal 
distribution in both younger (age ≤ 50) and older (age > 50) subgroups.  
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Figure 5.2. Kaplan Meier survival curves of obese versus non-obese patients 
according to age subgroups.  
IPAH refers to patients with idiopathic, heritable and anorexigen-associated pulmonary arterial 
hypertension, BMI = body mass index. 
 
1 = Younger subgroup and non obese (Age ≤ 50 and BMI < 30),  
2 = Older subgroup and non obese (Age > 50 and BMI < 30),  
3 = Younger subgroup and obese (Age ≤ 50 and BMI ≥ 30) and  
4 = Older subgroup and Obese (Age > 50 and BMI ≥ 30).  
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Figure 5.3. Survival of idiopathic, heritable and anorexigen-associated PAH 
according to age and body mass index. 
In the older idiopathic, heritable and anorexigen-associated PAH subgroup (age > 50), 
underweight patients had the worst survival, followed by normal weight patients, with mildly 
obese patients having the best survival.  In the younger subgroup (age ≤ 50), patients with 
normal BMI had the best survival. 
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Table 5.8. Comparison of baseline characteristics of obese (BMI ≥ 30) and non 
obese (BMI < 30) incident idiopathic, heritable and anorexigen-associated 
pulmonary arterial hypertension in younger (age ≤ 50) and older (age > 50) 
age subgroups. 
 
Definition of abbreviations: IHD = ischaemic heart disease, NS = not significant, PAOP = 
pulmonary artery occlusion pressure, PVRI = pulmonary vascular resistance index and see Table 
5.2.  
  
 Younger subgroup (age ≤50) Older subgroup (age >50) 
 BMI<30 BMI≥30 p-value BMI<30 BMI≥30 p-value 
% female 68.8%(99) 81.5%(44) NS 61.3%(73) 75.3%(61) 0.039 
Median duration, 
months 
12.0 
(6.0-24.0) 
13.0 
(8.0-24.0) 
NS 24.0 
(12.0-6.0) 
24.0 
(12.0-6.0) 
NS 
WHO FC 
I/II 
III 
IV 
 
20.1%(27) 
69.4%(93) 
10.4%(14) 
 
13.7%(7) 
72.5%(37) 
13.7%(7) 
 
NS 
 
11.1%(13) 
71.8%(84) 
17.1%(20) 
 
11.8%(9) 
67.1%(51) 
21.1%(16) 
 
NS 
6MWD 355.3 
(101.7) 
278.4 
(121.1) 
<0.001 249.7 
(109.2) 
249.4 
(112.7) 
NS 
%DLCO 66.6 
(17.7) 
67.2 
(19.9) 
NS 54.0 
(20.8) 
59.9 
(24.3) 
NS 
RAP 9.1(5.4) 10.7(6.0) NS 8.9(5.3) 11.5(6.7) 0.003 
mPAP 57.4 
(16.1) 
55.0 
(11.7) 
NS 50.4 
(12.7) 
50.8 
(11.8) 
NS 
PAOP 8.6(3.4) 8.9(3.7) NS 8.9(3.3) 10.3(3.8) 0.008 
CI 2.2(0.8) 2.0(0.7) 0.024 2.1(0.7) 2.1(0.7) NS 
SvO2 63.6(10.1) 61.1(9.9) NS 60.8(8.3) 61.1(8.4) NS 
PVRI 24.8 
(11.7) 
25.3 
(10.2) 
NS 21.7 
(9.3) 
21.1 
(9.1) 
NS 
Comorbidities: 
IHD 
 
Hypertension 
 
Diabetes 
 
0.7%(1) 
 
7.4%(10) 
 
2.2%(3) 
 
3.7%(2) 
 
17.0%(9) 
 
17.0%(9) 
 
NS 
 
0.050 
 
0.001 
 
22.7%(27) 
 
38.6%(44) 
 
14.0%(16) 
 
24.7%(20) 
 
45.6%(36) 
 
38.0%(30) 
 
NS 
 
NS 
 
<0.001 
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Age and response to treatment: 
 
Two types of walk tests (6-minute walk and incremental shuttle walk) are used 
to assess exercise capacity in the UK and Ireland. Patients whose exercise 
capacity were assessed using the incremental shuttle walk test were not 
included in the analysis of 6MWD. Paired baseline and 3 months 6MWD data were 
available in 158 patients. The mean increase in 6MWD at 3 months was 39.5 m 
(95% CI = 28.1 - 51.0 m) from baseline. The magnitude of change in 6MWD at 3 
months in response to treatment was not statistically different between younger 
(age ≤ 50) and older (age > 50) patients. In the younger subgroup, after 3 months 
of treatment, 40.4% (n= 59), 51.4% (n=75) and 8.2% (n=12) were in functional 
class I/II, III and IV respectively (Figure 5.4a). In the older subgroup, after 3 
months of treatment, 23.9% (n=28), 67.5% (n=79) and 8.5% (n=10) were in 
functional class I/II, III and IV respectively, p=0.016 (Figure 5.4b). 
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5.4a 
 
5.4b 
 
Figure 5.4. Distribution of functional class at baseline and at 3-month follow 
up according to age subgroups.  
IPAH refers to patients with idiopathic, heritable and anorexigen-associated pulmonary arterial 
hypertension.  
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5.5 Discussion 
 
We have shown in the previous chapter of this thesis (Chapter 3) that there was 
a difference in overall survival between idiopathic, heritable and anorexigen-
associated PAH patients who were younger and older than 50 years old (89). In 
this chapter, we further explored the hypothesis that variables predictive of 
patients’ outcomes may also be different between younger and older idiopathic, 
heritable and anorexigen-associated PAH patients. Our results suggested that 
prognostic variables may be different in younger and older incident idiopathic, 
heritable and anorexigen-associated PAH patients. Obesity was associated with 
better survival in older patients but worse survival in younger patients. 
 
The present study demonstrated that age, 6MWD, %DLCO and SvO2 were 
independent predictors of survival in the whole incident idiopathic, heritable 
and anorexigen-associated PAH cohort. This is consistent with results from 
previously published studies (22, 46, 57, 91). Although prognostic baseline 
variables of idiopathic PAH have been reported from registries and clinical trials, 
very few large studies had focused on purely incident, treatment-naive 
idiopathic PAH patients only. Contrary to results from the French (33) and 
REVEAL (57) registries that were comprised predominantly of prevalent patients, 
gender was not predictive of survival in multivariate analysis in our study. One 
possible explanation may be the over-representation of lower risk female 
patients in prevalent patients in the French and REVEAL registries. That 
potential bias is avoided in our study which comprised wholly of incident 
patient. Gender was also not predictive of survival in the NIH (26) registry (64% 
incident patient), Chinese  registry (31) (100% incident patient) and the Israeli 
(36) registry (100% incident patient) that comprised predominantly or wholly of 
incident patients. The reason for the survival advantage of female idiopathic 
PAH patients observed in the French and REVEAL registries is unclear as male 
and female patients have similar baseline characteristics and received similar 
treatment. Baseline demographics and haemodynamics parameters of idiopathic 
PAH patients in the French (22) registry were similar to our study cohort whereas 
female preponderance was more marked in the REVEAL idiopathic PAH 
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population (female:male ratio 4.1:1)(35) compared with our study cohort (ratio 
2.3:1).  
 
We found prognostic parameters independently associated with survival are 
different in younger and older patients. This is not surprising as younger and 
older incident idiopathic PAH patients have different characteristics and survival 
(89). As discussed in Chapter 3, compared with younger incident idiopathic, 
heritable and anorexigen-associated PAH patients, older patients had longer 
duration of symptoms, more co-morbidities (ischaemic heart disease, 
hypertension, atrial fibrillation, diabetes and hypothyroidism), worse functional 
class and exercise capacity, lower %DLCO, lower mPAP and lower PVRI.  Another 
possible explanation may be the difference in treatment between younger and 
older patients. In our study cohort, higher proportion of younger patients 
received combination therapy compared with their older counterparts.  
 
The association between obesity and mortality in younger patients but survival in 
older patients as observed in our study has not been reported previously in 
idiopathic, heritable and anorexigen-associated PAH. In our study, younger 
idiopathic, heritable and anorexigen-associated PAH patients with normal body 
mass index (BMI 20-25) have the longest survival, with excess mortality at both 
extremes of BMI. This U-shaped relationship between mortality and BMI is also 
noted in the general population (92). On the contrary, older patients in our 
study who were overweight or obese (BMI>25) have better survival compared 
with those who were normal or under-weight. Similar to findings from the 
REVEAL registry (93), obese idiopathic, heritable and anorexigen-associated PAH 
patients in our study were also older, had more co-morbidities and higher right 
atrial pressure compared with non-obese. To avoid the confounding effect of 
age, we compared baseline characteristics and survival of obese versus non-
obese patients in two different age-subgroups divided according to the median 
age. We found no significant differences in delay before diagnosis, severity of 
pulmonary hypertension or treatment to explain the discrepancy in survival 
between obese and non-obese patients.  
 
Although several recent studies have reported on the protective effect of obesity 
in pulmonary hypertension (88, 94, 95), no studies to date have examined the 
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relationship between age, obesity and survival. In addition, the population 
studied were heterogeneous, comprising of patients in different PAH aetiologies, 
a mixture of pre-and post capillary pulmonary hypertension or highly selective 
patients participating in clinical trials (88, 94, 95).  However, baseline 
characteristics and outcomes are different according to the PAH aetiologies and 
grouping various PAH aetiologies together may introduce bias. Idiopathic PAH 
patients had higher BMI and percentage of obese patients whereas PAH 
associated with connective tissue disease, congenital heart disease and HIV had 
lower BMI compared with the general population (93).  
 
The ‘obesity paradox’ of older idiopathic, heritable and anorexigen-associated 
PAH patients as observed in this study has also been reported in the general 
elderly population and in patients with heart failure, cancer, after cardiac 
surgery, percutaneous coronary intervention and in patients on haemodialysis 
(96-99). Several hypotheses have been proposed to explain the apparent 
improved survival of obese patients. Obese patients may be younger and 
‘healthier’ than their leaner counterparts. That does not appears to be the case 
in our patients. Adipose tissue has been shown to produce soluble tumour 
necrosis factor receptor, thought to neutralise the deleterious effects of tumour 
necrosis factor-α on the myocardium (100, 101). Obese patients have higher 
lipoprotein concentrations that may bind and remove circulating endotoxins that 
play a role in stimulating the release of inflammatory cytokines (97, 102).  
 
The relationship between obesity and all cause mortality appears conflicting 
between younger and older patients in our study. However, BMI may not be the 
optimal parameter for assessing the relationship between age, obesity and 
health outcomes. Age-dependent height decreases may induce a false BMI 
increase in elderly patients  despite minimal changes in body weight. Older 
patients may have different  body fat and lean muscle composition and 
distribution compared with younger patients despite similar BMI.  Older obese 
patients may also have better preservation of cognitive function, protection 
from oesteoporosis and better energy reserve compared with their non-obese 
counterparts (96). 
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The strength of this study is the inclusion of only incident, treatment-naive 
idiopathic, heritable and anorexigen-associated PAH. Our study population is 
homogeneous, and potential survival bias introduced by the inclusion of 
prevalent patients was avoided. As pulmonary hypertension is diagnosed and 
treated in designated pulmonary hypertension centres only in the UK and 
Ireland, it is likely we have included nearly all cases of idiopathic, heritable and 
anorexigen-associated PAH diagnosed and treated over the study period in the 
region. In the UK and Ireland, all PAH patients were diagnosed in designated 
centres by PH specialists in a multidisciplinary setting. We therefore believe it is 
unlikely many patients in this study were misclassified. 
 
The main limitation of our study is the observational nature of the study. There 
may be unseen confounding factors that may influence survival results. Many 
variables such as biomarkers or quality of life scores that may have additional 
prognostic values were not collected or had too many missing data. We have not 
controlled for treatment. Finally, our results are not generalisable to patients 
with other PAH aetiologies.  
 
Our results should be considered as hypothesis-generating. Future studies 
looking into the effect of aging, obesity, insulin resistance and metabolic 
syndrome on the pulmonary vasculature and right ventricle may provide insights 
to explain this survival discrepancy between younger and older idiopathic PAH 
patients. In addition to BMI, additional measures of adiposity such as mid arm 
circumference, waist circumference or waist to hip ratio should also be 
considered when examining the relationship between obesity and survival.  
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5.6 Conclusion 
 
Our data suggest prognostic variables may be different in younger and older 
incident idiopathic, heritable and anorexigen-associated pulmonary arterial 
hypertension. Obesity may have a protective effect in older idiopathic, heritable 
and anorexigen-associated PAH patients.  
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6 Chapter 6. Prognostic Significance of Change in Six 
Minute Walk Distance and Functional Class in Incident 
Idiopathic, Heritable and Anorexigen associated 
Pulmonary Arterial Hypertension. 
 
6.1 Summary 
 
Rationale: 
 
Pulmonary arterial hypertension treatment has been approved based on changes 
in six minute walk distance (6MWD) after 12-16 weeks of treatment. However, 
previous work has suggested that improvement in 6MWD with treatment does not 
impact on survival. 
 
Objectives: 
 
To evaluate whether short term changes in 6MWD and functional class in 
response to treatment translates into long term survival difference. 
 
Methods: 
 
482 consecutive, incident, treatment-naive idiopathic, heritable and anorexigen-
associated pulmonary arterial hypertension diagnosed in all eight pulmonary 
hypertension centres in the UK and Ireland between 2001-2009 were included. 
 
Results: 
 
Patients with more severe exercise limitations (6MWD ≤ 318 m) and worse 
functional class (III/IV) at baseline had greater improvement in 6MWD in 
response to treatment. Change in 6MWD >36 m at 3 months was associated with 
better survival but only in patients with baseline 6MWD ≤ 318 m. At 6 months 
follow-up, patients who improved from baseline functional class III/IV to I/II 
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have similar survival, whereas patients who deteriorated from baseline 
functional class I/II to III/IV have worse survival compared with patients who 
remained in functional class I/II at baseline and follow-up.  
 
Conclusions: 
 
Change in 6MWD after 3 months of treatment predicts survival in patients with 
more impaired baseline exercise tolerance. Change in functional class after 6 
months of treatment also has prognostic implication.  
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6.2  Introduction 
 
Despite recent advances in diagnosis and treatment, idiopathic pulmonary 
arterial hypertension (PAH) remains largely a progressive disease with a fatal 
outcome. Knowledge of adverse predictors of outcome at the time of diagnosis 
and subsequent follow up helps to identify patients who may benefit from early 
aggressive treatment and from closer monitoring. Change in six minute walk 
distance (6MWD) after 12-16 weeks of treatment has been used as the primary 
endpoint in many pivotal clinical trials. However, the consensus view is that 
although baseline 6MWD predicts survival, change in 6MWD may not. There is 
also recent evidence suggesting interval change in variables other than 6MWD in 
response to treatment may have additional prognostic values (103, 104). 
However, the course of disease of each individual idiopathic PAH patient is 
highly variable whereas the optimal tools and timing of follow up remain 
uncertain.  In the United Kingdom (UK) and Ireland, all newly diagnosed, 
treatment naive patients with idiopathic, heritable and anorexigen-associated 
PAH were diagnosed and treated in designated pulmonary hypertension centres. 
This provides a unique opportunity to study the prognostic significance of various 
variables in a large national, purely incident cohort of patients.  
 
The aim of this study was to evaluate the prognostic significance of short term 
changes in 6MWD and functional class (FC)  in response to treatment in patients 
with idiopathic, heritable and anorexigen-associated PAH. 
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6.3 Methods 
 
We performed a longitudinal observational study of all consecutive, newly 
diagnosed, treatment naive idiopathic, heritable and anorexigen-associated PAH 
patients diagnosed in all eight pulmonary hypertension centres in the UK and 
Ireland between 1st January 2001 and 31st December 2009. Details of inclusion 
and exclusion criteria of idiopathic, heritable and anorexigen-associated PAH 
have been described in previous chapter (Chapter 3.3: Methods). The date of 
diagnostic right heart catheterisation was taken as the date of diagnosis. Data 
were collected for 6MWD and FC assessment performed at fixed time points 
(baseline, three and six months) from the time of diagnosis. The choice of 
pulmonary hypertension treatment started at diagnosis was at the discretion of 
the treating pulmonary hypertension specialist and in accordance with 
contemporary pulmonary hypertension guidelines (5, 80, 81). This study was 
designed and conducted to describe current care and hence formal ethics 
approval was deemed unnecessary by the West of Scotland Research Ethics 
Committee.  
 
Statistical analysis: 
 
Statistical analysis was performed using SPSS 19 (SPSS Inc, Chicago, IL) and SAS 
(SAS institute, Cary, NC). Continuous variables were described by mean ± 
standard deviation and categorical variables described by frequencies and 
percentages unless otherwise indicated. Survival was estimated from the time of 
diagnosis and survival endpoint taken as either date of death or censoring. 
Patients were censored if they were transplanted (n=14), lost to follow up (date 
of last visit to pulmonary hypertension centre was used as censor date) or if they 
were alive on the last day of the study (31st December 2009). All cause mortality 
was used for survival analysis. P-value <0.05 were considered significant 
throughout. 
 
Two types of walk tests (six minute walk and incremental shuttle walk) are used 
to assess exercise capacity in the UK and Ireland. For analyses that determined 
the prognostic significance of 6MWD, patients who had incremental shuttle walk 
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test (n=120) were excluded. Paired t-test was used to compare the difference 
between mean values of 6MWD at baseline and follow-up. 6MWD at baseline, at 
3 months, and change in 6MWD at 3 months were dichotomised according to 
their median values and the Kaplan Meier survival curves compared using the 
log-rank test. The prognostic significance of change in 6MWD at 3 months was 
also assessed using univariate Cox regression analysis.  
 
To evaluate the prognostic significance of change in FC from baseline to 3 
months follow-up, patients were categorised into 4 groups:  
Group 1- FC I/II at baseline and FC I/II at follow-up,  
Group 2- FC III/IV at baseline and FC I/II at follow-up,  
Group 3- FC I/II at baseline and FC III/IV at follow-up and  
Group 4- FC III/IV at baseline and FC III/IV at follow-up.  
 
Kaplan Meier survival curves of the 4 groups of change in FC were compared 
using the log rank test. The same analysis was repeated for 6 months follow-up. 
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6.4 Results 
 
Absolute values and change in 6MWD at 3 month: 
 
Paired baseline and 3 months 6MWD data were available in 158 patients. The 
mean increase in 6MWD at 3 months was 39.5 m (95% CI 28.1-51.0) from baseline 
(baseline 6MWD was 304.2 ± 115.5 m, increasing to 343.7 ± 115.6 m at 3 
months). The magnitude of change in 6MWD at 3 months in response to 
treatment was not statistically different between younger vs. older patients or 
different gender. Patients with baseline 6MWD of ≤ 318 m (corresponding to the 
median 6MWD at diagnosis) had greater magnitude of change in 6MWD at 3 
months in response to treatment (Δ6MWD at 3 months = 59.1 m) compared with 
patients with baseline 6MWD of > 318 m (Δ6MWD at 3 months = 20.9 m, 
p=0.001). Patients in baseline FC III/IV also had greater magnitude of change in 
6MWD at 3 months in response to treatment (Δ6MWD at 3 months = 48.6 m) 
compared with patients in baseline FC I/II (Δ6MWD at 3 months = 15.8 m, p= 
0.022). 
 
Figure 6.1 shows Kaplan Meier survival curves according to baseline 6MWD 
(Figure 6.1a), 6MWD at 3 months (Figure 6.1b), change in 6MWD at 3 months for 
patients with baseline 6MWD ≤ 318 m(Figure 6.1c) and change in 6MWD at 3 
months for patients with baseline 6MWD >318m (figure 6.1d). Patients with 
baseline 6MWD of >318 m (p=0.001) and 3 months 6MWD of >360 m (p=0.006) had 
better survival. Change in 6MWD >36 m( corresponding to median Δ6MWD at 3 
month) was also associated with better survival but only in patients with 
baseline 6MWD ≤318 m. Change in 6MWD at 3 months was not associated with 
survival in those with baseline 6MWD of > 318 m. 
 
Result from univariate Cox regression showed that patients with greater change 
in 6MWD from baseline to 3 months had better post 3 months survival (hazard 
ratio 0.579 per 100 m, 95% CI 0.349-0.960, p=0.0343).  
 
  
168 
 
 
6.1a
 
6.1b
 
Years from 
diagnosis 
0 2 4 6 8 
No at risk 
6MWD>318 
6MWD≤318 
 
129 
131 
 
89 
67 
 
50 
27 
 
17 
10 
 
2 
0 
 
Years from 
diagnosis 
0 2 4 6 8 
No at risk 
6MWD>360 
6MWD≤360 
 
86 
94 
 
56 
59 
 
35 
23 
 
15 
10 
 
0 
0 
 
6.1c 
 
6.1d 
 
Years from 
diagnosis 
0 2 4 6 8 
No at risk 
6MWD>36 
6MWD≤36 
 
42 
35 
 
23 
19 
 
10 
6 
 
4 
3 
 
0 
0 
 
Years from 
diagnosis 
0 2 4 6 8 
No at risk 
6MWD>36 
6MWD≤36 
 
46 
35 
 
34 
22 
 
22 
13 
 
9 
3 
 
0 
0 
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6.1e 
 
 
Years from 
diagnosis 
0 2 4 6 8 
No at risk 
6MWD>36 
6MWD≤36 
 
81 
77 
 
47 
54 
 
24 
29 
 
8 
13 
 
0 
0 
 
  
Figure  6.1. Kaplan Meier survival curves according to 6MWD at baseline and 
follow-up and Δ6MWD at 3 months.  
 
6.1a) Patients who walked >318 m at the time of diagnosis (corresponds to median 6MWD at 
baseline) have better survival than those who walked ≤ 318 m.  
 
6.1b) Patients who walked > 360 m at 3 months (corresponds to median 6MWD at 3 months) have 
better survival than those who walked ≤ 360m.  
 
6.1c) In patients with below median baseline walk (≤ 318 m), Δ6MWD at 3 months of > 36 m 
(corresponds to median Δ6MWD at 3 months)  was associated with better survival compared to 
those with Δ6MWD ≤ 36 m).  
 
6.1d) In patients with above median baseline 6MWD (>318 m), Δ6MWD at 3 months was not 
associated with survival. 
 
6.1 e) ∆6MWD at 3 months was not associated with survival in the whole cohort. 
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Absolute values and change in 6MWD at 6 months: 
 
Paired baseline and 6 months 6MWD data were available in 136 patients. The 
mean increase in 6MWD at 6 months was 50.7 m (95% CI 35.2 – 66.1 m) from 
baseline (baseline 6MWD was 304.5 ± 114.1 m increasing to 355.2 ± 117.2 m at 6 
months). The magnitude of change in 6MWD at 6 months in response to 
treatment was not statistically significant between younger vs. older patients, 
between gender or between patients in baseline FC III/IV vs. baseline FC I/II. 
Patients with baseline 6MWD of ≤ 318 m (corresponding to median baseline 
6MWD) had greater magnitude of change in 6MWD at 6 months in response to 
treatment (Δ6MWD at 6 months = 77.5 m) compared with patients with baseline 
6MWD of > 318 m (Δ6MWD at 6 months = 27.5 m, p=0.002). Change in 6MWD at 6 
months was not associated with survival. 
 
Functional Class at 3 months:  
 
Out of 482 patients, 15 patients died before 3 months. In the remaining patients, 
paired baseline and 3 months FC data were available in 260 patients. FC at 3 
months was not associated with survival (Figure 6.2b). However, patients with 
missing FC data at baseline and/or 3 months (n=207) had worse survival 
compared with those with available data (Log rank, p=0.009). Change in FC 
group at 3 months was not associated with survival (Log rank, p=0.650, Figure 
6.3a). There was no change in the result when a missing data category was 
added to include patients with missing baseline and/or 3 months FC (Log rank, 
p=0.086).  
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6.2a 
 
6.2b 
 
Years from 
diagnosis 
0 2 4 6 8 
No at risk 
FC I/II 
FC III/IV 
 
72 
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46 
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24 
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11 
43 
 
0 
4 
 
Years from 
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0 2 4 6 8 
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51 
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20 
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6.2c 
 
Years from 
diagnosis 
0 2 4 6 8 
No at risk 
FC I/II 
FC III/IV 
 
105 
147 
 
74 
89 
 
36 
41 
 
17 
16 
 
1 
0 
 
 
  
Figure 6.2 . Kaplan Meier survival curves according to baseline FC (Figure 
6.2a), functional class at 3 months (Figure 6.2b) and functional class at 6 
months follow-up (Figure 6.2c). 
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Functional class at 6 months: 
 
Out of 482 patients, 20 patients died before 6 months. In the remaining patients, 
paired baseline and 6 months FC data were available in 249 patients. Patients 
with missing FC data at baseline and/or 6 months (n=213) had similar survival to 
those with available data (Log rank, p=0.240). Patients in FC I/II at 6 months had 
better survival compared with patients in FC III/IV (Figure 6.2c). Patients who 
improved from baseline FC III/IV to FC I/II after of 6 months of treatment (Group 
2) had similar survival to patients who were in FC I/II at baseline and remained 
in FC I/II (Group 1) after 6 months of treatment (Table 6.1). Conversely, patients 
who deteriorated from baseline FC I/II to FC III/IV at 6 months (Group 3) had 
worse survival compared with patients who remained at FC I/II at baseline and 
at 6 months (Group 1). Kaplan Meier survival curves for change in FC group after 
6 months of treatment are shown in Figure 6.3b (Log rank, p=0.018).  
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Table 6.1. Univariate and multivariate Cox proportional hazard models to 
determine the prognostic significance of change in functional class at 6 
months. 
 
Change in 
functional 
class at 6 
months 
Univariate analysis Multivariate analysis* 
p-value Hazard ratio 
(95% CI) 
p-value Hazard ratio 
(95% CI) 
Group 1 
 
Group 2 
 
Group 3 
 
Group 4 
0.025 
 
0.727 
 
0.035 
 
0.045 
1 
 
1.211 
(0.414-3.545) 
4.740 
(1.119-20.081) 
2.600(1.022-
6.616) 
0.034 
 
0.293 
 
0.003 
 
0.135 
1 
 
1.899 
(0.574-6.282) 
9.669 
(2.113-44.236) 
2.183 
(0.784-6.075) 
* Adjusted for age, mixed venous oxygen saturations and pulmonary vascular resistance index. 
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Figure 6.3. Kaplan Meier survival curves according to change in functional 
class from baseline to follow-up.  
 
6.3a) 3 months follow-up: Change in functional class at 3 months from baseline is not associated 
with survival.  
 
6.3b) 6 months follow-up: Patients who improved from FC III/IV at baseline to FC I/II at 6 months 
(Group 2) have similar survival as patients who remained stable at FC I/II from baseline to 6 
months (Group 1). Patients who deteriorated from FC I/II at baseline to FC III/IV at 6 months 
(Group 3) have similar survival to patients who started in FC III/IV at baseline and remained in FC 
III/IV at 6 months (Group 4). At 6 months follow-up, Group 1 and 2 patients have better survival 
than Group 3 and 4 patients.  
 
 
  
175 
 
Out of the whole cohort, baseline, 3 and 6 months FC data were all available in 
215 patients. 4 out of 34 (11.8%) patients with FC I/II at baseline and at 3 
months subsequently deteriorated to FC III/IV at 6 months. 24 out of 143 (16.8%) 
patients with FC III/IV at baseline and at 3 months subsequently improved to FC 
I/II at 6 months. 7 out of 34 (20.6%) patients with FC III/IV at baseline and 
improved to FC I/II at 3 months had subsequently deteriorated again to FC III/IV 
at 6 months.  
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6.5 Discussion 
 
In this chapter, we reported on the prognostic significance of change in 6MWD 
and functional class of idiopathic, heritable and anorexigens-associated PAH in 
response to treatment. Change in 6MWD after 3 months of treatment was 
associated with survival in patients with below median baseline 6MWD. Change 
in functional class at 6 months but not at an earlier time of follow-up in 
response to treatment also predicted survival. 
 
Change in 6MWD and survival: 
 
Change in invasive pulmonary haemodynamics in response to treatment has been 
shown to predict survival in PAH (48, 58, 104, 105). However, right heart 
catheterisation is expensive and invasive.  On the other hand, 6MWD is non-
invasive, cheap to perform and reproducible. Baseline 6MWD correlates with 
functional class and haemodynamics variables and predicts survival (46, 106). 
Change in 6MWD has been used as the primary endpoint in many pivotal PAH 
clinical trials. It is however unclear what constitutes a clinically meaningful 
change of 6MWD in PAH (107). Mathai et al found improvement of 33 m was 
associated with improvement in quality of life measures (51). The majority of 
randomised clinical trials in PAH were 12-16 weeks in duration. We have 
therefore chosen 3 months follow-up as a fixed time point to evaluate whether 
short term improvement in 6MWD has any long term prognostic implications.  
 
The magnitude of change in 6MWD at 3 months in this study of 39.5 m was 
similar to pooled results of 19 randomised clinical trials from a recent meta-
analysis (56). We observed that patients with more severe  functional 
impairment (lower baseline 6MWD and FC III/IV) had bigger magnitude of change 
in 6MWD after 3 months of treatment. Our results are consistent with findings 
from the clinical trials that showed bigger increases in 6MWD in advanced, 
severe patients and no significant change of 6MWD in less ill patients (68).  
 
We found absolute baseline 6MWD > 318m, absolute 3 months 6MWD > 360 m and 
change in 6MWD at 3 months > 36 m were all associated with better survival. 
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Each 100 metre improvement in 6MWD after 3 months of PAH treatment was 
associated with 42% reduction in mortality in our study population. The 
association between improvement in 6MWD at 3 months and survival appears to 
be stronger in the more compromised patients (those with lower baseline 6MWD 
< 318 m). Provencher et al also found increase in 6MWD after 4 months of 
treatment was associated with improved survival (105) That was a single centre 
study and was restricted to idiopathic PAH patients in functional class III and IV 
who were started on first-line bosentan. Better prognostic value of change in 
6MWD in more compromised patients was recently reported in the SUPER-2 study 
(66). Unlike patients in our study, patients recruited in the SUPER-2 study were 
highly selected and may be not representative of real-life patients seen in daily 
clinical practice. 
 
Patients with higher baseline walk may need a bigger change in 6MWD to 
translate into survival difference. The ceiling effect of 6MWD (44) may also 
mean there is less scope for 6MWD improvement in those with high baseline 
walk.  Our study demonstrated short term improvement in 6MWD in response to 
treatment has prognostic significance albeit only in those with severe functional 
impairment. Change in 6MWD is not a good surrogate marker to assess response 
to treatment in those with less functional impairment. 
 
Change in functional class and survival: 
 
FC at baseline and on treatment have been shown to be associated with survival 
(58). In this study, no association was found between FC at 3 months or change 
in FC at 3 months and survival. Patients with missing FC data at 3 months have 
worse survival than those at 3 months and this may explain the lack of 
significance of FC at 3 months follow up. It is also possible that 3 months may be 
too early for any real response to treatment to be translated into FC 
improvement. A bigger improvement may be needed to change a patient from 
FC III to II compared with a change of FC from IV to III.  
 
Change in functional class became prognostically significant at 6 months follow-
up. Irrespective of baseline FC, patients who were in FC I/II at 6 months have 
better survival than those who either deteriorated or remained at FC III/IV. 
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Nickel et al (104) also found changes in FC influenced outcomes. In that study, 
timing of follow-up was variable and defined as the date of the first follow-up 
right heart catheterisation after initiation of PAH therapy. 
 
The clinical relevance of any variables used to monitor response to treatment 
may also depend on the timing of their measurement following diagnosis. In our 
study, change in 6MWD translated into better survival (at least in those with low 
baseline walk) at 3 months, which was the length of most clinical pulmonary 
hypertension randomised clinical trials. Change in FC translated into survival 
difference at 6 months but not at earlier time of follow-up in the current study. 
The course of disease may also be highly variable in the first few months after 
diagnosis. A significant proportion of our patients who improved initially after 3 
months of treatment subsequently deteriorated at 6 months.  
 
Limitations: 
 
There are several limitations to our study. Not all tests were done in all centres 
at predefined follow-up time points leading to unavoidable missing data. 
Patients who died before the predefined follow-up time points were excluded 
from survival analysis. This may potentially bias the results although the 
numbers of such patients were small. Patients with missing data may have worse 
outcome and their exclusion may systematically bias our findings. For example, 
6MWD at follow-up may be missing because a patient was too ill to perform the 
test. However, similar conclusions were found using missing 6MWD data 
imputation (Table 6.2) suggesting that the relationship between change in 6MWD 
at 3 months and survival is likely to be true. 25% of this study population came 
from a single centre that used incremental shuttle walk test to assess exercise 
capacity and were therefore exluded from the 6MWD analyses. These excluded 
patients were otherwise similar in baseline characteristics and managed similarly 
according to contemporary UK and European pulmonary hypertension guidelines. 
Similarly, patients with missing data for change in FC at 3 months had worse 
survival compared with those with available data. This may therefore account 
for the lack of prognostic significance of change in FC at 3 months. Other factors 
such as change in NT-pro BNP or Quality of life scores at follow-up may also have 
prognostic significance but had too many missing data and were thus not 
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included in the analysis.  We have not controlled for the type of treatment in 
this study. Nevertheless, it is possible patients who persisted in FC III/IV at 3 
months may have changes to their treatment which may subsequently alter their 
outcome. Finally, our results are not generalisable to patients with other PAH 
aetiologies.  
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Table 6.2. Univariate Cox regression and missing data imputation on change 
in six-minute walk distance at 3 months.  
 
Method p-value Hazard ratio* 95% confidence interval 
1 0.0343 0.579 0.349-0.960 
2 0.0898 0.651 0.397-1.069 
3 0.0807 0.654 0.406-1.053 
4 0.0567 0.671 0.445-1.011 
5 0.0030 0.496 0.312-0.789 
6 0.0116 0.555 0.352-0.877 
7 0.0042 0.519 0.331-0.813 
  
*6MWD per 100 metres 
 
Method 1 corresponds to a complete case analysis. 
 
Method 2 incorporates a missing data indicator. 
 
Method 3 assumes no change in the case of missing 3-month assessments. 
 
Method 4 assumes a 20% reduction from baseline in the case of missing 3-month assessments. 
 
Method 5 uses linear interpolation to estimate 3 month 6MWD in patients who had 3- or 6-month 
assessments. 
 
Method 6 is based on method 5, but assumes an average increase of 38 metres to 3 month 6MWD 
for those patients with missing 3-, 6- or 12-month assessments. The increase in 6MWD of 38m 
was the observed mean change in patients with 3 month data. 
 
Method 7 is based on method 6, but uses a linear regression equation as follow: 3 month 6MWD = 
1.02727-0.21016x(baseline 6MWD). The equation was developed following a regression analysis of 
3 month 6MWD on baseline 6MWD in patients with 3 month data. 
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6.6 Conclusion 
 
Change in 6MWD at 3 months was associated with better survival in patients with 
more compromised exercise impairment. Improvement as well as deterioration 
of FC in response to treatment at 6 months but not 3 months follow-up has long 
term prognostic implications.  
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7 Chapter 7. Pre-capillary Pulmonary Hypertension with 
Co-existing Lung Disease: Response to Treatment and 
Survival. 
 
7.1 Summary 
 
Rationale: 
 
Patients with preserved pulmonary function who otherwise satisfied the standard 
haemodynamic criteria used to define idiopathic pulmonary arterial hypertension 
(PAH) in pulmonary hypertension registries and clinical trials may have some 
evidence of co-existing lung disease on thoracic CT. It is unclear how the 
response to treatment and survival in this group of patients (refers as Pre-
capillary pulmonary hypertension with co-existing lung disease or ‘pre-capillary 
PH-LD’ in this study) differ from idiopathic PAH. 
 
Objectives: 
 
To describe and compare the baseline characteristics and survival of pre-
capillary PH-LD with idiopathic, heritable and anorexigen-associated PAH. 
 
Methods: 
 
All consecutive, newly diagnosed patients with PAH with pre-capillary PH-LD  
were compared with idiopathic, heritable and anorexigen-associated PAH 
diagnosed concurrently between 2001 and 2009 in all eight pulmonary 
hypertension centres in the UK and Ireland. Both groups of patients had 
preserved pulmonary functions (% FEV1, % FVC and/or %TLC > 60%). However, 
patients with pre-capillary PH-LD also had evidence of parenchymal lung disease 
(of any severity) on thoracic CT.  
 
Results: 
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Compared with idiopathic, heritable and anorexigen-associated PAH (n=482), 
pre-capillary PH-LD (n=146) patients were older, predominantly male current 
and/or ex-smoker, and had lower six minute walk distance (6MWD), % predicted 
diffusion capacity for carbon monoxide, mean pulmonary arterial pressure and 
pulmonary vascular resistance index. After 3 months of pulmonary hypertension 
targeted treatment, 6MWD improved by 51.7m in pre-capillary PH-LD and by 
39.6 m in idiopathic, heritable and anorexigen-associated PAH (p=0.361). 
However, 1 year survival of pre-capillary PH-LD was only 73.8% compared with 
92.7% in idiopathic, heritable and anorexigen-associated PAH. 
 
Conclusion: 
 
Pre-capillary pulmonary hypertension with co-existing lung disease patients had 
different phenotype compared with idiopathic, heritable and anorexigen-
associated pulmonary arterial hypertension patients. Despite similar short term 
improvement in 6MWD in response to treatment, survival of pre-capillary 
pulmonary hypertension with co-existing lung disease was worse compared with 
idiopathic, heritable and anorexigen-associated PAH.  
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7.2 Introduction 
 
The development of pulmonary hypertension (PH) in patients with COPD and 
interstitial lung disease is associated with poor outcome (108-110). Patients with 
advanced lung diseases have been excluded from randomised controlled trials in 
the field of pulmonary arterial hypertension (PAH). Although PH targeted 
therapies have been used in selective patients outside the context of clinical 
trials, there is currently no consensus on the definition of the group of patients 
whose PH appears to be out of proportion to their underlying lung disease. There 
is also no evidence to date to support the use of PH targeted therapies in 
patients with PH secondary to chronic lung disease (Dana Point Group III 
patients) (5).  
 
In the United Kingdom (UK) and Ireland, the diagnosis and initiation of PH 
targeted therapies are centralised to eight PH centres. Between the period 2001 
to 2009, 628 patients who satisfied the traditional haemodynamic  (mPAP ≥ 
25mmHg, pulmonary artery occlusion pressure ≤ 15mmHg, cardiac output was 
normal or reduced) and pulmonary function criteria (FEV1, FVC and TLC  ≥ 60% 
predicted) used to define idiopathic, heritable and anorexigen-associated PAH in 
PH registries and clinical trials were diagnosed in all eight pulmonary 
hypertension centres in the UK and Ireland. We further refined our study 
exclusion criteria by excluding patients with evidence of co-existing lung 
diseases on thoracic CT from our idiopathic, heritable and anorexigen-associated 
PAH cohort. The baseline characteristics and outcomes of our idiopathic, 
heritable and anorexigen-associated PAH patients (n= 482) were discussed in 
Chapter 3 of this thesis and published as the Pulmonary Hypertension Registry of 
the United Kingdom and Ireland (89). Patients with evidence of co-existing lung 
disease on thoracic CT (n=146) who were excluded from this idiopathic PAH 
registry otherwise satisfied the traditional haemodynamic and pulmonary 
function criteria used to define idiopathic PAH in PH registries and clinical 
trials(32, 33) and were managed in a similar fashion to idiopathic PAH by their 
PH specialists in accordance with contemporary PH guidelines (5, 80, 81). It is 
however unclear whether the response to treatment and survival of this 
excluded group of patients (refers as pre-capillary pulmonary hypertension with 
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co-existing lung disease or ‘pre-capillary PH – LD’ in this study) are affected by 
the co-existence of modest lung disease. 
 
The objective of this study was to describe and compare the clinical 
characteristics, haemodynamics and outcomes of this selective group of 
incident, treatment-naive pre-capillary PH – LD patients with idiopathic PAH 
diagnosed concurrently in the UK and Ireland.  
 
The flow diagram of patients selection for idiopathic, heritable and anorexigen-
associated pulmonary arterial hypertension and pre-capillary PH – LD has been 
described in Chapter 2, Figure 2.1. 
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7.3 Methods 
 
We included all consecutive, treatment-naive, incident cases of pre-capillary PH 
– LD diagnosed between 1st January 2001 and 31st December 2009 in all eight 
pulmonary hypertension centres in the UK and Ireland.  PAH was defined as 
mean pulmonary arterial pressure (mPAP) ≥ 25mmHg and pulmonary artery 
occlusion pressure ≤ 15mmHg with a normal or reduced cardiac output. All 
patients underwent CT of the thorax as part of their multimodality assessment 
for pulmonary hypertension. For the purpose of this study, the presence of co-
existing lung disease was defined based on the reports of the thoracic CT 
performed at the time of diagnosis of PAH and included parenchymal 
abnormalities of all severity. 
 
The following patients were excluded from pre-capillary PH – LD: family history 
of PAH, previous anorexigens exposure, connective tissue/collagen vascular 
disease, portal hypertension, haemolytic anaemia, HIV, congenital heart disease 
and sarcoidosis. Patients who may have pulmonary hypertension secondary to 
significant hypoxic lung disease were excluded by abnormal pulmonary function 
test (defined as FEV1, FVC or TLC < 60% predicted) (32, 33).  
 
We compared the baseline characteristics, treatments started at the time of 
diagnosis, and functional class and 6 minute walk distance at 3 months follow up 
between idiopathic, heritable and anorexigen-associated PAH versus pre-
capillary PH – LD.  The date of diagnostic right heart catheterisation was taken 
as the date of diagnosis. Due to the nature of the study, ethical approval was 
deemed unnecessary by the West of Scotland Research Ethics Committee.  
 
Statistical Analysis: 
 
Analysis was performed using SPSS version 19 (SPSS, Chicago, IL). For 
quantitative variables, mean ± standard deviation was used to describe 
parametric data, whereas median and interquartile range (IQR) was used for 
non-parametric data. Comparisons between two independent groups were 
performed using Student’s t test or Mann-Whitney U test. Categorical variables 
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were described by frequencies and percentages and comparisons between groups 
performed using χ2 or Fisher‘s exact tests. Survival endpoint was taken as either 
date of death or censoring. Patients were censored if they were transplanted 
(n=14), lost to follow up (date of last visit to pulmonary hypertension centre was 
used as censor date) or if they were alive on the last day of the study (31st 
December 2009). Mortality was confirmed using pulmonary hypertension centres 
and general practitioners’ records and NHS strategic tracing services. All-cause 
mortality was used in survival analysis. Survival from time of diagnosis was 
estimated using the Kaplan Meier method and survival curves compared using 
log-rank test. Multivariate Cox regression was used to determine the 
independent predictors of survival in pre-capillary PH – LD. Variables with p <0.1 
in univariate analyses were entered into multivariate analysis. Multivariate Cox 
regression was also used to compare the survival of pre-capillary PH – LD versus 
idiopathic, heritable and anorexigen-associated PAH after adjusting for potential 
confounders. P-values <0.05 were considered to be significant. 
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7.4 Results 
 
A total of 146 patients satisfied the inclusion criteria for pre-capillary PH – LD. 
The types of parenchymal abnormalities reported on thoracic CT were as follow: 
emphysema only (n=88), pulmonary fibrosis only (n=35), emphysema and 
pulmonary fibrosis (n=16) and others (n=7).  
 
Demographics, pulmonary function and haemodynamics: 
 
Baseline characteristics of pre-capillary PH – LD patients were compared with 
idiopathic, heritable and anorexigen-associated PAH patients diagnosed over the 
same period in the UK and Ireland (Table 7.1). Compared with idiopathic, 
heritable and anorexigen-associated PAH, pre-capillary PH – LD patients were 
older, had lower body mass index and were predominantly male (Figure 7.1) 
current or ex-smoker. Like idiopathic, heritable and anorexigen-associated PAH, 
patients with pre-capillary PH – LD also had long delay in diagnosis with median 
symptom duration of 18 months before diagnosis. Despite similar functional class 
distribution, pre-capillary PH – LD patients had lower mean six minute walk 
distance (6MWD) at the time of diagnosis. Mean values of spirometry and lung 
volumes were within normal limits whereas %DLCO were severely impaired in pre-
capillary PH – LD (Figure 7.2). Pre-capillary PH – LD patients had severe 
precapillary pulmonary hypertension. However, mPAP and PVRI were 
significantly lower in pre-capillary PH – LD compared with idiopathic, heritable 
and anorexigen-associated PAH (Table 7.1). This differences in baseline 
characteristics remained significant when pre-capillary PH – LD was compared 
with the older (age > 50) subgroup of idiopathic heritable and anorexigen-
associated PAH patients. (Table 7.2).  
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Table 7.1. Comparison of baseline demographics, pulmonary function tests 
and haemodynamics between patients with pre-capillary pulmonary 
hypertension with co-existing lung disease and idiopathic, heritable and 
anorexigen-associated PAH.  
 
 pre-capillary PH – LD 
(n=146) 
IPAH (n=482) p-value 
Age, years 67.7(11.6) 50.1(17.1) <0.001 
% female 41.8%(61) 69.9%(337) <0.001 
Ethnicity, % non 
white 
1.6%(2) 12.3%(52) <0.001 
BMI≥30 17.1%(22) 33.9%(135) <0.001 
BMI, kg.m-2 26.1(6.0) 28.3(6.3) <0.001 
6MWD, metres 209.2(118.0) 292.4(123.0) <0.001 
Current/ex-
smoker 
89.7%(113) 55.7%(201) <0.001 
Median duration 
of symptoms, 
months 
18.0(11.0-36.0) 18.0(9.0-36.0) N.S 
Functional class: 
I/II 
III 
IV 
 
10.5%(15) 
69.9%(100) 
19.6%(28) 
 
15.8%(72) 
66.7%(304) 
17.5%(80) 
 
 
N.S 
FEV1% 88.8(18.0) 85.3(14.7) N.S 
FVC % 102.2(20.6) 94.0(16.4) <0.001 
TLC % 95.4(15.2) 95.4(13.9) N.S 
DLCO% 37.9(20.0) 62.0(20.9) <0.001 
RAP, mmHg 9.4(5.1) 10.1(6.0) N.S 
mPAP, mmHg 48.6(9.0) 54.1(13.9) <0.001 
PAOP, mmHg 9.3(3.3) 9.2(3.5) N.S 
SvO2, % 62.0(9.2) 61.5(9.5) N.S 
CI, L.min-1.m-2 2.1(0.7) 2.1(0.7) N.S 
PVRI, WU.m2 20.6(8.2) 23.1(10.3) 0.007 
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Definition of abbreviations: 6MWD = 6 minute walk distance, BMI = body mass index, CI = cardiac 
index, DLCO% = % predicted diffusion capacity for carbon monoxide, FEV1% = % predicted forced 
expiratory volume in 1 second, FVC% = % predicted forced vital capacity, IPAH = idiopathic, 
heritable and anorexigen-associated pulmonary arterial hypertension, mPAP = mean pulmonary 
artery pressure, N.S = not significant, pre-capillary PH – LD = pre-capillary pulmonary 
hypertension with co-existing lung disease, PAOP = pulmonary artery occlusion pressure, PVRI = 
pulmonary vascular resistance index, RAP = mean right atrial pressure, SvO2 = mixed venous 
oxygen saturations, TLC% = % predicted total lung capacity, WU = Woods Unit.  
 
Data were presented as mean (standard deviation) or % (number) unless otherwise stated. 
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Table 7.2. Comparison of baseline characteristics between pre-capillary PH – 
LD and idiopathic, heritable and anorexigen-associated PAH age > 50 years 
old. 
 
 pre-capillary PH – LD  
(n=146) 
Older IPAH 
subgroup*(n=236) 
p-value 
Age, years 67.7(11.6) 65.1(8.3) 0.016 
% female 41.8%(61) 66.5%(157) <0.001 
Ethnicity, % non 
white 
1.6%(2) 8.9%(18) 0.008 
BMI≥30 17.1%(22) 40.5%(81) <0.001 
BMI, kg.m-2 26.1(6.0) 29.2(6.2) <0.001 
6MWD, metres 209.2(118.0) 246.1(112.2) 0.029 
Current/ex-
smoker 
89.7%(113) 64.0%(119) <0.001 
Median duration 
of symptoms, 
months 
18.0(11.0-36.0) 24.0(12.0-36.0) N.S 
Functional class: 
I/II 
III 
IV 
 
10.5%(15) 
69.9%(100) 
19.6%(28) 
 
11.9%(27) 
67.4%(153) 
20.7%(47) 
 
 
N.S 
FEV1% 88.8(18.0) 85.1(15.8) N.S 
FVC % 102.2(20.6) 96.7(17.6) 0.015 
TLC % 95.4(15.2) 94.4(14.3) N.S 
DLCO% 37.9(20.0) 56.7(22.8) <0.001 
RAP, mmHg 9.4(5.1) 10.2(6.1) N.S 
mPAP, mmHg 48.6(9.0) 51.0(12.2) 0.028 
PAOP, mmHg 9.3(3.3) 9.5(3.5) N.S 
SvO2, % 62.0(9.2) 60.6(8.6) N.S 
CI, L.min-1.m-2 2.1(0.7) 2.1(0.7) N.S 
PVRI, WU.m2 20.6(8.2) 21.5(9.1) N.S 
Median survival, 
years (95% CI) 
2.5(1.4-2.6) 4.8(4.2-5.3) 0.001 
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See Table 7.1 for definition of abbreviations 
 
* IPAH patients were divided into younger and older subgroups according to the median age. 
Older IPAH refers to the subgroup of IPAH patients who were more than 50 years old.  
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7.1a 
 
7.1b 
 
 
Figure 7.1. Distribution of age by gender in idiopathic, heritable and 
anorexigen-associated PAH (7.1a) and pre-capillary PH – LD (7.1b).  
IPAH refers to patients with idiopathic, heritable and anorexigen associated PAH. 
  
Pre-capillary PH with co-existing lung disease 
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7.2a 
 
7.2b
 
7.2c 
 
7.2d 
 
 
Figure 7.2. Frequency distributions of selective baseline parameters in pre-
capillary PH – LD patients.  
See table 7.1 for definition of abbreviations. 
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Co-morbidities: 
 
pre-capillary PH – LD patients had more non-respiratory co-morbidities compared 
with idiopathic, heritable and anorexigen-associated PAH (Table 7.3). 
 
  
196 
 
Table 7.3. Comparisons of co-morbidities in pre-capillary PH – LD pre-
capillary PH – LD and idiopathic, heritable and anorexigen-associated PAH. 
 
Co-morbidities pre-capillary PH – LD 
(n=146) 
IPAH (n=482) p-value 
IHD 29.7%(43) 12.1%(58) <0.001 
Hypertension 25.9%(37) 26.6%(121) N.S 
Diabetes 21.0%(30) 14.3%(65) 0.056 
Definition of abbreviations: COPD = chronic obstructive pulmonary disease, IHD = ischaemic heart 
disease and ILD = interstitial lung disease, and see table 7.1.  
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Treatment: 
 
All patients were treatment-naive prior to the diagnosis of PAH. First line 
pulmonary hypertension treatment started at the time of diagnosis for patients 
with pre-capillary PH – LD was as follow: phosphodiesterase 5 inhibitors 52.1% 
(n=76), endothelin receptor antagonists 32.9% (n=48) and prostanoids 7.5% 
(n=11). 29.0% (n=42) of pre-capillary PH – LD patients received combination 
therapy over the study period compared with 46.3% (n=222) in idiopathic, 
heritable and anorexigen-associated PAH. No pre-capillary PH – LD patient 
received lung transplantation.  
 
6MWD and functional class at 3 months: 
 
6MWD improved by 51.7 ± 85.6 m after 3 months of disease targeted therapies in 
pre-capillary PH – LD compared with 39.6 ± 73.1m in idiopathic, heritable and 
anorexigen-associated PAH (p= N.S). After 3 months of PAH treatment, 73.6% 
(n=64) and 9.2% (n=8) of pre-capillary PH – LD patients remained in functional 
class III and IV respectively. This was significantly less compared with idiopathic, 
heritable and anorexigen-associated PAH patients. After 3 months of pulmonary 
hypertension treatment, 58.6% (n=154) and 8.4% (n=22) of idiopathic, heritable 
and anorexigen-associated PAH remained in functional class III and IV 
respectively (p=0.018). 
 
Survival: 
 
Out of the 146 pre-capillary PH – LD patients, 61 died by the end of the study. 
The mean follow-up period was 1.6 years. Kaplan Meier survival estimates at 1, 2 
and 3 years were 73.8%, 54.7% and 42.6% respectively. Pre-capillary PH – LD had 
worse survival compared with idiopathic, heritable and anorexigen-associated 
PAH (Figure 7.3). Compared with idiopathic, heritable and anorexigen-associated 
PAH, patients with pre-capillary PH – LD were more likely to die after adjusting 
for age, gender and smoking history (hazard ratio 1.669, 95% CI 1.130-2.464, p = 
0.010). 
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Age, smoking history, %DLCO, mean right atrial pressure, mixed venous oxygen 
saturations, cardiac index and pulmonary vascular resistance index were 
associated with survival in univariate analyses (Table 7.4). Age, smoking history, 
mean right atrial pressure were independent predictors of survival in pre-
capillary PH – LD in multivariate analysis (Table 7.5). 
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Years from diagnosis 0 2 4 6 8 
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IPAH 
Pre-capillary PH-LD 
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146 
 
283 
40 
 
136 
9 
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1 
 
9 
0 
 
 
Figure 7.3. Survival curves of pre-capillary PH – LD and IPAH.  
 
Pre-capillary PH – LD refers to pre-capillary pulmonary hypertension with co-existing lung disease 
and IPAH refers to idiopathic, heritable and anorexigen-associated PAH. 
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Table 7.4. Univariate Cox proportional hazard regression analyses of baseline 
variables in pre-capillary PH – LD. 
 
 p-value Hazard ratio 95% confidence 
interval 
Age, years <0.001 1.062 1.031-1.094 
Male gender 0.108 1.535 0.911-2.587 
Smoking history: 
Never smoke 
Current/ex-smoker 
 
 
0.029 
 
1 
4.845 
 
 
1.173-20.010 
Duration of symptoms, 
months 
0.896 1.001 0.990-1.012 
Functional class- 
I and II 
III 
IV 
 
0.331 
0.179 
0.138 
 
1 
2.237 
2.579 
 
 
0.692-7.232 
0.738-9.016 
Systemic hypertension 0.537 0.818 0.434-1.545 
Ischaemic heart disease 0.373 1.281 0.743-2.210 
Diabetes 0.062 1.733 0.972-3.088 
%FEV1 0.469 1.005 0.991-1.021 
%FVC 0.176 1.010 0.996-1.024 
%TLC 0.521 0.991 0.966-1.018 
%DLCO 0.038 0.980 0.962-0.999 
RAP, mmHg 0.002 1.083 1.030-1.139 
mPAP, mmHg 0.969 1.000 0.976-1.026 
PAOP, mmHg 0.686 0.984 0.908-1.065 
SvO2, % 0.030 0.970 0.943-0.997 
CI, L.min-1.m-2 0.002 0.431 0.253-0.732 
PVRI, WU.m-2 0.061 1.026 0.999-1.054 
See table 7.1 for definition of abbreviations. 
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Table 7.5. Multivariate Cox proportional hazard regression analysis of 
selected baseline variables in pre-capillary PH – LD. 
 
 p-value Hazard ratio 95% confidence 
interval 
Age, years 0.001 1.064 1.025-1.104 
Smoking history: 
Never smoke 
Current/ex-smoker 
 
 
0.035 
 
1 
4.111 
 
 
1.102-15.339 
Diabetes 0.165 1.634 0.817-3.268 
%DLCO 0.051 0.983 0.967-1.000 
RAP, mmHg 0.018 1.093 1.106-1.176 
SVO2, % 0.879 1.004 0.958-1.052 
CI, L.min-1.m-2 0.434 0.651 0.222-1.908 
PVRI, WU.m-2 0.746 1.011 0.948-1.077 
See table 7.1 for definition of abbreviations. 
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7.5 Discussion 
 
We report on the baseline characteristics and outcomes of a selective group of 
PAH patients with radiological evidence of lung disease who otherwise satisfied 
the traditional haemodynamic and pulmonary function criteria used to define 
idiopathic pulmonary arterial hypertension in PH registries and clinical trials. 
This selective group of pre-capillary PH – LD patients had preserved spirometry 
and lung volumes but severely reduced %DLCO, and had significant precapillary 
pulmonary hypertension that appeared disproportionate to their underlying lung 
disease. Our results show that despite similar baseline haemodynamic 
impairment, demographics of these pre-capillary PH – LD patients were different 
compared with idiopathic, heritable and anorexigen-associated PAH patients. 
Furthermore, despite similar short term improvement in 6MWD in response to PH 
disease targeted therapies, survival of pre-capillary PH – LD patients appeared 
significantly worse compared with idiopathic, heritable and anorexigen-
associated PAH patients.  
 
Pre-capillary PH – LD patients described in our study had normal spirometry and 
lung volumes. Most of the parenchymal abnormality in our study cohort was 
emphysema. Emphysema on CT may be noted in otherwise asymptomatic healthy 
smokers and may not be associated with airflow obstruction on spirometry (111) 
. Interstitial changes were also frequently seen on the CT of asymptomatic 
elderly patients and may not be of any clinical relevance (112). It is possible this 
selective group of pre-capillary PH – LD as reported in our study simply 
represents a subgroup of ‘idiopathic PAH’ patients where the predominant 
disease is idiopathic PAH and the parenchymal abnormality is an incidental 
insignificant finding noted on thoracic CT done as part of the standard 
assessment of PH. However, the differences in phenotypes and the worse 
survival of this selective group of patients compared with idiopathic PAH 
suggested that may not be the case. 
 
Although mPAP and PVR were lower than idiopathic PAH patients, pre-capillary 
PH – LD patients in our study still had significantly impaired pulmonary 
haemodynamics and depressed cardiac function. On the other hand PH that 
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complicates stable COPD usually occurs when airflow limitation is severe and 
associated with chronic alveolar hypoxia and tends to be mild to moderate in 
severity, with relatively preserved right ventricular function (108) . A subgroup 
of COPD patients with severe out of proportion PH and significantly worse 
survival had also been described. These patients had moderate to severe PH, 
severe hypoxaemia and markedly reduced DLCO (113, 114). However, these 
patients also had mild- to moderate airflow obstruction with FEV1 of ~50%, 
whereas spirometric values were within normal limits in our study cohort.  
 
A recent case report of 3 patients also described similar phenotype to our study 
cohort: elderly male smokers with normal spirometry and lung volumes, 
emphysema on CT, severely reduced DLCO and severe precapillary PH (115). With 
our  larger number of patients, our study not only confirmed the presence of this 
rare phenotype of PAH but also allowed comparison of this selective group of 
pre-capillary PH – LD patients with idiopathic PAH diagnosed and managed 
concurrently by PH physicians with similar practice within a single region (UK 
and Ireland).  
 
The normal spirometry and lung volumes noted in pre-capillary PH – LD patients 
in our study may also be similar to the mechanism of opposing effect of fibrosis 
and hyperinflation noted in the combined pulmonary fibrosis and emphysema 
syndrome (116). The combined pulmonary fibrosis and emphysema syndrome 
described a group of patients who were predominantly male current or ex-
smokers with relatively normal spirometry and lung volumes, significant 
dyspnoea and exercise limitation and higher prevalence of PH (117-119). 
However, the combination of pulmonary fibrosis and emphysema was only 
observed in 11% of our study cohort.  
 
One of the main features that differentiated pre-capillary PH – LD patients in our 
study from idiopathic PAH was the grossly reduced DLCO.  DLCO was 38% in pre-
capillary PH – LD compared with 62% in idiopathic PAH in our study. The lower 
DLCO in pre-capillary PH – LD may be secondary to a combination of factors 
including obliteration of small pulmonary arterioles, reduced cardiac output, 
local thrombosis, pulmonary alveolar-capillary membrane thickening from 
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fibrotic and/or proliferative process, ventilation-perfusion mismatching and loss 
of pulmonary capillaries in emphysema.  
 
Demographics of pre-capillary PH – LD in our study was different compared with 
idiopathic PAH diagnosed concurrently in the UK and Ireland. In this study, pre-
capillary PH – LD was significantly older, predominantly male with current or 
previous smoking history, less obese, worse exercise capacity and had more co-
morbidities compared with idiopathic PAH. We have recently reported that older 
idiopathic PAH patients had different phenotype compared with their younger 
counterparts (89). Older idiopathic PAH patients had more co-morbidities, worse 
exercise and functional impairment, more impaired DLCO, less severe 
haemodynamic impairment and worse survival compared with younger idiopathic 
PAH patients. However, the differences in demographic characteristics described 
above remained significant when we compared pre-capillary PH – LD patients 
with the older idiopathic PAH subgroup. 
 
Response to treatment as measured by change in 6MWD after 3 months of PAH 
specific therapies in pre-capillary PH – LD patients in this study was comparable 
to the improvement observed in concurrent idiopathic PAH patients. This 
improvement in exercise capacity was not observed in randomised controlled 
trials of PAH specific therapies in COPD and pulmonary fibrosis. Sildenafil had no 
effect on 6MWD in a study of 15 COPD patients, 5 of which had PH at rest (120). 
In another study of 30 patients with severe COPD, bosentan had no effect on 
exercise capacity (121) . Median pulmonary systolic pressure assessed by 
echocardiography was 32mmHg in the bosentan arm in that study. In BUILD-1 
trial, effect of bosentan on 6MWD was no better than placebo. However, patient 
with echocardiographic evidence of severe PH were excluded from the BUILD-1 
trial (122). Pulmonary haemodynamic data was not available in the STEP-IPF 
trial which showed no benefit in 6MWD with sildenafil in advanced IPF (123).  
Cottin et al studied the characteristics and outcome of 40 patients with 
combined pulmonary fibrosis and emphysema syndrome and severe pulmonary 
hypertension (mean pulmonary artery pressure was 40mmHg) (117).  No 
significant effect on functional class or 6MWD was noted after 3 to 6 months of 
PAH specific therapies in that study.  Currently, it remains unclear whether 
patients with so called disproportionate PH may benefit from PAH therapies. 
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The survival of idiopathic PAH patients has improved in the modern era of PAH 
disease targeted therapies (22, 26, 89). However, the short term improvement in 
6MWD observed in pre-capillary PH – LD in our study cohort did not appear to 
translate into similar survival benefit observed in idiopathic PAH. 1 year survival 
of pre-capillary PH – LD in our study was only 74% compared with 93% (89) in 
idiopathic PAH diagnosed and managed concurrently in the UK and Ireland. PAH 
specific therapies have vasodilatory and antiproliferative properties and may 
help to unload the right ventricle to account for the short term improvement in 
exercise capacity. However, other factors such as older age and associated co-
morbidities, and the effect of smoking may contribute to the worse survival of 
pre-capillary PH – LD compared with idiopathic PAH. In addition, higher 
proportion of idiopathic PAH (89) received combination therapy compared with 
pre-capillary PH – LD.   
 
The pre-capillary PH – LD patients described in this study otherwise satisfied the 
traditional haemodynamic and pulmonary function criteria of idiopathic PAH (32, 
33) and could have been recruited into clinical trials of PAH. Despite short term 
improvement in 6MWD, the primary endpoint of many pivotal PAH clinical trials, 
survival of this selective group of patients was poor, and even worse than 
idiopathic PAH despite treatment with PAH specific therapies. Our study may 
help to inform the design and better selection of patients for future PAH clinical 
trials.  
 
The strengths of this study included confirmation of PAH by right heart 
catheterisation in all patients. Only incident, treatment-naive patients were 
included. All patients were diagnosed and treated by PH specialist in designated 
centres only in the UK and Ireland. Patients were assessed by a multidisciplinary 
team and alternative causes of PH were excluded.  
 
Our study has several limitations. This was an observational study and we have 
not controlled for treatment. CT images were not reviewed by independent 
reviewer. We defined the presence of parenchymal lung disease based on what 
was recorded on the CT report. Data was not collected for hypoxaemia or use of 
long term oxygen therapy. Our study population comprised of a heterogenous 
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group of patients with different types, severity and combination of parenchymal 
lung diseases. However, the relatively small number of patients did not permit 
further subgroup analysis.   
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7.6 Conclusion 
 
Pre-capillary pulmonary hypertension with co-existing lung disease patients had 
different phenotype compared with idiopathic pulmonary arterial hypertension. 
Despite similar baseline haemodynamic impairment and short term response to 
treatment, survival of pre-capillary pulmonary hypertension with co-existing 
lung disease appeared worse compared with idiopathic pulmonary arterial 
hypertension. Age, the effect of smoking and the presence of age-related co-
morbidities may account for the difference in long term outcome between these 
two groups of patients. 
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8 Chapter 8. Conclusion 
 
The unique set up of the pulmonary hypertension service in the UK and Ireland 
allowed us to study a truly incident, treatment-naive cohort of PAH patients in a 
national setting over a nine year period. In this thesis, we studied the 
demographics, epidemiology and prognostic outcomes of idiopathic, heritable 
and anorexigen-associated PAH. We also identified a new phenotype of pre-
capillary pulmonary hypertension with co-existing lung disease in this thesis.  
 
Our main findings are as follow: 
 
1. The demographics and epidemiology of incident idiopathic, heritable and 
anorexigen-associated PAH has changed compared with the NIH era in the 1980s 
and continue to evolve over the past decade in the UK and Ireland. 
 
2. Age influenced the phenotypic characteristics, prognostic predictors and 
survival of incident idiopathic, heritable and anorexigen-associated PAH. 
 
3. Some of the survival prediction equations derived from non UK and Ireland 
patients cohorts more accurately predicted the survival of incident idiopathic, 
heritable and anorexigen-associated PAH patients in the UK and Ireland than 
others. 
 
4. Short term improvement in six minute walk distance and functional class in 
response to treatment have prognostic implications in incident idiopathic, 
heritable and anorexigen-associated PAH. 
 
5. Pre-capillary pulmonary hypertension with co-existing lung disease patients 
had different phenotypic charateristics and worse survival compared with 
idiopathic, heritable and anorexigen-associated PAH patients.  
 
The results presented in this thesis will help to improve our current knowledge 
of idiopathic, heritable and anorexigen-associated PAH. The identification of a 
separate phenotype of pre-capillary pulmonary hypertension with co-existing 
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lung disease will also help to inform the design and better selection of patients 
for future clinical trials.    
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9 Appendix  
 
1.  Classes of recommendations (5). 
 
Classes of recommendations Definitions 
Class I Evidence and/or general agreement 
that a given treatment or procedure is 
beneficial, useful and effective. 
Class II Conflicting evidence and/or a 
divergence of opinion about the 
usefulness/efficacy of the given 
treatment or procedure. 
Class IIa Weight of evidence/opinion is in favour 
of usefulness/efficacy. 
Class II b Usefulness/efficacy is less well 
established by evidence/opinion. 
Class III Evidence or general agreement that 
the given treatment or procedure is 
not useful/effective, and in some cases 
may be harmful. 
 
2. Levels of evidence (5). 
 
Level of evidence A Data derived from multiple randomised 
clinical trials or meta-analyses. 
Level of evidence B Data derived from a single randomised 
clinical trial or large non-randomised 
studies. 
Level of evidence C Consensus of opinion of the experts 
and/or small studies, retrospective 
studies, registries. 
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